Methods of assessing prostate cancer risk

Abstract

The present disclosure includes biomarkers, methods, reagents, systems, and kits for predicting an individual's risk of prostate cancer within a specified time frame, for example 5 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to predict an individual's risk of prostate cancer. In another aspect, methods are provided for predicting an individual's risk of prostate cancer, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1.

Description

METHODS OF ASSESSING PROSTATE CANCER RISK CROSS REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims the benefit of priority of US Provisional Patent Application No. 63 / 779,786 filed on March 28, 2025, the contents of which is incorporated by reference herein in its entirety for any purpose.FIELD

[0002] The present application relates generally to the detection of biomarkers and methods of assessing prostate cancer risk in an individual and, more specifically, to one or more biomarkers, methods, reagents, systems, and kits used to determine the risk of prostate cancer in an individual.BACKGROUND

[0003] The following description provides a summary of information that may be relevant to the present application and is not an admission that any of the information provided or publications referenced herein is prior art to the present application.

[0004] Prostate cancer is the most common cancer among men in the United States and Europe; approximately 1 in 8 men will be diagnosed in their lifetime. Incidence has steadily increased annually in the US since 2012 after two decades of decline. In Japan, prostate cancer surpassed gastric cancer in 2017 as the most common cancer type. While lower than other high-income countries, the incidence of prostate cancer in Japan increased 7.2% between 2000 and 2016.

[0005] In the US, the increase in prostate cancer incidence is likely partly attributable to changes in prostate cancer screening recommendations by the US Preventive Services Task Force (USPSTF). In 2008, the task force, an independent panel of experts in disease prevention, recommended against PSA- based screening for prostate cancer for men over age 75, and then for all men in 2012, out of concern that harms (such as false positives and unnecessary procedures for slow-growing cancers) outweighed the benefits. In 2018, the task force modified their advice again and recommended individual decision-making regarding screening for men aged 55-69 years. In their recommendation, the task force cited evidence that PSA-based screening programs may prevent 3 cases of metastatic cancer and 1.3 deaths per 1000 men screened, yet frequent false positives and psychological harms outweighed the benefits of widespread screening in men 55-69 years.

[0006] Prostate cancer is highly treatable, especially if diagnosed early and at a low stage. Once confirmed with biopsy, treatment options include active surveillance until the condition worsens, surgical removal of tumor, and / or radiation, chemo-, immuno-, and targeted therapies. Ten-year survival rates for localized prostate cancer are nearly 100%, suggesting that intervention prior to metastasis provides optimal outcomes.

[0007] Taken together, PSA-based screening programs are effective in decreasing the incidence rate of invasive prostate cancer and the undesirable side effects of screening (false positives, unnecessary procedures) could be minimized if regular screening occurred only in those at highest risk of invasive cancer. By determining an individual’s risk of future prostate cancer, a tailored screening program could be devised to maximize effectiveness of screening and decrease the likelihood of false positives and unnecessary invasive procedures.

[0008] Several screening methods exist for monitoring and detecting early-stage prostate cancer, in addition to PSA-based screening, digital rectal exam (DRE), prostate cancer antigen 3 (PC A3) mRNA test, free / total PSA ratio, and prostate imaging (MRI or ultrasound) are widely used. Prostate biopsy is performed if any of the prior methods indicate prostate tissue abnormality.

[0009] However, there is no standard method currently used in clinical practice to predict risk of future malignant prostate cancer. Healthcare providers consider age, family history, and ethnicity as the most important risk factors for prostate cancer. Prostate cancer is highly heritable and African American men are at higher risk compared to other ethnicities. Several online calculators exist to assist individuals in estimating their risk such as Prostate Cancer Prevention Trial (PCPT) calculator and the European Randomized Study of Screening for Prostate Cancer (ERSPC) calculator, yet none are standard of care in clinical practice

[0010] The development of a proteomic model for predicting an individual’s risk of prostate cancer would be highly desirable. A need exists for biomarkers, methods, reagents, systems, and kits that enable the prediction of the risk of prostate cancer for an individual. Non-limiting benefits of a prostate cancer risk test include: 1) a convenient blood-based test that is non- invasive and does not rely on self-reported demographic or genetic information and has superior ability to predict risk of future prostate cancer compared to common screening methods (i.e., PSA); 2) the test results could identify individuals who would benefit from more frequent screening with traditional methods (PSA, imaging, etc.), which would likely increase screening adherence among those identified as higher than average risk; and 3) the test results could identify individuals at lower risk of proslate cancer who could undergo traditional screening less frequently, resulting in a lower number of false positive PSA results and fewer unnecessary procedures.SUMMARY

[0011] The present application includes biomarkers, methods, reagents, systems, and kits for assessing prostate cancer risk. In some embodiments, methods of predicting the risk of prostate cancer in individuals are provided. In some embodiments, methods of predicting the risk of prostate cancer in an individual within a specified time, such as 5 years, are provided. In some embodiments, methods of detecting levels of N biomarker proteins in a sample are provided.

[0012] Embodiment 1. A method of predicting prostate cancer risk in a subject, comprising forming a biomarker panel comprising N biomarker proteins, and detecting a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3. at least 4, at least 5. at least 6. at least 7, at least 8, at least 9, or at least 10 and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or 10 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD. Tetranectin, and PTN,

[0013] Embodiment 2. A method of detecting levels of N biomarker proteins in a sample, comprising forming a biomarker panel comprising N biomarker proteins, and detecting the level of each of the N biomarker proteins in the sample from a subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10, and wherein at least 1, at least 2, at least 3. at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or 10 of the N biomarker proteins are selected from IDE, T106B, PS, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN

[0014] Embodiment 3. A method of predicting prostate cancer risk in a subject, comprising detecting a level of IDE and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN.

[0015] Embodiment 4. A method of predicting prostate cancer risk in a subject, comprising detecting a level of T106B and a level of each ofN biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4. at least 5, at least 6, at least 7. at least 8. or 9 of the N biomarker proteins are selected from IDE, PSA, CDON. DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN.

[0016] Embodiment 5. A method of predicting prostate cancer risk in a subject, comprising detecting a level of PSA and a level of each of N biomarker proteins in a sample from thesubject, wherein N is at least I, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4. at least 5, at least 6, at least 7. at least 8. or 9 of the N biomarker proteins are selected from IDE, T106B, CDON. DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN.

[0017] Embodiment (5. A method of predicting prostate cancer risk in a subject, comprising detecting a level of CDON and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4. at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8. or 9 of the N biomarker proteins are selected from IDE. T106B, PSA, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN.

[0018] Embodiment 7. A method of predicting prostate cancer risk in a subject, comprising detecting a level of DCE 1 and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4. at least 5. at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN.

[0019] Embodiment 8. A method of predicting prostate cancer risk in a subject, comprising detecting a level of PSMP and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least I, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCE1, SLIT2, Mn SOD, Tetranectin, and PTN

[0020] Embodiment 9. A method of predicting prostate cancer risk in a subject, comprising detecting a level of SLIT2 and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4. at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least 1. at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCE1, PSMP, Mn SOD, Tetranectin, and PTN.

[0021] Embodiment 10. A method of predicting prostate cancer risk in a subject, comprising detecting a level of Mn SOD and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least I, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCE1. PSMP. SLIT2, Tetranectin, and PTN.

[0022] Embodiment 11. A method of predicting prostate cancer risk in a subject, comprising detecting a level of and Tetranectin a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4. at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least 1. at least 2, at least 3, at least 4. at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, and PTN.

[0023] Embodiment 12. A method of predicting prostate cancer risk in a subject, comprising detecting a level of PTN and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8. or 9 of the N biomarker proteins are selected from IDE. T106B, PSA, CDON, DCE1. PSMP. SLIT2, Mn SOD, and Tetranectin.

[0024] Embodiment 13. The method according to any one of the preceding embodiments, wherein N is 2 to 10, N is 3 to 10, N is 4 to 10, N is 5 to 10, N is 6 to 10, N is 7 to 10, N is 8 to 10, orN is 9 to 10.

[0025] Embodiment 14. The method according to any one of the preceding embodiments, wherein N is 2, N is 3, N is 4, N is 5, N is 6, N is 7, N is 8, N is 9, or N is 10.

[0026] Embodiment 15. The method according to any one of the preceding embodiments, wherein at least one of the N biomarker proteins is IDE, or at least one of the N biomarker proteins is T106B, or at least one of the N biomarker proteins is PSA, or at least one of N biomarker proteins is CDON, or at least one of the N biomarker proteins is DCE1, or at least one of the N biomarker proteins is PSMP, or at least one of the N biomarker proteins is SLIT2, or at least one of the N biomarker proteins is Mn SOD, or at least one of the N biomarker proteins is Tetranectin, or at least one of the N biomarker proteins is PTN.

[0027] Embodiment 16. The method according to any one of the preceding embodiments, wherein each of the N biomarker proteins is selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN.

[0028] Embodiment 17. The method according to any one of the preceding embodiments, wherein at least 2, at least 3, at least 4, at least 5, at least 6, or at least 7, or at least 8, or at least 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN

[0029] Embodiment 18. The method according to any one of embodiments 1-3, wherein 2 of the N biomarker proteins are IDE and T106B, or 2 of the N biomarker proteins are IDE and PSA, or 2 of the N biomarker proteins are IDE and CDON, or 2 of the N biomarker proteins are IDE and DCE1, or 2 of the N biomarker proteins are IDE and PSMP, or 2 of the N biomarkerproteins are IDE and SLIT2, or 2 of the N biomarker proteins are IDE and Mn SOD, or 2 of the N biomarker proteins are IDE and Tetranectin, or 2 of the N biomarker proteins are IDE and PTN.

[0030] Embodiment 19. The method according to any one of embodiments 1, 2 or 4, wherein 2 of the N biomarker proteins are T106B and PSA, or 2 of the N biomarker proteins are T106B and CDON, or 2 of the N biomarker proteins are T106B and DCE1, or 2 of the N biomarker proteins are T106B and PSMP, or 2 of the N biomarker proteins are T106B and SLIT2, or 2 of the N biomarker proteins are T106B and Mn SOD, or 2 of the N biomarker proteins are T106B and Tetranectin, or 2 of the N biomarker proteins are T106B and PTN.

[0031] Embodiment 20. The method according to any one of embodiments 1, 2 or 5, wherein 2 of the N biomarker proteins are PSA and CDON, or 2 of the N biomarker proteins are PSA and DCE1. or 2 of the N biomarker proteins are PSA and PSMP, or 2 of the N biomarker proteins are PSA and SLIT2, or 2 of the N biomarker proteins are PSA and Mn SOD. or 2 of the N biomarker proteins are PSA and Tetranectin, or 2 of the N biomarker proteins are PSA and PTN.

[0032] Embodiment 21. The method according to any one of embodiments 1, 2 or 6. wherein 2 of the N biomarker proteins are CDON and DCE1, or 2 of the N biomarker proteins are CDON and PSMP, or 2 of the N biomarker proteins are CDON and SLIT2, or 2 of the N biomarker proteins are CDON and Mn SOD, or 2 of the N biomarker proteins are CDON and Tetranectin, or 2 of the N biomarker proteins are CDON and PTN.

[0033] Embodiment 22. The method according to any one of embodiments 1, 2 or 7, wherein 2 of the N biomarker proteins are DCE1 and PSMP, or 2 of the N biomarker proteins are DCE1 and SLIT2, or 2 of the N biomarker proteins are DCE1 and Mn SOD, or 2 of the N biomarker proteins are DCE1 and Tetranectin, or 2 of the N biomarker proteins are DCE1 and PTN.

[0034] Embodiment 23. The method according to any one of embodiments 1, 2 or 8, wherein 2 of the N biomarker proteins are PSMP and SLIT2, or 2 of the N biomarker proteins are PSMP and Mn SOD, or 2 of the N biomarker proteins are PSMP and Tetranectin, or 2 of the N biomarker proteins are PSMP and PTN.

[0035] Embodiment 24. The method according to any one of embodiments 1, 2 or 9, wherein 2 of the N biomarker proteins are SLIT2 and Mn SOD, or 2 of the N biomarker proteins are SLIT2 and Tetranectin, or 2 of the N biomarker proteins are SLIT2 and PTN.

[0036] Embodiment 25. The method according to any one of embodiments 1, 2 or 10, wherein 2 of the N biomarker proteins are Mn SOD and Tetranectin, or 2 of the N biomarker proteins are Mn SOD and PTN.

[0037] Embodiment 26. The method according to any one of embodiments 1, 2 or 11, wherein 2 of the N biomarker proteins are Tetranectin and PTN

[0038] Embodiment 27. The method according to any one of embodiments 1-4, wherein 3 of the N biomarker proteins are IDE, T106B, and PSA, or 3 of the N biomarker proteins are IDE, T106B, and CDON, or 3 of the N biomarker proteins are IDE, T106B, and DCE1, or 3 of the N biomarker proteins are IDE, T106B, and PSMP, or 3 of the N biomarker proteins are IDE, T106B, and SLIT2, or 3 of the N biomarker proteins are IDE, T106B, and Mn SOD, or 3 of the N biomarker proteins are IDE, T106B, and Tetranectin, or 3 of the N biomarker proteins are IDE, T106B, and PTN.

[0039] Embodiment 28. The method according to any one of the preceding embodiments, wherein the sample is a blood sample, a plasma sample, a serum sample, or a urine sample.

[0040] Embodiment 29. The method according to any one of the preceding embodiments, wherein the risk of the subject prostate cancer within 5 years from the date that the sample was taken from the subject is predicted.

[0041] Embodiment 30. The method according to any one of die preceding embodiments, wherein detecting is performed using mass spectrometry, an aptamer based assay, and / or an antibody based assay.

[0042] Embodiment 31. The method of any one of embodiments 1 -30, wherein the method comprises contacting biomarker proteins of the sample from the subject with a set of capture reagents, wherein each capture reagent of the set of capture reagents specifically binds to one biomarker protein being detected.

[0043] Embodiment 32. The method of embodiment 31, wherein 2, 3, or 4 of the capture reagents bind to the same biomarker protein being detected.

[0044] Embodiment 33. The method of embodiment 32, wherein 2, 3, or 4 capture reagents specifically bind to PSA.

[0045] Embodiment 34. The method of any one of embodiments 1 -33, wherein the method comprises contacting biomarker proteins of the sample from the subject with a set of capture reagents, wherein each capture reagent of the set of capture reagents specifically binds to a different biomarker protein being detected.

[0046] Embodiment 35. The method according to any one of embodiments.31-34. wherein each biomarker capture reagent is an antibody or an aptamer.

[0047] Embodiment 36. The method according to embodiment 35, wherein each biomarker capture reagent is an aptamer.

[0048] Embodiment 37. The method according to embodiment 36. wherein at least one aptamer is a slow off-rate aptamer

[0049] Embodiment 38. The method according to embodiment 37, wherein at least one slow off-rate aptamer comprises at least one, at least two. at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 nucleotides with modifications.

[0050] Embodiment 39. The method according to embodiment 37 or embodiment 38, wherein each slow off-rate aptamer binds to its target protein with an off rate (t’A) of > 20 minutes, > 30 minutes, > 60 minutes, > 90 minutes, > 120 minutes, > 150 minutes, > 180 minutes, > 210 minutes, or > 240 minutes.

[0051] Embodiment 40. The method according to any one of embodiments 30-39, wherein the level of each biomarker protein measured is determined from a relative florescence unit (RFU) or a protein concentration.

[0052] Embodiment 41. The method according to any one of the preceding embodiments, wherein predicting the risk of prostate cancer in the subject is based on input of the levels of the N biomarker proteins measured in a statistical model.

[0053] Embodiment 42. The method according to embodiment 41, wherein the predicting comprises analyzing the levels of the N biomarker protein using a survival model.

[0054] Embodiment 43. The method according to embodiment 42, wherein the survival model is an Accelerated Failure Time (AFT) model with a Weibull distribution.

[0055] Embodiment 44. The method according to any one of embodiments 41-43, wherein the model has an area under the curve (AUC) selected from at least 0.6, at least 0.61, at least 0.62, at least 0.63, at least 0.64, at least 0.65, at least 0.66. at least 0.67, at least 0.68, at least 0.69, at least 0.7, at least 0.75, at least 0.8, at least 0.85, at least 0.9. or at least 0.95.

[0056] Embodiment 45. The method according to any one of the preceding embodiments, wherein the method comprises predicting a risk of prostate cancer in a subject for the purpose of determining a medical insurance premium or life insurance premium.

[0057] Embodiment 46. The method according to embodiment 45, wherein the method further comprises determining coverage for medical insurance or life insurance.

[0058] Embodiment 47. The method according to any one of embodiments 1-47. wherein the method further comprises using information resulting from the method to predict and / or manage the utilization of medical resources.

[0059] Embodiment 48. A kit comprising N biomarker protein capture reagents, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 of the N biomarker protein capture reagents specifically binds to a biomarker protein selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN.

[0060] Embodiment 49. The kit according to embodiment 48, wherein 1, 2, 3, or 4 of the capture reagents bind to PSA and each of the remaining capture reagents binds to a different protein selected from IDE, T106B, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN.

[0061] Embodiment 50. The kit according to embodiment 48 or 49, wherein N is 2 to 13, or N is 3 to 13, or N is 4 to 13, or N is 5 to 13, or N is 6 to 13, or N is 7 to 13, or N is 8 to 13, or N is 9 to 13, or N is 10 to 13, orN is 11 to 13, or N is 12 to 13.

[0062] Embodiment 51. The kit according to any one of embodiments 48-50, wherein N is 2, N is 3, N is 4, N is 5, N is 6, N is 7, N is 8, N is 9, N is 10, N is 11, N is 12, or N is 13

[0063] Embodiment 52. The kit according to any one of embodiments 48-51, wherein each of the N biomarker protein capture reagents specifically binds to a biomarker protein selected from IDE. T106B, PSA. CDON, DCE1, PSMP. SLTT2. Mn SOD, Tetranectin, and PTN

[0064] Embodiment 53. The kit according to any one of embodiments 48-52, wherein the N biomarker protein capture reagent specifically bind to the N biomarker proteins of any one of embodiments 1-27.

[0065] Embodiment 54. A kit comprising N biomarker protein capture reagents, wherein the kit comprises biomarker protein capture reagents for carrying out the method of any one of embodiments 1-47.

[0066] Embodiment 55. The kit according to any one of embodiments 48-54, wherein each of the N biomarker protein capture reagents is an antibody or an aptamer.

[0067] Embodiment 56. The kit according to embodiment 55, wherein each biomarker protein capture reagent is an aptamer.

[0068] Embodiment 57. The kit according to embodiment 56, wherein at least one aptamer is a slow- off-rate aptamer.

[0069] Embodiment 58. The kit according to embodiment 57, wherein at least one slow off-rate aptamer comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 nucleotides with modifications.

[0070] Embodiment 59. The kit according to embodiment 57 or embodiment 58, wherein each slow off-rate aptamer binds to its target protein with an off rate (t½) of > 20 minutes. > 30 minutes, > 60 minutes. > 90 minutes, > 120 minutes, > 150 minutes, > 180 minutes, > 210 minutes, or > 240 minutes.

[0071] Embodiment 60. The kit according to any one of embodiments 48-59, for use in detecting the N biomarker proteins in a sample from a subject.

[0072] Embodiment 61. The kit according to embodiment 60, for use in predicting an individual’s risk of prostate cancer.BRIEF DESCRIPTION OF THE DRAWINGS

[0073] FIG. 1 illustrates certain exemplary 5-position modified uridines and cytidines that may be incorporated into aptamers.

[0074] FIG. 2 illustrates certain exemplary modifications that may be present at the 5-position of uridine. The chemical structure of the C-5 modification includes the exemplary amide linkage that links the modification to the 5-position of uridine. The 5-position moieties shown include two phenyl groups covalently attached to one another. The 5 -position moieties shown include a phenylbenzyl moiety (e.g., BPE, PBnd, DBM), a 4-phenoxy benzyl moiety (e.g., POP), a diphenylpropyl moiety (e.g., DPP), a benzhydryl moiety (e.g., BH).

[0075] FIG. 3 illustrates certain exemplary modifications that may be present at the 5-position of cytidine. The chemical structure of the C-5 modification includes the exemplary amide linkage that links the modification to the 5-position of cytidine. The 5-position moieties shown include two phenyl groups covalently attached to one another. The 5-position moieties shown include a phenylbenzyl moiety (e.g., BPE, PBnd, DBM), a 4-phenoxy benzyl moiety (e.g., POP), a diphenylpropyl moiety (e.g., DPP), a benzhydryl moiety (e.g., BH).

[0076] FIG. 4 illustrates certain exemplary modifications that may be present at the 5-position of uridine. The chemical structure of the C-5 modification includes the exemplary amide linkage that links the modification to the 5-position of the uridine. The 5-position moieties shown include a benzyl moiety (e.g., Bn, PE and a PP), a naphthyl moiety (e.g., Nap, 2Nap, NE), a butyl moiety (e.g., iBu), a fluorobenzyl moiety (e.g., FBn), a tyrosyl moiety (e.g., a Tyr), a 3,4-methylenedioxy benzyl (e.g., MBn), a morpholino moiety (e.g., MOE), a benzofuranyl moiety (e.g., BF), an indole moiety (e.g., Trp) and a hydroxypropyl moiety (e.g., Thr).

[0077] FIG. 5 illustrates certain exemplary' modifications that may be present at the 5-position of cytidine. The chemical structure of the C-5 modification includes the exemplary' amide linkage that links the modification to the 5-position of the cytidine. The 5-position moieties shown include a benzyl moiety (e.g., Bn, PE and a PP), a naphthyl moiety (e.g.. Nap, 2Na.p, NE, and 2NE) and a tyrosyl moiety' (e.g., a Tyr).

[0078] FIG. 6 illustrates an exemplary' computer system for use with various computer-implemented methods described herein.

[0079] FIG. 7 is a flowchart for a method of evaluating an individual’s risk of prostate cancer in accordance with one or more embodiments.

[0080] FIG. 8 illustrates a Kaplan-Meier (KM) survival curve for the selected 5-y ear Malignant Prostate Cancer Risk model, stratified by quartiles of predicted 5-year risk of malignant prostate cancer diagnosis (‘‘Event”) from the training dataset.

[0081] FIG. 9 is a calibration plot for the selected 5-year Prostate Cancer Risk model

[0082] FIG. 10 illustrates a Kaplan-Meier (KM) survival curve for the selected 5-year Prostate Cancer Risk model on the validation dataset, stratified by quartiles of predicted 5-year risk of malignant prostate cancer diagnosis (" Event7’) from the training dataset.

[0083] FIG. 11 illustrates the concordance plot for the prostate cancer risk model predictions between Citrate plasma training and simulated EDTA plasma training data.DETAILED DESCRIPTION

[0084] Reference will now be made in detail to representative embodiments of the invention. While the invention will be described in conjunction with the enumerated embodiments, it will be understood that the invention is not intended to be limited to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents that may be included within the scope of the present invention as defined by the claims.

[0085] One skilled m the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in and are within the scope of the practice of the present invention. The present invention is in no way limited to the methods and materials described.

[0086] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, certain methods, devices and materials are now described.

[0087] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, published patent documents, and patent applications cited in this application are indicative of the level of skill in the art(s) to which the application pertains. All publications, published patent documents, and patent applications cited herein are hereby incorporated by reference to the same extent as though each individual publication, published patent document, or patent application was specifically and individually indicated as being incorporated by reference.

[0088] As used in this application, including the appended claims, the singular forms “a,” “an.” and “the” include plural references, unless the content clearly dictates otherwise, and are used interchangeably with “at least one” and “one or more.” Thus, reference to “a SOMAmer” includes mixtures of SOMAmers, reference to “a probe” includes mixtures of probes, and the like. It is further to be understood that all base sizes or amino acid sizes, and all molecularweight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description.

[0089] Further, ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (as well as fractions thereof unless the context clearly dictates otherwise). Any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. Also, any number range recited herein relating to any physical feature are to be understood to include any integer within the recited range, unless otherwise indicated.

[0090] As used herein, the term "about’" represents an insignificant modification or variation of the numerical value such that the basic function of the item to which the numerical value relates is unchanged.

[0091] As used herein, the terms "comprises,” "comprising.” “includes."’ “including,” “contains,” “containing,"’ and any variations thereof, are intended to cover a non-exclusive inclusion, such that a process, method, product-by-process, or composition of matter that comprises, includes, or contains an element or list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, product-by-process, or composition of matter.

[0092] The present application includes biomarkers, methods, reagents, systems, and kits for the determining the risk of prostate cancer in an individual.

[0093] “Prostate cancer"" as used herein as malignant neoplasm of the prostate (code C61) according to the International Classification of Diseases-Tenth Revision and the second revision of the International Classification of Diseases for Oncology (ICD-O-2).

[0094] “Biological sample.” “sample,” and “test sample” are used interchangeably herein to refer to any material, biological fluid, tissue, or cell obtained or otherwise derived from an individual. This includes blood (including whole blood, leukocytes, peripheral blood mononuclear cells, buffy coat, plasma, and serum), dried blood spots, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, bronchial brushing, synovial fluid, joint aspirate, organ secretions, cells, a cellular extract, and cerebrospinal fluid. This also includes experimentally separated fractions of all of the preceding. For example, a blood sample can be fractionated intoserum, plasma or into fractions containing particular types of blood cells, such as red blood cells or white blood cells (leukocytes). If desired, a sample can be a combination of samples from an individual, such as a combination of a tissue and fluid sample. Hie term “biological sample” also includes materials containing homogenized solid material, such as from a stool sample, a tissue sample, or a tissue biopsy, for example. The term “biological sample” also includes materials derived from a tissue culture or a cell culture. Any suitable methods for obtaining a biological sample can be employed; exemplary methods include, e.g., phlebotomy, swab (e.g.. buccal swab), and a fine needle aspirate biopsy procedure. Exemplary tissues susceptible to fine needle aspiration include lymph node, lung, lung washes, BAL (bronchoalveolar lavage), thyroid, breast, pancreas, and liver. Samples can also be collected, e.g., by micro dissection (e.g., laser capture micro dissection (LCM) or laser micro dissection (LMD)), bladder wash, smear (e.g., a PAP smear), or ductal lavage. A “biological sample”' obtained or derived from an individual includes any such sample that has been processed in any suitable manner after being obtained from the individual.

[0095] For purposes of this specification, the phrase “data attributed to a biological sample from an individual” is intended to mean that the data in some form derived from, or were generated using, the biological sample of the individual. The data may have been reformatted, revised, or mathematically altered to some degree after having been generated, such as by conversion from units in one measurement system to units in another measurement system; but, the data are understood to have been derived from, or were generated using, the biological sample.

[0096] “Target,” “target molecule,” and “analyte” are used interchangeably herein to refer to any molecule of interest that may be present in a biological sample. A “molecule of interest” includes any minor variation of a particular molecule, such as, in the case of a protein, for example, minor variations in amino acid sequence, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component, which does not substantially alter the identity of the molecule. A “target molecule,” “target,” or “analyte” is a set of copies of one type or species of molecule or multi-molecular structure. “Target molecules,” “targets,” and “’analytes” refer to more than one such set of molecules. Exemplary target molecules include proteins, polypeptides, nucleic acids, carbohydrates, lipids, polysaccharides, glycoproteins, hormones, receptors, antigens, antibodies, affybodies, antibody mimics, viruses, pathogens, toxic substances, substrates, metabolites, transition state analogs, cofactors, inhibitors, drugs, dyes, nutrients, growth factors, cells, tissues, and any’ fragment or portion of any of the foregoing. In someembodiments, a target molecule is a protein, in which case the target molecule may be referred to as a "‘target protein."

[0097] As used herein, a “captur e agent’ or “capture reagent” refers to a molecule that is capable of binding specifically to a biomarker. A “target protein capture reagent” refers to a molecule that is capable of binding specifically to a target protein. Nonlimiting exemplary' capture reagents include aptamers, antibodies, adnectins, ankyrins, other antibody mimetics and other protein scaffolds, autoantibodies, chimeras, small molecules, nucleic acids, lectins, ligandbinding receptors, imprinted polymers, avimers, peptidomimetics, hormone receptors, cytokine receptors, synthetic receptors, and modifications and fragments of any of the aforementioned capture reagents. In some embodiments, a capture reagent is selected from an aptamer and an antibody.

[0098] As used herein, “polypeptide,” “peptide.” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. Polypeptides can be single chains or associated chains. Also included within the definition are preproteins and intact mature proteins; peptides or polypeptides derived from a mature protein; fragments of a protein; splice variants; recombinant forms of a protein; protein variants with amino acid modifications, deletions, or substitutions; digests; and post-translational modifications, such as glycosylation, acetylation, phosphorylation, and the like.

[0099] The term “antibody” refers to full-length antibodies of any’ species and fragments and derivatives of such antibodies, including Fab fragments. F(ab')2 fragments, single chain antibodies, Fv fragments, and single chain Fv fragments. The term “antibody” also refers to synthetically-derived antibodies, such as phage display-derived antibodies and fragments, affybodies, nanobodies, etc.

[0100] As used herein, “marker” and “biomarker” and “feature” are used interchangeably to refer to a target molecule that indicates or is a sign of a normal or abnormal process in an individual or of a disease or other condition in an individual. More specifically, a “marker” or “biomarker” or “feature” is an anatomic, physiologic, biochemical, or molecular parameter associated with the presence of a specific physiological state or process, whether normal orabnormal, and, if abnormal, whether chronic or acute. Biomarkers are detectable and measurable by a variety of methods including laboratory assays and medical imaging. When a biomarker is a protein, it is also possible to use the expression of the corresponding gene as a surrogate measure of the amount or presence or absence of the corresponding protein biomarker in a biological sample or methylation state of the gene encoding the biomarker or proteins that control expression of the biomarker. In certain aspects, a feature is an analyte / SOMAmer reagent of other predictors in a statistical model.

[0101] As used herein, “biomarker value,” “value,” “biomarker level,” ‘‘feature level,” and “level” are used interchangeably to refer to a measurement that is made using any analytical method for detecting the biomarker in a biological sample and that indicates the presence, absence, absolute amount or concentration, relative amount or concentration, liter, a level, an expression level, a ratio of measured levels, or the like, of, for, or corresponding to the biomarker in the biological sample. The exact nature of the “value” or “level” depends on the specific design and components of the particular analytical method employed to detect the biomarker.

[0102] When a biomarker indicates or is a sign of an abnormal process or a disease or other condition in an individual, that biomarker is generally described as being either over-expressed or under-expressed as compared to an expression level or value of the biomarker that indicates or is a sign of a normal process or an absence of a disease or other condition in an individual, “Up-regulation," “up-regulated,” “over-expression,” “over-expressed,” and any variations thereof are used interchangeably to refer to a value or level of a biomarker in a biological sample that is greater than a value or level (or range of values or levels) of the biomarker that is typically detected in similar biological samples from healthy or normal individuals. The terms may also refer to a value or level of a biomarker in a biological sample that is greater than a value or level (or range of values or levels) of the biomarker that may be detected at a different stage of a particular disease.

[0103] “Down-regulation,” “down-regulated.” “under-expression,” “under-expressed,” and any variations thereof are used interchangeably to refer to a value or level of a biomarker in a biological sample that is less than a value or level (or range of values or levels) of the biomarker that is typically detected in similar biological samples from healthy or normal individuals. The terms may also refer to a value or level of a biomarker in a biological sample that is less than a value or level (or range of values or levels) of the biomarker that may be detected at a different stage of a particular disease.

[0104] Further, a biomarker that is either over-expressed or under-expressed can also be referred to as being “differentially expressed” or as having a “differential level” or “differentialvalue” as compared to a “normal” expression level or value of the biomarker that indicates or is a sign of a normal process or an absence of a disease or other condition in an individual. Thus, “differential expression” of a biomarker can also be referred to as a variation from a “normal” expression level of the biomarker.

[0105] The term “differential gene expression” and “differential expression” are used interchangeably to refer to a gene (or its corresponding protein expression product) whose expression is activated to a higher or lower level in a subject suffering from a specific disease or condition, relative to its expression in a normal or control subject. The terms also include genes (or the corresponding protein expression products) whose expression is activated to a higher or lower level at different stages of the same disease or condition. It is also understood that a differentially expressed gene may be either activated or inhibited at the nucleic acid level or protein level, or may be subject to alternative splicing to result in a different polypeptide product. Such differences may be evidenced by a variety' of changes including mRNA levels, surface expression, secretion or other partitioning of a polypeptide. Differential gene expression may include a comparison of expression between two or more genes or their gene products; or a comparison of the ratios of the expression between two or more genes or their gene products; or even a comparison of two differently processed products of the same gene, which differ between normal subjects and subjects suffering from a disease; or between various stages of the same disease. Differential expression includes both quantitative, as well as qualitative, differences in the temporal or cellular expression pattern m a gene or its expression products among, for example, normal and diseased cells, or among cells which have undergone different disease events or disease stages.

[0106] A “control level” of a target molecule refers to the level of the target molecule in a properly handled sample of the same sample type. Control level may refer to the average level of the target molecule in properly handled samples from a population of individuals.

[0107] As used herein, “individual” refers to a test subject or patient. The individual can be a mammal or a non-mammal. In various embodiments, the individual is a mammal. A mammalian individual can be a human or non-human. In various embodiments, the individual is a human.

[0108] “Diagnose,” “diagnosing,” “’diagnosis,” and variations thereof refer to the detection, determination, or recognition of a health status or condition of an individual on the basis of one or more signs, symptoms, data, or other information pertaining to that individual. The health status of an individual can be diagnosed as healthy / normal (i.e., a diagnosis of the absence of a disease or condition) or diagnosed as ill / abnormal (i.e., a diagnosis of the presence, or an assessment of the characteristics, of a disease or condition). The terms “diagnose,” “diagnosing,” "diagnosis,” etc., encompass, with respect to a particular disease or condition, theinitial detection of the disease; the characterization or classification of the disease; the detection of the progression, remission, or recurrence of the disease; and the detection of disease response after the administration of a treatment or therapy to the individual.

[0109] ‘" Prognose,” “prognosing,” “prognosis,” and variations thereof refer to the prediction of a future course of a disease or condition in an individual who has the disease or condition (e.g., predicting patient survival), and such terms encompass the evaluation of disease or condition response after the administration of a treatment or therapy to the individual.

[0110] “Evaluate,” “evaluating,” “‘evaluation,” and variations thereof encompass both “diagnose” and “prognose” and also encompass determinations or predictions about the future course of a disease or condition m an individual who does not have the disease as well as determinations or predictions regarding the risk that a disease or condition will recur in an individual who apparently has been cured of the disease or has had the condition resolved. The term "‘evaluate” also encompasses assessing an individual's response to a therapy, such as, for example, predicting whether an individual is likely to respond favorably to a therapeutic agent or is unlikely to respond to a therapeutic agent (or will experience toxic or other undesirable side effects, for example), selecting a therapeutic agent for administration to an individual, or monitoring or determining an individual’s response to a therapy that has been administered to the individual. Thus, “evaluating” risk of prostate cancer can include, for example, predicting the future risk of prostate cancer in an individual. Evaluation of risk of prostate cancer can include embodiments such as the assessment of risk of prostate cancer as the probability (absolute risk) of a first primary malignant prostate cancer diagnosis which is a continuous variable within the range from 0.0000 to 1.0000. The evaluation of risk of prostate cancer is for a defined period; such period can be, for example, 1, 2, 3, 4, 5, (5, 7, 8, 9, and / or 10 years. Tn some aspects, evaluation of risk of prostate cancer is for subjects aged 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46. 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58. 59. 60. 61. 62. 63, 64, or 65 years of age or older.

[0111] As used herein, “additional biomedical information” refers to one or more evaluations of an individual, other than using any of the biomarkers described herein, that are associated with prostate cancer. “Additional biomedical information” includes any of the following: physical descriptors of an individual, including the height and / or weight of an individual: the age of an individual; the gender of an individual: change in weight; the ethnicity of an individual; occupational history; family history of prostate cancer; the presence of a genetic marker(s); clinical symptoms such as abdominal pain, weight gain or loss gene expression values: physical descriptors of an individual, including physical descriptors observed by radiologic imaging; tobacco use status; alcohol use history; occupational history; dietary habits - salt, saturated fatand cholesterol intake; caffeine consumption; and imaging information. Additional biomedical information can be obtained from an individual using routine techniques known in the art, such as from the individual themselves by use of a routine patient questionnaire or health history questionnaire, etc., or from a medical practitioner, etc,

[0112] As used herein, “detecting” or “determining” with respect to a biomarker value includes the use of both the instrument required to observe and record a signal corresponding to a biomarker value and the matenal / s required to generate that signal. In various embodiments, the biomarker value is detected using any suitable method, including fluorescence, chemiluminescence, surface plasmon resonance, surface acoustic waves, mass spectrometry, infrared spectroscopy, Raman spectroscopy, atomic force microscopy, scanning tunneling microscopy, electrochemical detection methods, nuclear magnetic resonance, quantum dots, and the like.

[0113] “Solid support” refers herein to any substrate having a surface to which molecules may be attached, directly or indirectly, through either covalent or non-covalent bonds. A “solid support” can have a variety of physical formats, which can include, for example, a membrane; a chip (e.g., a protein chip); a slide (e.g., a glass slide or coverslip): a column: a hollow, solid, semi-solid, pore- or cavity- containing particle, such as, for example, a bead; a gel; a fiber, including a fiber optic material; a matrix; and a sample receptacle. Exemplary sample receptacles include sample wells, tubes, capillaries, vials, and any other vessel, groove or indentation capable of holding a sample. A sample receptacle can be contained on a multi¬ sample platform, such as a microtiter plate, slide, microfluidics device, and the like. A support can be composed of a natural or synthetic material, an organic or inorganic material The composition of the solid support on which capture reagents are attached generally depends on the method of attachment (e.g., covalent attachment). Other exemplary receptacles include microdroplets and microfluidic controlled or bulk oil / aqueous emulsions within which assays and related manipulations can occur Suitable solid supports include, for example, plastics, resms, polysaccharides, silica or silica-based materials, functionalized glass, modified silicon, carbon, metals, inorganic glasses, membranes, nylon, natural fibers (such as, for example, silk, wool and cotton), polymers, and the like. The material composing the solid support can include reactive groups such as, for example, carboxy, amino, or hydroxyl groups, which are used for attachment of the capture reagents. Polymeric solid supports can include, e g., polystyrene, polyethylene glycol tetraphthalate, polyvinyl acetate, polyvinyl chloride, polyvinyl pyrrolidone, polyacrylonitrile, polymethyl methacrylate, polytetrafluoroethylene, butyl rubber, styrenebutadiene rubber, natural rubber, polyethylene, polypropylene, (poly)tetrafluoroethylene, (poly)vinylidenefluoride, polycarbonate, and polymethylpentene Suitable solid support particlesthat can be used include, e g., encoded particles, such as Luminex®-type encoded particles, magnetic particles, and glass particles,[00114| As used herein, "analyte” is the protein target of a capture reagent. In certain aspects, the capture reagent is an aptamer In certain further aspects, the capture reagent is a SOMAmer.

[0115] As used herein, "nucleic acid ligand,” "aptamer,” " SOMAmer,” “modified aptamer,” and “clone” are used interchangeably to refer to a non-naturally occurring nucleic acid that has a desirable action on a target molecule. A desirable action includes, but is not limited to, binding of the target, catalytically changing the target, reacting with the target in a way that modifies or alters the target or the functional activity of the target, covalently attaching to the target (as in a suicide inhibitor), and facilitating the reaction between the target and another molecule. In one embodiment, the action is specific binding affinity for a target molecule, such target molecule being a three dimensional chemical structure other than a polynucleotide that binds to the aptamer through a mechanism which is independent of Watson / Crick base pairing or triple helix formation, wherein the aptamer is not a nucleic acid having the known physiological function of being bound by the target molecule. Aptamers to a given target include nucleic acids that are identified from a candidate mixture of nucleic acids, where the aptamer is a ligand of the target, by a method comprising: (a) contacting the candidate mixture with the target, wherein nucleic acids having an increased affinity to the target relative to other nucleic acids in the candidate mixture can be partitioned from the remainder of the candidate mixture; (b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and (c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids, whereby aptamers of the target molecule are identified. It is recognized that affinity interactions are a matter of degree; however, in this context, the "specific binding affinity” of an aptamer for its target means that the aptamer binds to its target generally with a much higher degree of affinity than it binds to other, non-target, components in a mixture or sample. An "aptamer,” “SOMAmer,” or “nucleic acid ligand” is a set of copies of one type or species of nucleic acid molecule that has a particular nucleotide sequence. An aptamer can include any suitable number of nucleotides. " Aptamers” refer to more than one such set of molecules. Different aptamers can have either the same or different numbers of nucleotides. Aptamers may be DNA or RNA and may be single stranded, double stranded, or contain double stranded or triple stranded regions. In some embodiments, the aptamers are prepared using a SELEX process as described herein, or known in the art.

[0116] As used herein, “study,” refers to a set of samples and clinical data that are analyzed to derive the test.

[0117] As used herein, “training dataset,’’ refers to a subset of data from a study used to fit a model.[00118| As used herein, “validation dataset.” refers to a final subset of data used to assess the performance of a selected model developed on a verification dataset.

[0119] As used herein, “verification dataset,” means a separate subset of data used to provide an unbiased evaluation of a model fit on the training dataset while tuning model parameters.

[0120] As used herein, “elastic net logistic regression” refers to a machine learning method that utilizes penalized regression techniques to select the features that best predict the endpoint while allowing correlated features to be grouped together.

[0121] As used herein, “feature” refers to an analyte / SOMAmer reagent or other predictors in a statistical model.

[0122] As used herein, “forward selection” refers to a method for feature selection and reduction. Forward selection is a form of stepwise regression that starts with zero features included in the model. In an iterative process, features are considered for addition using t-tests as the selection criterion.

[0123] As used herein, the term “Adaptive Normalization using Maximum Likelihood (ANML) ‘ refers to a process for normalizing the analytes which allows for comparison across plates, studies, and sites.

[0124] As used herein, the term “principle component analysis” refers to a method for assessing and identifying large sources of variation in the data.

[0125] As used herein, the term “consensus-features nested cross validation (CNCV)” refers to a method for feature selection and reduction that uses regularization techniques and subsampling approaches such that candidate features are determined by relevance across multiple subsets of the data.

[0126] As used herein, the term “need” or “needed” refers to a judgement made by a health care provider regarding treatment of a patient which is considered by the health care provider to be beneficial to the health status of the patient.Prostate Cancer Risk Assessment

[0127] In some embodiments, the number of biomarkers useful for a biomarker subset or panel is based on the sensitivity and specificity value for the particular combination of biomarker levels. The terms “sensitivity” and “specificity” are used herein with respect to the ability to correctly classify an individual, based on one or more biomarker levels detected in their biological sample, as a risk of prostate cancer. “Sensitivity” indicates the performance of the biomarker(s) with respect to correctly classifying individuals that have a risk of prostatecancer or are healthy, “Specificity” indicates the performance of the biomarker(s) with respect to correctly classifying individuals who have a risk of prostate cancer,[00128| In some embodiments, overall performance of a panel of one or more biomarkers is represented by the area-under-the-curve (AUC) value. The AUC value is derived from a receiver operating characteristic (ROC) curve. The ROC curve is the plot of the true positive rate (sensitivity) of a test against the false positive rate (1 -specificity) of the test. The term “area under the curve” or “AUC” refers to the area under the curve of a receiver operating characteristic (ROC) curve, both of which are well known in the art. AUC measures are useful for comparing the accuracy of a classifier across the complete data range. Classifiers with a greater AUC have a greater capacity to classify unknowns correctly between two groups of interest (e.g., individuals having a risk of prostate cancer or healthy individuals). ROC curves are useful for plotting the performance of a particular feature (e.g,, any of the biomarkers described herein and / or any item of additional biomedical information) in distinguishing between two populations. Typically, the feature data across the entire population are sorted in ascending order based on the value of a single feature. Then, for each value for that feature, the true positive and false positive rates for the data are calculated. The true positive rate is determined by counting the number of cases above the value for that feature and then dividing by the total number of cases. The false positive rate is determined by counting the number of controls above the value for that feature and then dividing by the total number of controls. Although this definition refers to scenarios in which a feature is elevated in cases compared to controls, this definition also applies to scenarios m which a feature is lower in cases compared to the controls (m such a scenario, samples below the value for that feature would be counted). ROC curves can be generated for a single feature as well as for other single outputs, for example, a combination of two or more features can be mathematically combined (e.g., added, subtracted, multiplied, etc.) to provide a single sum value, and this single sum value can be plotted in a ROC curve. Additionally, any combination of multiple features, in which the combination derives a single output value, can be plotted in a ROC curve.Exemplary Uses of Biomarkers

[0129] In various exemplary embodiments, methods are provided for predicting an individual’s risk of prostate cancer by detecting one or more biomarker values corresponding to one or more biomarkers that are present in the circulation of an individual, such as in blood, serum or plasma, by any number of analytical methods, including any of the analytical methods described herein. These biomarkers are, for example, differentially expressed m individuals who have a risk of prostate cancer as compared to an individual who does not. Detection of thedifferential expression of a biomarker in an individual can be used, for example, to predict an individual’s risk of prostate cancer. In some embodiments, the detection of the differential expression of a biomarker in an individual can be used, for example, to predict an individual's risk of prostate cancer within a period of time In some embodiments, the prediction of an individual’s risk of prostate cancer is within a 5-year period.

[0130] In addition to testing biomarker levels as a stand-alone diagnostic test, biomarker levels can also be done in conjunction with determination of SNPs or other genetic lesions or variability that are indicative of increased risk of susceptibility of disease or condition. (See, e.g., Amos et al,, Nature Genetics 40, 616-622 (2009)).

[0131] Any of the described biomarkers may also be used in imaging tests. For example, an imaging agent can be coupled to any of the described biomarkers, which can be used to aid in predicting an individual’s risk of prostate cancer, to monitor response to therapeutic interventions, to select for target populations in a clinical trial among other uses.Detection and Determination of Biomarkers and Biomarker Levels

[0132] A biomarker level for the biomarkers described herein can be detected using any of a variety of known analytical methods. In one embodiment, a biomarker level is detected using a capture reagent. As used herein, a “capture agent’’ or “capture reagent” refers to a molecule that is capable of binding specifically to a biomarker. In various embodiments, the capture reagent can be exposed to the biomarker in solution or can be exposed to the biomarker while the capture reagent is immobilized on a solid support. In other embodiments, the capture reagent contains a feature that is reactive with a secondary feature on a solid support. In these embodiments, the capture reagent can be exposed to the biomarker in solution, and then the feature on the capture reagent can be used in conjunction with the secondary feature on the solid support to immobilize the biomarker on the solid support. The capture reagent is selected based on the type of analysis to be conducted Capture reagents include but are not limited to SOMAmers, antibodies, adnectins, ankyrins, other antibody mimetics and other protein scaffolds, autoantibodies, chimeras, small molecules, a F(ab’)2 fragment, a single chain antibody fragment, an Fv fragment, a single chain Fv fragment, a nucleic acid, a lectin, a ligand-binding receptor, affybodies, nanobodies, imprinted polymers, avimers, peptidomimetics. a hormone receptor, a cytokine receptor, and synthetic receptors, and modifications and fragments of these.

[0133] In some embodiments, a biomarker level is detected using a biomarker / capture reagent complex.

[0134] In other embodiments, the biomarker level is derived from the biomarker / capture reagent complex and is detected indirectly, such as, for example, as a result of a reaction that issubsequent to the biomarker / capture reagent interaction, but is dependent on the formation of the biomarker / capture reagent complex.[00135| In some embodiments, the biomarker level is detected directly from the biomarker in a biological sample.

[0136] In one embodiment, the biomarkers are detected using a multiplexed format that allows for the simultaneous detection of two or more biomarkers in a biological sample. In one embodiment of the multiplexed format, capture reagents are immobilized, directly or indirectly, covalently or non-covalently, in discrete locations on a solid support. In another embodiment, a multiplexed format uses discrete solid supports where each solid support has a unique capture reagent associated with that solid support, such as, for example quantum dots. In another embodiment, an individual device is used for the detection of each one of multiple biomarkers to be detected in a biological sample. Individual devices can be configured to permit each biomarker in the biological sample to be processed simultaneously. For example, a microtiter plate can be used such that each well in the plate is used to uniquely analyze one of multiple biomarkers to be detected in a biological sample.

[0137] In one or more of the foregoing embodimen ts, a fluorescent tag can be used to label a component of the biomarker / capture complex to enable the detection of the biomarker value. In various embodiments, the fluorescent label can be conjugated to a capture reagent specific to any of the biomarkers described herein using known techniques, and the fluorescent label can then be used to detect the corresponding biomarker value. Suitable fluorescent labels include rare earth chelates, fluorescein and its derivatives, rhodamine and its derivatives, dansyl, allophycocyanin, PBXL-3, Qdot 605, Lissamine, phycoerythrin, Texas Red, and other such compounds.

[0138] In one embodiment, the fluorescent label is a fluorescent dye molecule. In some embodiments, the fluorescent dye molecule includes at least one substituted indolium ring system in which the substituent on the 3-carbon of the indolium ring contains a chemically reactive group or a conjugated substance. In some embodiments, the dye molecule includes an AlexaFluor molecule, such as, for example, AlexaFluor 488, AlexaFluor 532, AlexaFluor 647, AlexaFluor 680, or AlexaFluor 700. In other embodiments, the dye molecule includes a first type and a second type of dye molecule, such as. e.g., two different AlexaFluor molecules. In other embodiments, the dye molecule includes a first type and a second type of dye molecule, and the two dye molecules have different emission spectra.

[0139] Fluorescence can be measured with a variety of instrumentation compatible with a wide range of assay formats. For example, spectrofluorimeters have been designed to analyze microtiter plates, microscope slides, printed arrays, cuvettes, etc. See Principles of FluorescenceSpectroscopy, by J. R. Lakowicz, Springer Science + Business Media, Inc., 2004. See Bioluminescence & Chemiluminescence. Progress & Current Applications; Philip E. Stanley and Larry J. Kricka editors, World Scientific Publishing Company, January 2002.

[0140] In one or more of the foregoing embodiments, a chemiluminescence tag can optionally be used to label a component of the biomarker / capture complex to enable the detection of a biomarker value. Suitable chemiluminescent materials include any of oxalyl chloride, Rodamin 6G, Ru(bipy)32+, TMAE (tetrakis(dimethylamino)ethylene), Pyrogallol (1,2,3-trihydroxybenzene), Lucigenin, peroxyoxalates, Aryl oxalates, Acridinium esters, dioxetanes, and others.

[0141] In yet other embodiments, the detection method includes an enzyme / substrate combination that generates a detectable signal that corresponds to the biomarker value.Generally, the enzyme catalyzes a chemical alteration of the chromogenic substrate which can be measured using various techniques, including spectrophotometry, fluorescence, and chemiluminescence. Suitable enzy mes include, for example, luciferases, luciferin, malate dehydrogenase, urease, horseradish peroxidase (HRPO), alkaline phosphatase, beta¬ galactosidase, glucoamylase, lysozyme, glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, uncase, xanthine oxidase, lactoperoxidase, microperoxidase, and the like.

[0142] In yet other embodiments, the detection method can be a combination of fluorescence, chemiluminescence, radionuclide or enzyme / substrate combinations that generate a measurable signal. Multimodal signaling could have unique and advantageous characteristics in biomarker assay formats.

[0143] More specifically, the biomarker levels for the biomarkers described herein can be detected using known analytical methods including, singleplex SOMAmer assays, multiplexed SOMAmer assays, singleplex or multiplexed immunoassays, mRNA expression profiling, miRNA expression profiling, mass spectrometric analysis, histological / cytological methods, etc. as detailed below.Determination of Biomarker Levels using Aptamer-Based Assays

[0144] Assays directed to the detection and quantification of physiologically significant molecules in biological samples and other samples are important tools in scientific research and in the health care field. One class of such assays involves the use of a microarray that includes one or more aptamers immobilized on a solid support. The aptamers are each capable of binding to a target molecule in a highly specific manner and with very high affinity. See, e.g., U. S. Patent No. 5,475,096 entitled ‘'Nucleic Acid Ligands”; see also, e.g., U. S. Patent No 6,242,246,U. S. Patent No. 6,458,543, and U. S. Patent No. 6,503,715, each of which is entitled “Nucleic Acid Ligand Diagnostic Biochip”. Once the microarray is contacted with a sample, the aptamers bind to their respective target molecules present in the sample and thereby enable a determination of a biomarker value corresponding to a biomarker.

[0145] As used herein, an “aptamer” refers to a nucleic acid that has a specific binding affinity' for a target molecule. It is recognized that affinity interactions are a matter of degree: however, in this context, the “specific binding affinity'” of an aptamer for its target means that the aptamer binds to its target generally with a much higher degree of affinity than it binds to other components in a test sample. An “aptamer” is a set of copies of one type or species of nucleic acid molecule that has a particular nucleotide sequence. An aptamer can include any suitable number of nucleotides, including any number of chemically modified nucleotides. “Aptamers” refers to more than one such set of molecules. Different aptamers can have either the same or different numbers of nucleotides. Aptamers can be DNA or RNA or chemically modified nucleic acids and can be single stranded, double stranded, or contain double stranded regions, and can include higher ordered structures. An aptamer can also be a photoaptamer, where a photoreactive or chemically reactive functional group is included in the aptamer to allow it to be covalently linked to its corresponding target. Any of the aptamer methods disclosed herein can include the use of two or more aptamers that specifically bind the same target molecule. As further described below, an aptamer may include a tag. If an aptamer includes a tag, all copies of the aptamer need not have the same tag. Moreover, if different aptamers each include a tag, these different aptamers can have either the same tag or a different tag.

[0146] An aptamer can be identified using any known method, including the SELEX process. Once identified, an aptamer can be prepared or synthesized in accordance with any known method, including chemical synthetic methods and enzymatic synthetic methods.

[0147] As used herein, a “SOMAmer” or Slow Off-Rate Modified Aptamer refers to an aptamer having improved off-rate characteristics. SOMAmers can be generated using the improved SELEX methods described in U. S. Patent No. 7,947,447, entitled “Method for Generating Aptamers with Improved Off-Rates.” In some embodiments, a slow off-rate aptamer (including an aptamers comprising at least one nucleotide with a hydrophobic modification) has an off-rate (t½) of > 20 minutes > 30 minutes, > 60 minutes, > 90 minutes, > 120 minutes, > 150 minutes, > 180 minutes, > 210 minutes, or > 240 minutes.

[0148] The terms “SELEX” and “SELEX process” are used interchangeably herein to refer generally to a combination of (1) the selection of aptamers that interact with a target molecule in a desirable manner, for example binding w ith high affinity to a protein, with (2) theamplification of those selected nucleic acids. The SELEX process can be used to identify aptamers with high affinity' to a specific target or biomarker.[00149| SELEX generally includes preparing a candidate mixture of nucleic acids, binding of the candidate mixture to the desired target molecule to form an affinity complex, separating the affinity complexes from the unbound candidate nucleic acids, separating and isolating the nucleic acid from the affinity complex, purifying the nucleic acid, and identifying a specific aptamer sequence. The process may include multiple rounds to further refine the affinity’ of the selected aptamer. The process can include amplification steps at one or more points in the process. See, e.g., U. S. Patent No. 5,475,096, entitled “Nucleic Acid Ligands”. The SELEX process can be used to generate an aptamer that covalently’ binds its target as well as an aptamer that non-covalently binds its target. See, e.g., U. S. Patent No. 5,705,337 entitled “Systematic Evolution of Nucleic Acid Ligands by Exponential Enrichment: Chemi-SELEX.”

[0150] The SELEX process can be used to identify’ high-affinity’ aptamers containing modified nucleotides that confer improved characteristics on the aptamer, such as, for example, improved in vivo stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and / or phosphate and / or base positions. SELEX process-identified aptamers containing modified nucleotides are described in U. S. Patent No. 5,660,985, entitled “High Affinity’ Nucleic Acid Ligands Containing Modified Nucleotides”, which describes oligonucleotides containing nucleotide derivatives chemically modified at the 5'- and 2’ -positions of pyrimidines. U. S. Patent No. 5,580,737, see supra, describes highly specific aptamers containing one or more nucleotides modified with 2’ -amino (2’-NH2), 2"-lluoro (2’-F), and / or 2’-O-methyl (2’-OMe). See also, U. S. Patent Application Publication 20090098549, entitled “SELEX and PHOTOSELEX”, which describes nucleic acid libraries having expanded physical and chemical properties and their use in SELEX and photoSELEX.

[0151] SELEX can also be used to identify aptamers that have desirable off-rate characteristics. See U. S. Patent Application Publication 2009 / 0004667, entitled “Method for Generating Aptamers with Improved Off-Rates”, which describes improved SELEX methods for generating aptamers that can bind to target molecules. As mentioned above, these slow off-rate aptamers are known as “SOMAmers.” Methods for producing aptamers or SOMAmers and photoaptamers or SOMAmers having slower rates of dissociation from their respective target molecules are described. The methods involve contacting the candidate mixture with the target molecule, allowing the formation of nucleic acid-target complexes to occur, and performing a slow off-rate enrichment process wherein nucleic acid-target complexes with fast dissociation rates will dissociate and not reform, while complexes with slow dissociation rates will remain intact Additionally, the methods include the use of modified nucleotides in the production ofcandidate nucleic acid mixtures to generate aptamers or SOMAmers with improved off-rate performance. Nonlimiting exemplary modified nucleotides include, for example, the modified pyrimidines shown in FIGS. 1-5.

[0152] A variation of this assay employs aptamers that include photoreactive functional groups that enable the aptamers to covalently bind or “photocrosslink” their target molecules. See, e.g., U. S. Patent No. 6,544,776 entitled “Nucleic Acid Ligand Diagnostic Biochip". These photoreactive aptamers are also referred to as photoaptamers. See, e.g., U. S. Patent No.5,763,177, U. S. Patent No. 6,001,577, and U. S. Patent No. 6,291,184, each of which is entitled “Systematic Evolution of Nucleic Acid Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution SELEX’; see also, e.g., U. S. Patent No. 6,458,539, entitled “Photoselection of Nucleic Acid Ligands". After the microarray is contacted with the sample and the photoaptamers have had an opportunity to bind to their target molecules, the photoaptamers are photoactivated, and the solid support is washed to remove any non-specifically bound molecules. Harsh wash conditions may be used, since target molecules that are bound to the photoaptamers are generally not removed, due to the covalent bonds created by the photoactivated functional group(s) on the photoaptamers. In this manner, the assay enables the detection of a biomarker value corresponding to a biomarker in the test sample.

[0153] In both of these assay formats, the aptamers or SOMAmers are immobilized on the solid support prior to being contacted with the sample. Under certain circumstances, however, immobilization of the aptamers or SOMAmers prior to contact with the sample may not provide an optimal assay. For example, pre-immobilization of the aptamers or SOMAmers may result in inefficient mixing of the aptamers or SOMAmers with the target molecules on the surface of the solid support, perhaps leading to lengthy reaction times and, therefore, extended incubation periods to permit efficient binding of the aptamers or SOMAmers to their target molecules. Further, when photoaptamers or photoSOMAmers are employed in the assay and depending upon the material utilized as a solid support, the solid support may tend to scatter or absorb the light used to effect the formation of covalent bonds between the photoaptamers or photoSOMAmers and their target molecules. Moreover, depending upon the method employed, detection of target molecules bound to their aptamers or photoSOMAmers can be subject to imprecision, since the surface of the solid support may also be exposed to and affected by any labeling agents that are used. Finally, immobilization of the aptamers or SOMAmers on the solid support generally involves an aptamer or SOMAmer-preparation step (i.e., the immobilization) prior to exposure of the aptamers or SOMAmers to the sample, and this preparation step may affect the activity or functionality of the aptamers or SOMAmers.

[0154] SOMAmer assays that permit a SOMAmer to capture its target in solution and then employ separation steps that are designed to remove specific components of the SOMAmer-target mixture prior to detection have also been described (see U. S. Patent Application Publication 20090042206, entitled “Multiplexed Analyses of Test Samples”). The described SOMAmer assay methods enable the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., a SOMAmer). The described methods create a nucleic acid surrogate (i.e, the SOMAmer) for detecting and quantifying a non-nucleic acid target, thus allowing the wide variety of nucleic acid technologies, including amplification, to be applied to a broader range of desired targets, including protein targets.

[0155] SOMAmers can be constructed to facilitate the separation of the assay components from a SOMAmer biomarker complex (or photoSOMAmer biomarker covalent complex) and permit isolation of the SOMAmer for detection and / or quantification. In some embodiments, these constructs can include a cleavable or releasable element within the SOMAmer sequence. In other embodiments, additional functionality can be introduced into the SOMAmer, for example, a labeled or detectable component, a spacer component, or a specific binding tag or immobilization element. For example, the SOMAmer can include a tag connected to the SOMAmer via a cleavable moiety, a label, a spacer component separating the label, and the cleavable moiety. In one embodiment, a cleavable element is a photocl eav able linker. The photocleavable linker can be attached to a biotin moiety and a spacer section, can include an NHS group for derivatization of amines, and can be used to introduce a biotin group to an aptamer, thereby allowing for the release of the aptamer later in an assay method.

[0156] Homogenous assays, done with all assay components in solution, do not require separation of sample and reagents prior to the detection of signal. These methods are rapid and easy to use. These methods generate signal based on a molecular capture or binding reagent that reacts with its specific target. For predicting an individual’s risk of prostate cancer, the molecular capture reagents would be an aptamer or an antibody or the like and the specific target would be one or more of the biomarkers in Table 1.

[0157] In some embodiments, a method for signal generation takes advantage of anisotropy signal change due to the interaction of a fluorophore-labeled capture reagent with its specific biomarker target When the labeled capture reagent reacts with its target, the increased molecular weight causes the rotational motion of the fluorophore attached to the complex to become much slower changing the anisotropy value. By monitoring the anisotropy change, binding events may be used to quantitatively measure the biomarkers in solutions. Other methods include fluorescence polarization assays, molecular beacon methods, time resolvedfluorescence quenching, chemiluminescence, fluorescence resonance energy transfer, and the like.[00158| An exemplary solution-based aptamer assay that can be used to detect a biomarker value corresponding to a biomarker in a biological sample includes the following: (a) preparing a mixture by contacting the biological sample wi th an aptamer that includes a first tag and has a specific affinity for the biomarker, wherein an aptamer affinity complex is formed when the biomarker is present in the sample; (b) exposing the mixture to a first solid support including a first capture element, and allowing the first tag to associate with the first capture element; (c) removing any components of the mixture not associated with the first solid support; (d) attaching a second tag to the biomarker component of the aptamer affinity complex; (e) releasing the aptamer affinity complex from the first solid support; (f) exposing the released aptamer affinity complex to a second solid support that includes a second capture element and allowing the second tag to associate with the second capture element; (g) removing any non¬ complexed aptamer from the mixture by partitioning the non-complexed aptamer from the aptamer affinity complex, (h) eluting the aptamer from the solid support; and (i) detecting the biomarker by detecting the aptamer component of the aptamer affinity complex,

[0159] Any means known in the art can be used to detect a biomarker value by detecting the aptamer component of an aptamer affinity complex. A number of different detection methods can be used to detect the aptamer component of an affinity complex, such as, for example, hybridization assays, mass spectroscopy, or QPCR. In some embodiments, nucleic acid sequencing methods can be used to detect the aptamer component of an aptamer affinity complex and thereby detect a biomarker value. Briefly, a test sample can be subjected to any kind of nucleic acid sequencing method to identify and quantify the sequence or sequences of one or more aptamers present in the test sample. In some embodiments, the sequence includes the entire aptamer molecule or any portion of the molecule that may be used to uniquely identity the molecule. In other embodiments, the identifying sequencing is a specific sequence added to the aptamer; such sequences are often referred to as “tags,” “barcodes,” or “zipcodes.” In some embodiments, the sequencing method includes enzymatic steps to amplify’ the aptamer sequence or to convert any kind of nucleic acid, including RNA and DNA that contain chemical modifications to any position, to any other kind of nucleic acid appropriate for sequencing

[0160] In some embodiments, the sequencing method includes one or more cloning steps In other embodiments the sequencing method includes a direct sequencing method without cloning.

[0161] In some embodiments, the sequencing method includes a directed approach with specific primers that target one or more aptamer in the test sample. In other embodiments, the sequencing method includes a shotgun approach that targets all aptamer in the test sample

[0162] In some embodiments, the sequencing method includes enzymatic steps to amplify the molecule targeted for sequencing. In other embodiments, the sequencing method directly sequences single molecules. An exemplary nucleic acid sequencing-based method that can be used to detect a biomarker value corresponding to a biomarker in a biological sample includes the following: (a) converting a mixture of aptamers that contain chemically modified nucleotides to unmodified nucleic acids with an enzymatic step; (b) shotgun sequencing the resulting unmodified nucleic acids with a massively parallel sequencing platform such as, for example, the 454 Sequencing System (454 Life Sciences / Roche), the Illumina Sequencing System (Illumina), the ABI SOLiD Sequencing System (Applied Biosystems), the Heli Scope Single Molecule Sequencer (Helicos Biosciences), or the Pacific Biosciences Real Time Single¬ Molecule Sequencing System (Pacific BioSciences) or the Polonator G. Sequencing System (Dover Systems); and (c) identifying and quantifying the SOMAmers present in the mixture by specific sequence and sequence count.Determination of Biomarker Values using Immunoassays

[0163] Immunoassay methods are based on the reaction of an antibody to its corresponding target or analyte and can detect the analyte in a sample depending on the specific assay format. To improve specificity and sensitivity of an assay method based on immuno-reactivity, monoclonal antibodies are often used because of their specific epitope recognition. Polyclonal antibodies have also been successfully used in various immunoassays because of their increased affinity for the target as compared to monoclonal antibodies. Immunoassays have been designed for use with a wide range of biological sample matrices Immunoassay formats have been designed to provide qualitative, semi-quantitative, and quantitative results.

[0164] Quantitative results are generated through the use of a standard curve created with known concentrations of the specific analyte to be detected. The response or signal from an unknown sample is plotted onto the standard curve, and a quantity or value corresponding to the target in the unknown sample is established.

[0165] Numerous immunoassay formats have been designed. ELISA or El A can be quantitative for the detection of an analyte. This method relies on attachment of a label to either the analyte or the antibody and the label component includes, either directly or indirectly, an enzyme. ELISA tests may be formatted for direct, indirect, competitive, or sandwich detection of the analy te. Other methods rely on labels such as, for example, radioisotopes (I125) or fluorescence. Additional techniques include, for example, agglutination, nephelometry’, turbidimetry. Western blot, immunoprecipitation, immunocytochemistry,immunohistochemistry, flow cytometry, Luminex assay, and others (see ImmunoAssay: A Practical Guide, edited by Brian Law, published by Taylor & Francis, Ltd., 2005 edition).[00166| Exemplary assay formats include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, fluorescent, chemiluminescence, and fluorescence resonance energy transfer (FRET) or time resolved-FRET (TR-FRET) immunoassays Examples of procedures for detecting biomarkers include biomarker immunoprecipitation followed by quantitative methods that allow size and peptide level discrimination, such as gel electrophoresis, capillary electrophoresis, planar electrochromatography, and the like.

[0167] Methods of detecting and / or quantifying a detectable label or signal generating material depend on the nature of the label. The products of reactions catalyzed by appropriate enzymes (where the detectable label is an enzyme; see above) can be, without limitation, fluorescent, luminescent, or radioactive or they may absorb visible or ultraviolet light. Examples of detectors suitable for detecting such detectable labels include, without limitation, x-ray film, radioactivity counters, scintillation counters, spectrophotometers, colorimeters, fluorometers, luminometers, and densitometers.

[0168] Any of the methods for detection can be performed in any format that allows for any suitable preparation, processing, and analysis of the reactions. This can be, for example, in multi-well assay plates (e.g., 96 wells or 384 wells) or using any suitable array or microarray. Stock solutions for various agents can be made manually or robotically, and all subsequent pipetting, diluting, mixing, distribution, washing, incubating, sample readout, data collection and analysis can be done robotically using commercially available analysis software, robotics, and detection instrumentation capable of detecting a detectable labelDetermination of Biomarker Values using Gene Expression Profiling

[0169] Measuring mRNA in a biological sample may be used as a surrogate for detection of the level of the corresponding protein in the biological sample. Thus, any of the biomarkers or biomarker panels described herein can also be detected by detecting the appropriate RNA.

[0170] mRNA expression levels are measured by reverse transcription quantitative polymerase chain reaction (RT-PCR followed with qPCR) RT-PCR is used to create a cDNA from the mRNA. The cDNA may be used m a qPCR assay to produce fluorescence as the DNA amplification process progresses. By comparison to a standard curve, qPCR can produce an absolute measurement such as number of copies of mRNA per cell. Northern blots, microarrays. Invader assays, and RT-PCR combined with capillary’ electrophoresis have all been used to measure expression levels of mRNA in a sample. See Gene Expression Profiling: Methods and Protocols, Richard A. Shimkets, editor, Humana Press, 2004.

[0171] miRNA molecules are small RNAs that are non-coding but may regulate gene expression. Any of the methods suited to the measurement of mRNA expression levels can also be used for the corresponding miRNA. Recently many laboratories have investigated the use of miRNAs as biomarkers for disease. Many diseases involve wide-spread transcriptional regulation, and it is not surprising that miRNAs might find a role as biomarkers. The connection between miRNA concentrations and disease is often even less clear than the connections between protein levels and disease, yet the value of miRNA biomarkers might be substantial. Of course, as with any RNA expressed differentially during disease, the problems facing the development of an in vitro diagnostic product will include the requirement that the miRNAs survive in the diseased cell and are easily extracted for analysis, or that the miRNAs are released into blood or other matrices where they must survive long enough to be measured. Protein biomarkers have similar requirements, although many potential protein biomarkers are secreted intentionally at the site of pathology and function, during disease, in a paracrine fashion Many potential protein biomarkers are designed to function outside the cells within which those proteins are synthesized.Detection of Biomarkers Using In Vivo Molecular Imaging Technologies

[0172] Any of the described biomarkers (see, e.g., Table 1) may also be used in molecular imaging tests. For example, an imaging agent can be coupled to any of the described biomarkers, which can be used to aid in assessing an individual's risk of prostate cancer, to monitor response to therapeutic interventions, to select a population for clinical trials among other uses.

[0173] In vivo imaging technologies provide non-invasive methods for determining the state of a particular disease or condition in the body of an individual. For example, entire portions of the body, or even the entire body, may be viewed as a three-dimensional image, thereby providing valuable information concerning morphology and structures in the body Such technologies may be combined with the detection of the biomarkers described herein to provide information concerning predicting an individual’s risk of prostate cancer.

[0174] The use of in vivo molecular imaging technologies is expanding due to various advances m technology. These advances include the development of new contrast agents or labels, such as radiolabels and / or fluorescent labels, which can provide strong signals within the body; and the development of powerful new imaging technology, which can detect and analyze these signals from outside the body, with sufficient sensitivity’ and accuracy to provide useful information. The contrast agent can be visualized in an appropriate imaging system, thereby providing an image of the portion or portions of the body in which the contrast agent is located.The contrast agent may be bound to or associated with a capture reagent, such as an aptamer or an antibody, for example, and / or with a peptide or protein, or an oligonucleotide (for example, for the detection of gene expression), or a complex containing any of these with one or more macromolecules and / or other particulate forms.

[0175] The contrast agent may also feature a radioactive atom that is useful in imaging. Suitable radioactive atoms include technetium-99m or iodine-123 for scintigraphic studies Other readily detectable moieties include, for example, spin labels for magnetic resonance imaging (MRI) such as, for example, iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron. Such labels are well known in the art and could easily be selected by one of ordinary skill in the art

[0176] Standard imaging techniques include but are not limited to magnetic resonance imaging, computed tomography scanning (coronary calcium score), positron emission tomography (PET), single photon emission computed tomography (SPECT), computed tomography angiography, and the like. For diagnostic in vivo imaging, the type of detection instrument available is a major factor in selecting a given contrast agent, such as a given radionuclide and the particular biomarker that it is used to target (protein, mRNA, and the like). The radionuclide chosen typically has a type of decay that is detectable by a given type of instrument. Also, when selecting a radionuclide for in vivo diagnosis, its half-life should be long enough to enable detection at the time of maximum uptake by the target tissue but short enough that deleterious radiation of the host is minimized.

[0177] Exemplary imaging techniques include but are not limited to PET and SPECT, which are imaging techniques in which a radionuclide is synthetically or locally administered to an individual. The subsequent uptake of the radiotracer is measured over time and used to obtain information about the targeted tissue and the biomarker. Because of the high-energy (gamma-ray) emissions of the specific isotopes employed and the sensitivity and sophistication of the instruments used to detect them, the two-dimensional distribution of radioactivity may be inferred from outside of the body.

[0178] Commonly used positron-emitting nuclides in PET include, for example, carbon-11, nitrogen-13, oxygen- 15, and fluorine- 18. Isotopes that decay by electron capture and / or gamma-emission are used in SPECT and include, for example iodine-123 and technetium-99m. An exemplary method for labeling amino acids with technetium-99m is the reduction of pertechnetate ion in the presence of a chelating precursor to form the labile technetium-99m-precursor complex, which, in turn, reacts with the metal binding group of a bifunctionally modified chemotactic peptide to form a technetium-99m-chemotactic peptide conjugate.

[0179] Antibodies are frequently used for such in vivo imaging diagnostic methods. The preparation and use of antibodies for in vivo diagnosis is well known in the art. Labeled antibodies which specifically bind any of the biomarkers in Table 1 can be injected into an individual, detectable according to the particular biomarker used, for the purpose of diagnosing or evaluating the disease status or condition of the individual. The label used will be selected in accordance with the imaging modality to be used, as previously described. Localization of the label permits determination of the tissue damage or other indications related to an individual's risk of prostate cancer. The amount of label within an organ or tissue also allows determination of the involvement of the biomarkers predicting an individual’s risk of prostate cancer

[0180] Similarly, aptamers may be used for such in vivo imaging diagnostic methods. For example, an aptamer that was used to identify a particular biomarker described in Table 1 (and therefore binds specifically to that particular biomarker) may be appropriately labeled and injected into an individual being evaluated for determination of an individual’s risk of prostate cancer, detectable according to the particular biomarker, for the purpose of diagnosing or evaluating the levels of tissue damage, components of inflammatory response, and other factors associated with the risk of prostate cancer in the individual. The label used will be selected in accordance with the imaging modality to be used, as previously described. Localization of the label permits determination of the site of the processes leading to increased risk. The amount of label within an organ or tissue also allows determination of the infiltration of the pathological process in that organ or tissue. Aptamer-directed imaging agents could have unique and advantageous characteristics relating to tissue penetration, tissue distribution, kinetics, elimination, potency, and selectivity as compared to other imaging agents.

[0181] Such techniques may also optionally be performed with labeled oligonucleotides, for example, for detection of gene expression through imaging with antisense oligonucleotides. These methods are used for in situ hybridization, for example, with fluorescent molecules or radionuclides as the label. Other methods for detection of gene expression include, for example, detection of the activity of a reporter gene.

[0182] Another general type of imaging technology is optical imaging, in which fluorescent signals within the subject are detected by an optical device that is external to the subject. These signals may be due to actual fluorescence and / or to bioluminescence. Improvements in the sensitivity of optical detection devices have increased the usefulness of optical imaging for in vivo diagnostic assays.

[0183] The use of in vivo molecular biomarker imaging is increasing, including for clinical trials, for example, to more rapidly measure clinical efficacy in trials for new disease or condition therapies and / or to avoid prolonged treatment with a placebo for those diseases, suchas multiple sclerosis, in which such prolonged treatment may be considered to be ethically questionable.[00184| For a review of other techniques, see N. Blow, Nature Methods, 6. 465-469. 2009. Determination of Biomarker Values using Mass Spectrometiy Methods

[0185] A variety of configurations of mass spectrometers can be used to detect biomarker values. Several types of mass spectrometers are available or can be produced wi th various configurations. In general, a mass spectrometer has the following major components: a sample inlet, an ion source, a mass analyzer, a detector, a vacuum system, and instrument-control system, and a data system. Difference in the sample inlet, ion source, and mass analyzer generally define the type of instrument and its capabilities. For example, an inlet can be a capillary-column liquid chromatography source or can be a direct probe or stage such as used m matrix-assisted laser desorption. Common ion sources are, for example, electrospray, including nanospray and microspray or matrix-assisted laser desorption. Common mass analyzers include a quadrupole mass filter, ion trap mass analyzer and time-of-flight mass analyzer. Additional mass spectrometry methods are well known in the art (see Burlingame et al. Anal. Chem. 70:647 R-716R ( 1998); Kinter and Sherman, New York (2000)).

[0186] Protein biomarkers and biomarker values can be detected and measured by any of the following: electrospray ionization mass spectrometry (ESI-MS), ESI-MS / MS, ESI-MS / (MS)n, matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS), surface-enhanced laser desorption / ionization time-of-flight mass spectrometry (SELDI-TOF-MS), desorption / ionization on silicon (DIOS), secondary ion mass spectrometry (SIMS), quadrupole time-of-flight (Q-TOF), tandem time-of-flight (TOF / TOF) technology, called ultraflex III TOF / TOF. atmospheric pressure chemical ionization mass spectrometry (APCI- MS). APCI-MS / MS. APCI-(MS)N, atmospheric pressure photoionization mass spectrometry (APPI-MS), APPI-MS / MS, and APPI-(MS)N, quadrupole mass spectrometry, Fourier transform mass spectrometry (FTMS), quantitative mass spectrometry, and ion trap mass spectrometry.

[0187] Sample preparation strategies are used to label and enrich samples before mass spectroscopic characterization of protein biomarkers and determination biomarker values.Labeling methods include but are not limited to isobaric tag for relative and absolute quantitation (iTRAQ) and stable isotope labeling with amino acids in cell culture (SILAC). Capture reagents used to selectively enrich samples for candidate biomarker proteins prior to mass spectroscopic analysis include but are not limited to aptamers, antibodies, nucleic acid probes, chimeras, small molecules, an F(ab’)2 fragment, a single chain antibody fragment, an Fv fragment, a single chain Fv fragment, a nucleic acid, a lectin, a ligand-binding receptor.affybodies, nanobodies, ankyrins, domain antibodies, alternative antibody scaffolds (e.g. diabodies etc) imprinted polymers, avimers, peptidomimetics, peptoids, peptide nucleic acids, threose nucleic acid, a hormone receptor, a cytokine receptor, and synthetic receptors, and modifications and fragments of these.Determination of Biomarker Values using a Proximity Ligation Assay

[0188] A proximity ligation assay can be used to determine biomarker values. Briefly, a test sample is contacted with a pair of affinity probes that may be a pair of antibodies or a pair of aptamers, with each member of the pair extended with an oligonucleotide. The targets for the pair of affinity probes may be two distinct determinates on one protein or one determinate on each of two different proteins, which may exist as homo- or hetero-multimeric complexes. When probes bind to the target determinates, the free ends of the oligonucleotide extensions are brought into sufficiently close proximity to hybridize together. The hybridization of the oligonucleotide extensions is facilitated by a common connector oligonucleotide which serves to bridge together the oligonucleotide extensions when they are positioned in sufficient proximity. Once the oligonucleotide extensions of the probes are hybridized, the ends of the extensions are joined together by enzymatic DNA ligation.

[0189] Each oligonucleotide extension comprises a primer site for PCR amplification. Once the oligonucleotide extensions are ligated together, the oligonucleotides form a continuous DNA sequence which, through PCR amplification, reveals information regarding the identity and amount of the target protein, as well as information regarding protein-protein interactions where the target determinates are on two different proteins. Proximity ligation can provide a highly sensitive and specific assay for real-time protein concentration and interaction information through use of real-time PCR. Probes that do not bind the determinates of interest do not have the corresponding oligonucleotide extensions brought into proximity and no ligation or PCR amplification can proceed, resulting in no signal being produced.

[0190] The foregoing assays enable the detection of biomarker levels that are useful in methods for predicting the risk of prostate cancer in an individual, where the methods comprise detecting, in a biological sample from an individual, biomarker levels that each correspond to a biomarker selected from the group of the biomarkers provided m Table 1, wherein a classification, as described in detail below, using the biomarker levels indicates the individual’s risk of prostate cancer. While certain of the described biomarkers are useful alone for determining a risk of prostate cancer in an individual, methods are also described herein for the grouping of multiple subsets of the biomarkers that are each useful as a panel of two or more biomarkers. In accordance with any of the methods described herein, biomarker levels can bedetected and classified individually or they can be detected and classified collectively, as for example in a multiplex assay format.Classification of Biomarkers and Calculation of Disease Scores[001911 In some embodiments, biomarker “signature” for a given diagnostic or predictive test contains a set of markers, each marker having different levels in the populations of interest. Different levels, in this context, may refer to different means of the marker levels for the individuals in two or more groups, or different variances in the two or more groups, or a combination of both. For the simplest form of a diagnostic test, these markers can be used to assign an unknown sample from an individual into one of two groups, such as having or not having a risk of prostate cancer. The assignment of a sample into one of two or more groups is known as classification, and the procedure used to accomplish this assignment is known as a classifier or a classification method. Classification methods may also be referred to as scoring methods. There are many classification methods that can be used to construct a diagnostic classifier from a set of biomarker values. In general, classification methods are most easily performed using supervised learning techniques where a data set is collected using samples obtained from individuals within two (or more, for multiple classification states) distinct groups one wishes to distinguish. Since the class (group or population) to which each sample belongs is known in advance for each sample, the classification method can be trained to give the desired classification response. It is also possible to use unsupervised learning techniques to produce a diagnostic classifier.

[0192] Common approaches for developing diagnostic classifiers include decision trees; bagging, boosting, forests and random forests; rule inference based learning; Parzen Windows; linear models; logistic; neural network methods; unsupervised clustering; K-means; hierarchical ascending / descending: semi-supervised learning; prototype methods; nearest neighbor; kernel density estimation; support vector machines; hidden Markov models; Boltzmann Learning; and classifiers may be combined either simply or in ways which minimize particular objective functions. For a review, see, e.g., Pattern Classification, R. O. Duda, et al., editors, John Wiley & Sons. 2nd edition, 2001; see also, The Elements of Statistical Learning - Data Mining, Inference, and Prediction, T. Hastie, et al., editors, Springer Science+Business Media, LLC, 2nd edition, 2009; each of which is incorporated by reference in its entirety.

[0193] To produce a classifier using supervised learning techniques, a set of samples called training data are obtained. In the context of diagnostic tests, training data includes samples from the distinct groups (classes) to which unknown samples will later be assigned. For example, samples collected from individuals in a control population and individuals in a particulardisease, condition or event population, such as individuals having a risk of prostate cancer, can constitute training data to develop a classifier that can classify unknown samples (or. more particularly, the individuals from whom the samples were obtained) as either having a risk of prostate cancer or healthy The development of the classifier from the training data is known as training the classifier. Specific details on classifier training depend on the nature of the supervised learning technique (see, e.g., Pattern Classification, R. O. Duda, et al., editors. John Wiley & Sons, 2nd edition, 2001; see also, The Elements of Statistical Learning - Data Mining, Inference, and Prediction, T. Hastie, et al., editors, Springer Science+Business Media, LLC, 2nd edition, 2009).

[0194] Since typically there are many more potential biomarker values than samples in a training set, care must be used to avoid over-fitting. Over-fitting occurs when a statistical model describes random error or noise instead of the underlying relationship. Over-fitting can be avoided in a variety of ways, including, for example, by limiting the number of markers used in developing the classifier, by assuming that the marker responses are independent of one another, by limiting the complexity of the underlying statistical model employed, and by ensuring that the underlying statistical model conforms to the data.

[0195] In order to identify a set of biomarkers associated with occurrence of events, the combined set of control and early event samples were analyzed using Principal Component Analysis (PCA), PCA displays the samples with respect to the axes defined by the strongest variations between all the samples, without regard to the case or control outcome, thus mitigating the risk of overfitting the distinction between case and control. Since the occurrence of serious thrombotic events has a strong component of chance involved, requiring unstable plaque to rupture in vital vessels to be reported, one would not expect to see a clear separation between the control and event sample sets. While the observed separation between case and control is not large, it occurs on the second principal component, corresponding to around 10% of the total variation in this set of samples, which indicates that the underlying biological variation is relatively simple to quantify.

[0196] In the next set of analyses, biomarkers can be analyzed for those components of difference between samples which were specific to the separation between the control samples and early event samples. One method that may be employed is the use of DSGA (Bair, E. and Tibshirani. R. (2004) Semi-supervised methods to predict patient survival from gene expression data. FLOS Biol., 2, 511-522) to remove (deflate) the first three principal component directions of variation between the samples in the control set. Although the dimensionality reduction is performed on the control set to discover, both the samples in the control and the samples fromthe early event samples are run through the PCA. Separation of cases from early events can be observed along the horizontal axis.Cross Validated Selection of Proteins Relevant to the Prediction of Risk of Prostate Cancer

[0197] In order to avoid over-fitting of protein predictive power to idiosyncratic features of a particular selection of samples, a cross-validation and dimensional reduction approach can be taken. Cross-validation involves the multiple selection of sets of samples to determine the association of risk by protein combined with the use of the unselected samples to monitor the ability of the method to apply to samples which were not used in producing the model of risk (The Elements of Statistical Learning - Data Mining, Inference, and Prediction, T. Hastie, et al., editors. Springer Science+Business Media, LLC, 2nd edition, 2009). We applied the supervised PCA method of Tibshirani et al (Bair, E. and Tibshirani, R. (2004) Semi-supervised methods to predict patient survival from gene expression data. PLOS Biol., 2, 511-522.) which is applicable to high dimensional datasets in the modeling of the prediction of an individual’s risk of prostate cancer. The supervised PCA (SPCA) method involves the univariate selection of a set of proteins statistically associated with the observed event hazard in the data and the determination of the correlated component which combines information from all of these proteins. This determination of the correlated component is a dimensionality reduction step which not only combines information across proteins, but also mitigates the likelihood of overfitting by reducing the number of independent variables from the full protein menu of over 1000 proteins down to a few principal components (in this work, we only examined the first principal component).Univariate analysis and multivariate analysis of the relationship of individual proteins to time to event

[0198] The Cox proportional hazard model (Cox, David R (1972). " Regression Models and Life-Tables". Journal of the Royal Statistical Society. Series B (Methodological) 34 (2): 187— 220.)) is widely used in medical statistics. Cox regression avoids fitting a specific function of time to the cumulative survival, and instead employs a model of relative risk referred to a baseline hazard function (which may vary with time). The baseline hazard function describes the common shape of the survival time distribution for all individuals, while the relative risk gives the level of the hazard for a set of covariate values (such as a single individual or group), as a multiple of the baseline hazard. I’he relative risk is constant with time in the Cox model.

[0199] Accelerated failure time (AFT) models are a sub-class of survival models. Survival models predict time-to-event data under partial information. For example, in the data for the prostate cancer risk model, the event is prostate cancer diagnosis, but time-to-diagnosis event data is available for a fraction of the subjects m the study. For the rest of the subjects, theavailable information is that the subjects were not diagnosed with prostate cancer from the time of the blood draw up to the end of the study. This second category is partial information, called ''censoring ”, because it is uncertain if or when they would ever be diagnosed with prostate cancer.

[0200] Because survival models account for censoring, they can still use the data from those censored subjects, where other longitudinal models trying to predict when an event occurs can only use the information from subjects with prostate cancer diagnoses. And because survival models take into account time-to-event, they can produce predicted probabilities of the event occurring within any time frame, which is different from most classification models (logistic regression, random forest).

[0201] AFT survival models in particular are a regression model which specifies / assumes a linear relationship between the model’s covariates and log( time-to-event). So, a subject with 2x higher covariates (protein RFU counts) than baseline may be predicted to “survive” a prostate cancer diagnosis 2x longer than baseline.

[0202] The two most common survival models are AFT models and proportional hazards models, and an AFT Weibull model is both. The definition of a proportional hazards model is a little more complicated than that of an AFT model - m a proportional hazards model, a subject with 2x higher covariates than baseline may have a 2x higher hazard at any time point, where hazard is the negative derivative of the survival curve over time.

[0203] Other common proportional hazards models are exponential and Cox models.Exponential models are a sub-type of Weibull model. Cox models are more limited in use - predicted probabilities of time-to-event are not available from Cox models, only relative risk AFT models can give both absolute and relative risk.Kits

[0204] Any combination of the biomarkers of Table 1 can be detected using a suitable kit, such as for use in performing the methods disclosed herein. Furthermore, any kit can contain one or more detectable labels as described herein, such as a fluorescent moiety, etc.

[0205] In one embodiment, a kit includes (a) one or more capture reagents (such as. for example, at least one aptamer or antibody) for detecting one or more biomarkers m a biological sample, wherein the biomarkers include any of the biomarkers set forth in Table 1 and optionally (b) one or more software or computer program products for classifying the individual from whom the biological sample was obtained as either having or not having a risk of prostate cancer, as further described herein. Alternatively, rather than one or more computer programproducts, one or more instructions for manually performing the above steps by a human can be provided.

[0206] The combination of a solid support with a corresponding capture reagent having a signal generating material is referred to herein as a ‘‘detection device” or ‘‘kit” The kit can also include instructions for using the devices and reagents, handling the sample, and analyzing the data. Further the kit may be used with a computer system or software to analyze and report the result of the analysis of the biological sample.

[0207] The kits can also contain one or more reagents (e.g., solubilization buffers, detergents, washes, or buffers) for processing a biological sample. Any of the kits described herein can also include, e.g., buffers, blocking agents, mass spectrometry matrix materials, antibody capture agents, positive control samples, negative control samples, software and information such as protocols, guidance and reference data.

[0208] In one aspect, the invention provides kits for the assessment of an individual’s risk of prostate cancer. The kits include PCR primers for one or more aptamers specific to biomarkers selected from Table 1. The kit may further include instructions for use and correlation of the biomarkers with prediction of an individual’s risk of prostate cancer, Tire kit may also include a DNA array containing the complement of one or more of the aptamers specific for the biomarkers selected from Table 1, reagents, and / or enzymes for amplifying or isolating sample DNA, The kits may include reagents for real-time PCR, for example, TaqMan probes and / or primers, and enzymes.

[0209] For example, a kit can comprise (a) reagents comprising at least one capture reagent for quantifying one or more biomarkers in a test sample, wherein said biomarkers comprise the biomarkers set forth in Table 1, or any other biomarkers or biomarkers panels described herein or elsewhere, and optionally (b) one or more algorithms or computer programs for performing the steps of comparing the amount of each biomarker quantified in the test sample to one or more predetermined cutoffs and assigning a score for each biomarker quantified based on said comparison, combining the assigned scores for each biomarker quantified to obtain a total score, comparing the total score with a predetermined score, and using said comparison to determine an individual’s risk of prostate cancer. Alternatively, rather than one or more algorithms or computer programs, one or more instructions for manually performing the above steps by a human can be provided.

[0210] In one aspect a kit comprising N biomarker protein capture reagents is provided, wherein N is at least 1. at least 2, at least 3, at least 4, at least 5. at least 6, at least 7, at least 8, at least 9, or at least 10, and wherein at least 1. at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 of the N biomarker protein capture reagentsspecifically binds to a biomarker protein selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN, In some aspects, 1, 2, 3, or 4 of the capture reagents bind to PSA and each of the remaining capture reagents binds to a different protein selected from IDE, T106B, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN. In some aspects, N is 2 to 13, or N is 3 to 13, or N is 4 to 1, or N is 5 to 13, or N is 6 to 13, or N is 7 to 13, or N is 8 to 13, or N is 9 to 13, or N is 10 to 13, or N is 11 to 13, or N is 12 to 13, for example, N is 2, N is 3, N is 4. N is 5, N is 6, N is 7, N is 8. N is 9, N is 10. N is 11, N is 12, or N is 13. In some aspects, each of the N biomarker protein capture reagents specifically binds to a biomarker protein selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD. Tetranectin, and PTN. In further aspects, the N biomarker protein capture reagent specifically bind to the N biomarker proteins described herein.

[0211] In another aspect, the disclosure provides a kit comprising N biomarker protein capture reagents, wherein the kit comprises biomarker protein capture reagents for carrying out the methods described herein. In some aspects, each of the N biomarker protein capture reagents is an antibody or an aptamer. For example, each biomarker protein capture reagent is an aptamer, including, e.g,, at least one aptamer is a slow off-rate aptamer. In some aspects, at least one slow off-rate aptamer comprises at least one. at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 nucleotides with modifications. The aspects further may include wherein each slow off-rate aptamer binds to its target protein with an off rate (t½) of > 20 minutes. > 30 minutes, > 60 minutes, > 90 minutes, > 120 minutes, > 150 minutes. > 180 minutes, > 210 minutes, or > 240 minutes.

[0212] In some aspects, the kit is for use in detecting the N biomarker proteins in a sample from a subject. In further aspects, the kit is for use in predicting an individual’s risk of prostate cancer.Biomarker Panels

[0213] In some embodiments, one or more of the biomarkers listed in Table 1 are detected. In some embodiments, one, two, three, four, five, six, seven, eight, nine, or ten of the biomarkers listed in Table 1 are detected. In some embodiments, all of the biomarkers listed m Table 1 are detected. In some embodiments, the level of each protein listed in Table I is detected. In some embodiments, the detecting of the one, two, three, four, five, six, seven, eight, nine, or all of the biomarkers is performed in order to determine an individual’s risk of prostate cancer. In some embodiments, the detecting of the one, two, three, four, five, six, seven, eight, nine, or all of the biomarkers is performed in order to determine the individual "s risk of prostate cancer within a defined time period. In some such embodiments, the defined time period is 1. 2, 3, 4, 5, 6, 7, 8, 9, or 10 years In some such embodiments, the defined time period is 5 years.Table 1. Analytes included in the selected prostate cancer risk prediction modelUniprot EntrezProtein Target Protein Target Full Name ID / GenBank ID GeneSymbolP14735 (2008- II >1 IDE: Insulin-degrading enzyme11-25 v4) / AAA52712.1Q9NUM4 TMEM106B T106B Transmembrane protein 106B(2006-06-27 v2) / BAA92099.1P07288 (1989- KLK3 PSA Prostate-specific antigen07-01 v2) / AAA59996.1Q4KMG0 CDON CDON Cell adhesion molecule-related / down- (2010-10-05 v2) / regulated by oncogenesAAC34901.2Q99259 (1996- GAD1 DCE1 Glutamate decarboxylase 102-01 vl) / AAA62368.1Q1L6U9 (2006- MSMP PSMP Prostate-associated microseminoprotein 05-30 vl) / AAY68208.1094813 (1999- SLIT2 SLIT2 Slit homolog 2 protein05-01 vl) / BAA35185.1PO4179 (2017- SOD2 Mn SOD Superoxide dismutase [Mn], mitochondrial 12-20 v3) / CAA42066.1P05452 (2011- CLEC3B Tetranectin Tetranectin01-11 v3) / CAA45860.1P21246 (1991- PTN PTN Pleiotrophin05-01 vl) / BAA14261.1

[0214] Protein sequences are incorporated by reference from the Uniprot / GenBank ID’s listed in the Tables herein, as one skilled in the art is able to find such sequences.

[0215] In some embodiments, at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8. at least 9, or 10 of the biomarker proteins selected from IDE, T106B, PSA, CDON. DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN are detected. In some embodiments, IDE is detected. In some embodiments, IDE and at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN are detected. In some embodiments, T106B is detected. In some embodiments. T106B and at least at least 1, at least 2. at least 3. at least 4, at least 5, at least 6. at least 7. at least 8, or 9 of the biomarker proteins selected from IDE. PSA, CDON. DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN are detected. In some embodiments, PSA is detected. In some embodiments, PSA and at least 1, at least 2, at least 3. at least 4, at least 5, at least 6, at least 7. at least 8, at least 9, or 10 of the biomarker proteins selected from IDE. T106B, CDON, DCE1, PSMP. SLIT2. Mn SOD,Tetranectin, and PTN are detected. In some embodiments, CDON is detected. In some embodiments, CDON and at least 1, at least 2, at least 3. at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from IDE. T106B. PSA. DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN are detected. In some embodiments, DCE1 is detected. In some embodiments, DCEI and at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from IDE, T106B. PSA, CDON, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN are detected, in some embodiments. PSMP is detected. In some embodiments, PSMP and at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected IDE, T106B, PSA, CDON, DCEI, SLIT2, Mn SOD, Tetranectin, and PTN are detected. In some embodiments, SLIT2 is detected. In some embodiments, SLIT2 and at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from IDE, T106B. PSA CDON. DCEi. PSMP, Mn SOD, Tetranectin, and PTN are detected. In some embodiments, Mn SOD is detected. In some embodiments, Mn SOD and at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from IDE, T106B, PSA, CDON, DCEI, PSMP, SLIT2, Tetranectin, and PTN are detected. In some embodiments, Tetranectin is detected. In some embodiments. Tetranectin and at least 1, at least 2, at least 3, at least 4, at least 5. at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from IDE, T106B, PSA, CDON, DCEI, PSMP, SLIT2, Mn SOD, and PTN are detected. In some embodiments, PTN is detected. In some embodiments, P TN and at least I, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from IDE, T106B. PSA, CDON, DCEI, PSMP, SLIT2, Mn SOD, and Tetranectin are detected In any of the embodiments described herein, 1, 2, 3, or 4 N biomarker protein capture reagents may specifically bind to PSA and be detected. Any of the embodiments described herein may be for use in predicting an individual’s risk of prostate cancer.

[0216] In some embodiments, kits comprise N biomarker protein capture reagents that specifically bind to at least I, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or 10 of the biomarker proteins selected from IDE, T106B, PSA, CDON, DCEI, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN. In some embodiments, kits comprise N biomarker protein capture reagents that specifically bind to IDE and at least 1, at least 2, at least 3. at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from T106B, PSA, CDON, DCEI, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN. In some embodiments, kits comprise N biomarker protein capture reagents that specifically bind to T106B and at least 1, at least 2. at least 3, at least 4, at least 5, at least 6, at least 7. at least 8. or 9 of the biomarker proteins selected from IDE, PSA, CDON, DCEI, PSMP, SLIT2, Mn SOD,Tetranectin, and PTN. In some embodiments, kits comprise N biomarker protein capture reagents that specifically bind to PSA and at least 1, at least 2, at least 3, at least 4, at least 5, at least 6. at least 7. at least 8, or 9 of the biomarker proteins selected from IDE, T106B, CDON, DCE1, PSMP, SLIT2. Mn SOD, Tetranectin, and PTN. In some embodiments, kits comprise N biomarker protein capture reagents that specifically bind to CDON and at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8. or 9 of the biomarker proteins selected from IDE, T106B, PSA, DCE1, PSMP. SLIT2. Mn SOD, Tetranectin, and PTN. In some embodiments, kits comprise N biomarker protein capture reagents that specifically bind to DCE1 and at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from IDE, T106B, PSA, CDON, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN. In some embodiments, kits comprise N biomarker protein capture reagents that specifically bind to PSMP and at least 1. at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from IDE, T106B. PSA, CDON, DCE1, SLIT2, Mn SOD, Tetranectin, and PTN. In some embodiments, kits comprise N biomarker protein capture reagents that specifically bind to SLIT2 and at least 1, at least 2, at least 3. at least 4. at least 5, at least 6, at least 7, at least 8. or 9 of the biomarker proteins selected from IDE, T106B, PSA, CDON, DCE1, PSMP. Mn SOD. Tetranectin, and PTN. In some embodiments, kits comprise N biomarker protein capture reagents that specifically bind to Mn SOD and at least 1. at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from IDE, T106B, PSA, CDON, DCE1, PSMP. SLIT2.Tetranectin, and PTN. In some embodiments, kits comprise N biomarker protein capture reagents that specifically bind to Tetranectin and at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from IDE, T106B, PSA, CDON. DCE1, PSMP, SLIT2, Mn SOD, and PTN. In some embodiments, kits comprise N biomarker protein capture reagents that specifically bind to PTN and at least 1. at least 2. at least 3, at least 4. at least 5, at least 6, at least 7, at least 8, or 9 of the biomarker proteins selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, and Tetranectin. In any of the kits described herein, 1, 2, 3, or 4 N biomarker protein capture reagents may specifically bind to PSA. Any of the kits described herein may be for use in predicting an individual’s risk of prostate cancer.Computer Methods and Software

[0217] Once a biomarker or biomarker panel is selected, a method for diagnosing an individual can comprise the following: 1) collect or otherwise obtain a biological sample; 2) perform an analytical method to detect and measure the biomarker or biomarkers in the panel inthe biological sample; 3) perform any data normalization or standardization required for the method used to collect biomarker levels; 4) calculate the marker score; 5) combine the marker scores to obtain a total diagnostic or predictive score; and 6) report the individual’s diagnostic or predictive score. In this approach, the diagnostic or predictive score may be a single number determined from the sum of all the marker calculations that is compared to a preset threshold value that is an indication of the presence or absence of disease or risk of prostate cancer. Or the diagnostic or predictive score may be a series of bars that each represent a biomarker level and the pattern of the responses may be compared to a pre-set pattern for determination of the presence or absence of disease, condition or the increased risk (or not) of an event.

[0218] At least some embodiments of the methods described herein can be implemented with the use of a computer. An example of a computer system 100 is shown in FIG. 6. With reference to FIG. 6, system 100 is shown comprised of hardware elements that are electrically coupled via bus 108, including a processor 101, input device 102, output device 103, storage device 104, computer-readable storage media reader 105a, communications system 106, processing acceleration (e.g., DSP or special-purpose processors) 107 and memory 109. Computer-readable storage media reader 105a is further coupled to computer-readable storage media 105b, the combination comprehensively representing remote, local, fixed and / or removable storage devices plus storage media, memory, etc. for temporarily and / or more permanently containing computer-readable information, which can include storage device 104, memory 109 and / or any other such accessible system 100 resource. System 100 also comprises software elements (shown as being currently located within working memory 191) including an operating system 192 and other code 193, such as programs, data and the like.

[0219] With respect to FIG. 6, system 100 has extensive flexibility and configurability. Thus, for example, a single architecture might be utilized to implement one or more servers that can be further configured in accordance with currently desirable protocols, protocol variations, extensions, etc However, it will be apparent to those skilled in the art that embodiments may well be utilized in accordance with more specific application requirements. For example, one or more system elements might be implemented as sub-elements within a system 100 component (e.g., within communications system 106). Customized hardware might also be utilized and / or particular elements might be implemented in hardware, software or both. Further, while connection to other computing devices such as network input / output devices (not shown) may be employed, it is to be understood that wired, wireless, modem, and / or other connection or connections to other computing devices might also be utilized,

[0220] In one aspect, the system can comprise a database containing features of biomarkers characteristic of an individual’s risk of prostate cancer. The biomarker data (or biomarkerinformation) can be utilized as an input to the computer for use as part of a computer implemented method. The biomarker data can include the data as described herein.

[0221] In one aspect, the system further comprises one or more devices for providing input data to the one or more processors.

[0222] The system further comprises a memory for storing a data set of ranked data elements.

[0223] In another aspect, the device for providing input data comprises a detector for detecting the characteristic of the data element, e.g.. such as a mass spectrometer or gene chip reader.

[0224] The system additionally may comprise a database management system. User requests or queries can be formatted in an appropriate language understood by the database management system that processes the query to extract the relevant information from the database of training sets.

[0225] The system may be connectable to a network to which a network server and one or more clients are connected. The network may be a local area network (LAN) or a wide area network (WAN), as is known in the art. Preferably, the server includes the hardware necessary for running computer program products (e.g,, software) to access database data for processing user requests.

[0226] The system may include an operating system (e g., UNIX or Linux) for executing instructions from a database management system. In one aspect, the operating system can operate on a global communications network, such as the internet, and utilize a global communications network server to connect to such a network.

[0227] The system may include one or more devices that comprise a graphical display interface comprising interface elements such as buttons, pull down menus, scroll bars, fields for entering text, and the like as are routinely found in graphical user interfaces known in the art. Requests entered on a user interface can be transmitted to an application program in the system for formatting to search for relevant information in one or more of the system databases Requests or queries entered by a user may be constructed in any suitable database language.

[0228] The graphical user interface may be generated by a graphical user interface code as part of the operating system and can be used to input data and / or to display inputted data. The result of processed data can be displayed in the interface, printed on a printer in communication with the system, saved in a memory device, and / or transmitted over the network or can be provided in the form of the computer readable medium.

[0229] The system can be in communication with an input device for providing data regarding data elements to the system (e.g., expression values). In one aspect, the input devicecan include a gene expression profiling system including, e.g., a mass spectrometer, gene chip or array reader, and the like.

[0230] The methods and apparatus for analyzing the risk of prostate cancer biomarker information according to various embodiments may be implemented in any suitable manner, for example, using a computer program operating on a computer system A conventional computer system comprising a processor and a random access memory', such as a remotely-accessible application server, network server, personal computer or workstation may be used. Additional computer system components may include memory devices or information storage systems, such as a mass storage system and a user interface, for example a conventional monitor, keyboard and tracking device. The computer system may be a stand-alone system or part of a network of computers including a server and one or more databases.

[0231] The risk of prostate cancer assessment biomarker analysis system can provide functions and operations to complete data analysis, such as data gathering, processing, analysis, reporting and / or diagnosis. For example, in one embodiment, the computer system can execute the computer program that may receive, store, search, analyze, and report information relating to the prostate cancer risk biomarkers. The computer program may comprise multiple modules performing various functions or operations, such as a processing module for processing raw data and generating supplemental data and an analysis module for analyzing raw data and supplemental data to generate a prostate cancer risk status. Determination of the probability of an individual's risk for prostate cancer may optionally comprise generating or collecting any other information, including additional biomedical information, regarding the condition of the individual relative to the disease, condition or event, identifying whether further tests may be desirable, or otherwise evaluating the health status of the individual.

[0232] Referring now to FIG. 7, an example of a method of utilizing a computer in accordance with principles of a disclosed embodiment can be seen. In FIG. 7, a flowchart 3000 is shown. In block 3004, biomarker information can be retrieved for an individual The biomarker information can be retrieved from a computer database, for example, after testing of the individual’s biological sample is performed. The biomarker information can comprise biomarker levels that each correspond to one or more of the biomarkers of Table 1. In block 3008, a computer can be utilized to classify each of the biomarker levels. And, in block 3012, a determination can be made as to an individual's risk of prostate cancer based upon a plurality of classifications. The indication can be output to a display or other indicating device so that it is viewable by a person. Thus, for example, it can be displayed on a display screen of a computer or other output device.

[0233] Some embodiments described herein can be implemented so as to include a computer program product A computer program product may include a computer readable medium having computer readable program code embodied in the medium for causing an application program to execute on a computer with a database.

[0234] As used herein, a “computer program product” refers to an organized set of instructions in the form of natural or programming language statements that are contained on a physical media of any nature (e.g.. written, electronic, magnetic, optical or otherwise) and that may be used with a computer or other automated data processing system. Such programming language statements, when executed by a computer or data processing system, cause the computer or data processing system to act in accordance with the particular content of the statements. Computer program products include without limitation: programs in source and object code and / or test or data libraries embedded in a computer readable medium. Furthermore, the computer program product that enables a computer system or data processing equipment device to act in pre-selected ways may be provided in a number of forms, including, but not limited to, original source code, assembly code, object code, machine language, encrypted or compressed versions of the foregoing and any and all equivalents.

[0235] In one aspect, a computer program product is provided for assessment of risk of prostate cancer. The computer program product includes a computer readable medium embodying program code executable by a processor of a computing device or system, the program code comprising: code that retrieves data attributed to a biological sample from an individual, wherein the data comprises biomarker values that each correspond to one or more of the biomarkers of Table 1; and code that executes a classification method that indicates an individual’s risk of prostate cancer as a function of the biomarker values.

[0236] While various embodiments have been described as methods or apparatuses, it should be understood that embodiments can be implemented through code coupled with a computer, e g., code resident on a computer or accessible by the computer. For example, software and databases could be utilized to implement many of the methods discussed above. Thus, in addition to embodiments accomplished by hardware, it is also noted that these embodiments can be accomplished through the use of an article of manufacture comprised of a computer usable medium having a computer readable program code embodied therein, which causes the enablement of the functions disclosed in this description. Therefore, it is desired that embodiments also be considered protected by this patent in their program code means as well. Furthermore, the embodiments may be embodied as code stored in a computer-readable memory of virtually any kind including, without limitation, RAM. ROM, magnetic media, optical media, or magneto-optical media. Even more generally, the embodiments could be implemented insoftware, or in hardware, or any combination thereof including, but not limited to, software running on a general purpose processor, microcode, PLAs, or ASICs.

[0237] It is also envisioned that embodiments could be accomplished as computer signals embodied in a carrier wave, as well as signals (e.g., electrical and optical) propagated through a transmission medium. Thus, the various types of information discussed above could be formatted in a structure, such as a data structure, and transmitted as an electrical signal through a transmission medium or stored on a computer readable medium.

[0238] It is also noted that many of the structures, materials, and acts recited herein can be recited as means for performing a function or step for performing a function. Therefore, it should be understood that such language is entitled to cover all such structures, materials, or acts disclosed within this specification and their equivalents, including the matter incorporated by reference.

[0239] The biomarker identification process, the utilization of the biomarkers disclosed herein, and the various methods for determining biomarker values are described in detail above with respect to evaluation of a risk of prostate cancer in an individual. However, the application of the process, the use of identified biomarkers, and the methods for determining biomarker values are fully applicable to other specific types of diseases or medical conditions, or to the identification of individuals who may or may not be benefited by an ancillary medical treatment.Other Methods

[0240] In some embodiments, the biomarkers and methods described herein are used to determine a medical insurance premium or coverage decision and / or a life insurance premium or coverage decision. In some embodiments, the results of the methods described herein are used to determine a medical insurance premium and / or a life insurance premium. In some such instances, an organization that provides medical insurance or life insurance requests or otherwise obtains information concerning an individual’s risk of prostate cancer and uses that information to determine an appropriate medical insurance or life insurance premium for the subject In some embodiments, the test is requested by, and paid for by, the organization that provides medical insurance or life insurance. In some embodiments, the test is used by the potential acquirer of a practice or health system or company to predict future liabilities or costs should the acquisition go ahead.

[0241] In some embodiments, the biomarkers and methods described herein are used to predict and / or manage the utilization of medical resources. In some such embodiments, the methods are not carried out for the purpose of such prediction, but the information obtained from the method is used in such a prediction and / or management of the utilization of medical resources. For example, a testing facility or hospital may assemble information from the presentmethods for many subjects in order to predict and / or manage the utilization of medical resources at a particular facility or in a particular geographic area.EXAMPLES

[0242] The following examples are provided for illustrative purposes only and are not intended to limit the scope of the application as defined by the appended claims. All examples described herein were carried out using standard techniques, which are well known and routine to those of skill in the art. Routine molecular biology techniques described in the following examples can be carried out as described in standard laboratory’ manuals, such as Sambrook et al.. Molecular Cloning: A Laboratory Manual, 3rd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y., (2001).Example 1. Multiplex Aptamer Assay and Statistical Approaches for Biomarker Identification

[0243] A multiplex aptamer assay was used to analyze test samples and control samples to identify biomarkers for predicting an individual’s risk of prostate cancer within a specified time frame. The multiplexed analysis used in this experiment included aptamers to detect approximately 5.000 proteins in blood from small sample volumes (—65 pl of serum or plasma), with low' limits of detection (1 pM median), ~7 logs of dynamic range, and ~5% median coefficient of variation. The multiplex aptamer assay- is described, generally, e.g., in Gold et al. (2010) Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery. PLoS ONE 5(12): e15004; and U. S. Publication Nos: 2012 / 0101002 and 2012 / 0077695.Example 2. Model Specification

[0244] Endpoint Description: The endpoint for this model was a survival endpoint based on time-to-event, which has two components. The first is a binary variable which indicates whether the subject received a diagnosis of primary prostate cancer over the study period (1) or not (0). This was adjudicated through record linkage with regional cancer registries. Cancer types were defined using the tenth edition of the International Classification of Disease (ICD10) and the second edition of the International Classification of Disease for Oncology (ICD-O-2). Prostate cancers were defined as malignant neoplasm of the prostate (C61). The second component to the endpoint is the “time-to-event.” which in this case is the time in follow-up days from the blood draw to: 1) the time of diagnosis of first primary prostate cancer, or 2) censor date for participants that did not have a primary prostate cancer diagnosis, which can occur due to end of study or removal from study for reasons not related to prostate cancer (including death or registration).

[0245] Model Information: The selected model is a 10-feature, protein-only (see Table 1) Accelerated Failure Time (AFT) model with a Weibull distribution

[0246] The model was trained on the entire follow-up period, with performance maximized at 5 years. The output is the absolute probability of not having a prostate cancer diagnosis, a value between 0.0000 and 1.0000. within 5 years. When delivered as a result and assessed by business rules, the resulting predicted probability will be subtracted from 1 to provide an absolute 5-year probability of a prostate cancer diagnosis.

[0247] The baseline risk probability score represents the absolute risk for the ‘'average’' person in the training cohort based on the model algorithm. A “baseline” individual is defined as an individual with model feature values set to zero. All features in the model are centered on the overall mean of the training data, which means a value of 0 for any given feature is equal to the mean (i.e., the average). The baseline value is calculated by setting all the features to zero and then generating the absolute risk probability on those “zeroed” features.

[0248] The baseline absolute risk of prostate cancer in the training dataset is 0.428%. The rate of 5-year prostate cancer diagnosis in the EPIC dataset is comparable to the U. S. population prostate cancer event rate in the intended use population (EPIC dataset described below).

[0249] Absolute risk scores were stratified by quartiles of absolute risk probabilities in the training dataset. Kaplan-Meier (KM) survival (“Event-free”) curves were generated for these quartiles for the training and verification datasets. The survival curves showed close agreement between training and verification datasets (FIG. 8). Note that the first two risk bins (Quartile 1 and 2) roughly correspond to individuals whose predicted risk of prostate cancer is lower than the average risk based on our data (baseline score = 0.428%while Quartiles 3 and 4 correspond to predicted risk that is higher than the baseline. The summary of absolute probability risk stratification and corresponding event rates is shown in Table 2 Both the mean predicted event rate and (observed) KM event rates are shown. KM event rates consider censoring and are weighted to reflect overall population instead of the analyzed cohort.Table 2. Risk tables from final 5-year Malignant Prostate Cancer Risk model predictions in training and verification data Risk bin ranges were derived by partitioning predicted 5-year event probabilities on the training dataset into quartilesBin cutoffs (in N N N Mean Kaplan- Risk Quartile absolute probability) Cancer- Events2Censored3Predicted Meier Event free1Event Rate Rate (95% c to 0000 Qi 0.000 < X< 0.002 1046 0 101 0.000 (0.000,0.000) Q2 0.002 < X < 0.004 1012 6 104 0.003 0.001 Absolute (0.000,0003)Q3 0.004 < X < 0.007 634 8 70 00060.004 (0.001, 0.006) Q4 0.007 < X < 1.000 704 59 91 0.026 0.039 (0.028,0.050)^Individuals neither censored nor diagnosed with malignant prostate cancer within 5 years (1,825 days) of blood draw (i.e., cancer-free).^Individuals diagnosed with malignant prostate cancer within 5 years (1,825 days) of blood draw.^Individuals lost to follow-up (censored) within 5 years (1,825 days) of blood draw, with unknown status after the censoring time.^Kaplan-Meier (KM) event rate takes into account loss to follow-up (censoring) within 5 years (1,825 days).

[0250] Based on this stratification, the scoring rules for the absolute risk for the prostate cancer risk test are shown in Table 3.Table 3. Scoring rules for absolute risk probabilitiesTest outcome X (absoluterisk probability) Predicted Class Plain language0.000 < X <0.002 Low Absolute risk predictions between 0.000 and 0.002(inclusive) are labeled as “Low”.0.002 < X < 0.004 Medium-Low Absolute risk predictions between 0.002 and 0.004(inclusive of 0.004) are labeled as “Medium-Low”.0.004 < X < 0.007 Medium-High Absolute risk predictions between 0.004 and 0.007(inclusive of 0.007) are labeled as “Medium-High”.0.007 < X < 1.000 High Absolute risk predictions between 0.007 and 1 (inclusive of 1 ) are labeled as “1 hgh”

[0251] Model calibration was assessed by comparing predicted event rates and Kaplan-Meier (KM) event rates. Specifically, predicted event probabilities on the training dataset were divided into deciles. The mean predicted event rate and case-cohort weighted KM event rate were calculated for each decile, respectively, along with the 95% confidence intervals for the weighted KM event rates. These data were visualized in a calibration plot (FIG. 9). For the top two deciles, the observed 5-year event rate is elevated relative to the predicted 5 -year event rate. Risk bins were created by partitioning predictions of 5-year malignant prostate cancer risk (■’Event”) on training samples into deciles. Kaplan-Meier event rates (observed event rate) were calculated using case-cohort weights. Mean predicted 5-year risk of prostate cancer (predicted event rate) and KM event rate was calculated for each decile of predi cted risk from selected prostate cancer model. The solid, black line is the reference line of identity, representing all points where predicted risks agree with observed KM event rates. Vertical bars about each decile’s point estimate are the 95% confidence intervals of the Kaplan-Meier event rate.

[0252] The model output is the Pr(No MPC) at 5 years (1,825 days), where “MPC” is first primary malignant prostate cancer. The output will be reported as the probability of a first primary malignant prostate cancer diagnosis, which is (1 - Pr(No MPC)). The event probability at 5 years will be reported as a continuous variable, rounded to three decimal places. Because the output of this model is a probabili ty, absolute risk values outside of the range [0,1] are failures and will not be reported.Table 4. Model performance in predicting first primary malignant prostate cancer risk within 5 years of blood draw in cancer-free individuals, along with age-only comparator model on training, verification, and validation data. The AUC, sensitivity, and specificity were calculated at 5 years (1,825 days). CI = confidence intervals;AUC - area under the curve; PEC ~ predictive error curve.AUC at 5 Sensitivity1at Specificity1C-index2(95% PEC Model Dataset N years 5 years at 5 years CI) at 5 (95% CI) (95% CI) (95% CI) years (95% Cl) Training 3835 0876 0.863 0.757 0.688 0.019 (0.841, (0790, 0.935) (0740, (0648, 0.728) (0.015, 0910) 0.771) 0.023) Proteomic Verification 989 0887 0.929 0.744 0.680 0.014 (0.829, (0700, 1.000) (0719, (0634,0.730) (0.008, 0942) 0.779) 0.022) Validation 0837 0.767 0.737 0.484 0.0201571 (0.764, (0600.0900) (0.717, (0411.0.727) (0.013, 089.3) 0.769) 0.027) Training 3835 0704 0.808 0.505 0.589 0.021(0.651, (0707, 0884) (0.485, (0557,0.619) (0.016, 0759) 0.519) 0.026) Age-only1Verification 989 0821 1.000 0.492 0.559 0.015 (0.762, (1 000, 1000) (0.463, (0491,0.623) (0.008, 0877) 0.526) 0.023) V alidation 1571 0746 0.900 0.492 0.569 0.021(0.673, (0791, 1.000) (0.462, (0378,0.740) (0.013,0819) 0.518) 0.028) ‘Sensitivity7and specificity7calculated using the cutoff that maximized Youden's J on the training dataset cutoffs -9.960 (Proteomic) and cutoffs -10.198 (Age-only).2C-index is not time specific“Model includes only participant age at the time of blood draw as a covariate.

[0253] Description of Clinical Model Used as a Comparator: There are currently no prostate cancer risk prediction tests that are used as standard of care in routine clinical practice. Prostate cancer has one of the highest heritabilities of any cancer, therefore risk calculators often include family history, age, ethnicity, and if available, genetic information as inputs. Blood tests that measure PSA are the most common screening test, however PSA does not have a high predictive performance when assigning risk of future prostate cancer diagnosis from a single measurement (AUC = 0.58).

[0254] A clinical risk calculator developed from the National Cancer Institute-sponsored Prostate, Lung. Colon, and Ovarian Cancer Screening (PLCO) and the Selenium and Vitamin E Cancer Prevention (SELECT) trials was used as the clinical comparator for the proteomic model. Both SELECT and PLCO were prospective cohorts with a combined enrollment of65,000 men aged 50 and older with median follow- up of 11.7 and 8.1 years, respectively. The calculator was independently validated on a third NCI- sponsored cohort: the San Antonio Biomarkers of Risk (SABOR) cohort (n=1790). Variables that most strongly predicted increasing risk of prostate cancer were PSA, age, BMI, and African American race. The 5-year SELECT-PLCO model discriminated risk for prostate cancer in the SABOR cohort with a C-index of 0.76 (95% CI 0.72 -0.79). Because the prostate cancer risk test could have possible future clinical use, maximizing performance at a specific, near-term point in time (5 years), while also considering sensitivity and specificity, was desired Therefore, the AUC metric was used to evaluate model performance rather than C-index.

[0255] An AUC greater than or equal to 0.760 was set as the performance threshold during model development for the prostate cancer risk test.

[0256] Development and Validation Cohort(s): The European Prospective Investigation into Cancer and Nutrition (EPIC) is an ongoing multi-center prospective cohort study designed to investigate the relationship between nutrition and cancer. (Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002:5(6B): 1113-1124.) The EPIC study is a collaborative effort between Imperial College London, the International Agency for Research on Cancer (IARC), and 23 European institutes within 10 countries. More than 500,000 individuals aged 35-75 who w ere cancer-free w ere enrolled between 1992 and 2000, Individuals were followed for cancer incidence and cause-specific mortality for several decades. Participant eligibility w'as based on geographic boundaries. The source population was identified according to age and sex. and the actual study populations were convenience samples of volunteers agreeing to participate from among the general adult population residing in a given town or geographical area who were invited to participate.

[0257] SomaLogic was provided with citrate plasma samples for 14,787 individuals obtained at enrollment and clinical data for up to 20.4 years of follow-up from 14 centers within four countries (Italy, Spain, The Netherlands, and the United Kingdom). The prostate cancer risk test was developed using samples from male participants (n=6,599), among whom n=978 developed malignant prostate cancer within the follow up period. Cancer diagnoses w ere adjudicated through record linkage with regional cancer registries. Cancer types were defined using the International Classification of Diseases-Tenth Revision and the second revision of the International Classification of Diseases for Oncology (ICD-O-2).

[0258] Prostate cancers were defined as malignant neoplasm of the prostate (code C61). Case-cohort sample weights w'ere assigned to each study participant by the EPIC research team. Sample w eights were used to account for the probability of study inclusion of each EPICparticipant who fulfilled the study inclusion criteria. These weights were estimated as a function of center of recruitment, sex, and disease status (i.e., incidence of cancer, type II diabetes, cardiovascular disease, and death during follow-up). Ethnicity information was not provided by the EPIC research team.

[0259] Current data on cancer incidence in the US suggest the lifetime risk of prostate cancer in the average male is 12.5% or 0.117% annually, which corresponds to a 5-year risk of -'0.581%. The baseline, or average, 5-year risk of incident prostate cancer in the EPIC dataset was 0.428%, and therefore is within the range of incident prostate cancer risk estimates for adult men living in the U. S.

[0260] The EPIC dataset was split independently into three sets (60% training / 15% verification / 25% validation), which allowed identification of a robust model while mitigating overfitting issues. The validation dataset was not used in the POC or refinement stages.

[0261] Model development data: A total of 6,489 samples were available after data QC for analysis. Demographic information for model development data (training and verification) are provided for the full follow-up period (19.9 years) and for 5-year (1,825-day) censoring in Tables 5-8.Table 5. Demographic information for the model development (training) dataset for the full follow-up period (up to 199 years) for the Prostate Cancer risk testMalignant Prostate Cancer Diagnosis Covariate Measure TotalNo Yes Sample Size N 3835 3262 573Asturias 325 (8.5%) 282 (8.6%) 43 (75%) Bilthoven 360 (9.4%) 309 (9.5%) 51 (8.9%) Cambridge 837 (21.8%) 712 (21 8%) 125 (21.8%) Florence 215 (5.6%) 177 (5.4%) 38 (6.6%) Granada 153 (4%) 138 (4.2%) 15 (2.6%) Murcia 249 (6.5%) 229 (7%) 20 (3.5%) Navarra 371 (9.7%) 314 (9.6%) 57 (9.9%) Subject Site IDOxford 244 (6.4%) 202 (6.2%) 42 (7.3%) Ragusa 168 (4.4%) 151 (4.6%) 17 (3%) San Sebastian 387 (10.1%) 325 (10%) 62 (10.8%) Turin 388 (10.1%) 313 (9.6%) 75 (13.1%) Varese 138 (3.6%) 110 (3.4%) 28 (4.9%)Unknown 10 (0.3%) 9 (0.3%) 1 (0.2%) Type II Diabetes StatusNo 3639 (94.9%) 3083 (94.5%) 556 (97%) Yes 186 (4.9%) 170 (5.2%) 16 (2.8%) Current 1385 (36.1%) 1227 (37.6% ) 158 (27.6%) Tobacco Use StatusNever 1003 (26.2%) 822 (25.2%) 181 (31.6%) Past 1447 (37.7%) 1213 (37.2%) 234 (40.8%) Mean (SD) 55.727 (8.73) 55.498 (8.934) 57.031 (7.34) Subject Age (years) Median 56 55.5 57Range 35 - 75 35 - 75 37 - 75 Mean (SD) 27.367 (3.773) 27.454 (3.823) 26.871 (3.436) Body Mass Index(kg / mA2) Median 27.03 27.1 26.71Range 15.86 - 59.99 16.74 - 59.99 15.86 - 42.04 Mean (SD) 4413.097 4522.608 3789.67 (1785.486) (1808.025) (1507.994) Time-to-Event / Censoring(days) Median 4891 5102 3982Range 7 - 7266 7 - 7266 176 - 6806Table 6. Demographic information for the model development (training) dataset for 5-year (1,825-day) censoring for the Prostate Cancer risk testCovariate Measure Total Malignant Prostate Cancer Diagnosis No Yes Censored Sample Size N 3835 3396 73 366Asturias 325 (8.5%) 304 (9%) 5 (6.8%) 16 (4.4%) Subject Site IDBilthoven 360 (9.4%) 321 (9.5%) 8 (11%) 31 (8.5%) Cambridge 837 (21.8%) 711 (20.9%) 25 (34,2%) 101 (27.6%) Florence 215 (5.6%) 178 (5.2%) 6 (8.2%) 31 (8.5%) Granada 153 (4%) 139 (4.1%) 0 (0.0%) 14 (3.8%) Murcia 249 (6.5%) 234 (6.9%) 2 (2.7%) 13 (3.6%) Navarra 371 (9.7%) 338 (10%) 1 (1.4%) 32 (8.7%) Oxford 244 (6.4%) 205 (6%) 9 (12.3%) 30 (8.2%) Ragusa 168 (4.4%) 158 (4.7%) 1 (1.4%) 9 (2.5%) San Sebastian 387 (10.1%) 354 (10.4%) 3 (4.1%) 30 (8.2%) Turin 388 (10.1%) 344 (10.1%) 10 (13.7%) 34 (9.3%) Varese 138 (3.6%) 110 (3.2%) 3 (4.1%) 25 (6.8%) Type II Diabetes Unknown 10 (0.3%) 8 (0.2%) 0 (0.0%) 2 (0.5%) Status No 3639 (94.9%) 3226 (95%) 72 (98.6%) 341 (93.2%)Yes 186 (4.9%) 162 (4.8%) 1 (1.4%) 23 (6.3%) Current 1385 (36.1%) 1231 (36.2%) 17 (23.3%) 137 (37.4%) Tobacco Use Status Never 1003 (26.2%) 896 (26.4%) 23 (31.5%) 84 (23% ) Past 1447 (37.7%) 1269 (37.4%) 33 (45.2%) 145 (39.6%) Mean (SD) 55.727 (8.73) 55.351 (8.673) 61.562 (7.397) 58.057 Subject Age (years) (8.753)Median 56 55 62 58 Range 35 - 75 35 - 75 43 - 75 36 - 75 Body Mass Index Mean ( SD) 27.367 (3.773) 27.407 (3.776) 26.247 (3.661) 27.217 (3.74) (kg / mA2) Median 27.03 27.08 26 26.85Range 15.86 - 59.99 15.86 - 5999 17.89 - 34.16 16.74 - 41.1 Tinie-to- Mean (SD) 4413.097 4858.845 1075.192 942.902 Event / Censoring (1785.486) (1352.573) (501.106) (518 173) (days)Median 4891 5166.5 1192 993.5 Range 7 - 7266 1826 - 7266 176 - 1825 7 - 1822Table 7. Demographic information for the model development (verification) dataset for the full followup period (up to 19.9 years) for the Prostate Cancer risk test. _Malign an t Pros ta te Can cer Diagno sis Co variate Measure Total No YesSample Size N 989 841 148Subject Site ID Asturias 78 (7.9%) 68 (8.1%) 10 (68%)Bilthoven 90 (9.1%) 77 (9.2%) 13 (8.8%) Cambridge 249 (25.2%) 212 (25.2%) 37 (25%) Florence 43 (4.3%) 38 (4.5%) 5 (3.4%) Granada 42 (4.2%) 37 (4.4%) 5 (3.4%) Murcia 60 (6.1%) 49 (5.8%) 11 (7.4%) Navarra 117 (11.8%) 100 (11.9%) 17 (11.5%) Oxford 61 (6.2%) 48 (5.7%) 13 (8.8%) Ragusa 51 (5.2%) 44 (5.2%) 7 (4.7%)San Sebastian 87 (8.8%) 72 (8.6%) 15 (10.1%) Turin 83 (8.4%) 70 (8.3%) 13 (8.8%) Varese 28 (2.8%) 26 (3.1%) 2 (1.4%) Type II Diabetes Unknown 3 (0.3%) 2 (0.2%) 1 (0.7%) Status No 933 (94.3%) 793 (94.3%) 140 (94.6%)Yes 53 (5.4%) 46 (5.5%) 7 (4.7%) Tobacco Use Status Current 354 (35.8%) 316 (37.6%) 38 (25.7%)Never 261 (26.4%) 204 (24.3%) 57 (38.5%) Past 374 (37.8%) 321 (38.2%) 53 (35.8%) Subject Age (years) Mean (SD) 55.915 (8.803) 55.919 (8.976) 55.892 (7.773) Median 56 56 56Range 36 - 75 36 - 75 40 - 75Body Mass Index Mean (SD) 27.506 (3.726) 27.575 (3.787) 27.116 (3.346) (kg / mA2) Median 27.17 27.19 27.015Range 18.04 - 43.82 18.04 - 43.82 19.31 - 37.33 Time-to- Mean(SD) 4463.696 4540.919 4024.878 Event / Censoring (1734.172) (1755.093) (1543.598) (days) Median 4942 5062 4100Range 10 - 7147 117 - 7147 10 - 6621Table 8. Demographic information for the model development (verification) dataset for 5-year (1,825-day) censoring for the Prostate Cancer risk test.Malignant Prostate Cancer Diagnosis Covariate Measure TotalNo Yes Censored Sample Size N 989 880 14 95Asturias 78 (7.9%) 72 (8.2%) 2 (14.3%) 4 (4.2%) Bilthoven 90 (9.1%) 86 (9.8%) 0 (0.0%) 4 (42%) Cambridge 249 (25.2%) 207 (23.5%) 6 (42.9%) 36 (379%) Florence 43 (43%) 35 (4%) 0 (00%) 8 (84%) Granada 42 (4.2%) 39 (4.4%) 1 (7 1%) 2 (2 1%) Murcia 60 (6.1%.) 52 (5.9%) 1 (7.1%) 7 (7.4%) Subject Site IDNavarra 117 (11.8%) 113 (12.8%) 1 (7.1%) 3 (3.2%) Oxford 61 (6.2%) 52 (5.9%) 1 (7.1%) 8 (8.4%) Ragusa 51 (5.2%) 46 (5.2%) 0 (0.0%) 5 (5.3%) San Sebastian 87 (8.8%) 79 (9%) 2 (14.3%) 6 (6.3%) Turin 83 (8.4%) 74 (8.4%) 0 (0.0%) 9 (9.5%) Varese 28 (2.8%) 25 (2.8%) 0 (0.0%) 3 (3.2%) Unknown 3 (0.3%) 1 (0.1%) 0 (0.0%) 2 (2.1%) Type II Diabetes Status No 933 (94.3%) 834 (94.8%) 12 (85.7%) 87 (91.6%) Yes 53 (5.4%) 45 (5.1%) 2 (14.3%) 6 (6.3%) Current 354 (35.8%) 326 (37%) 1 (7.1%) 27 (28.4%) Tobacco Use StatusNever 261 (26.4%) 242 (27.5%) 6 (42.9%) 13 (13.7%) Past 374 (37.8%) 312 (35.5%) 7 (50%) 55 (57.9%) Mean (SD) 55.915 (8.803) 55.39 (8.686) 64.786 (4.823) 59.474 (8.872) Subject Age (years) Median 56 56 65 60Range 36 - 75 36 - 75 58 - 75 40 - 75 Body Mass Index Mean (SD) 27.506 (3.726) 27.505 (3.758) 29.056 (2.555) 27.293 (3.545) (kg / mA2)Median 27.17 27.195 28.42 26.64 Range 18.04 - 43.82 18.52 - 43.82 26.1 - 34.69 18.04 - 37.47 Mean (SD) 4463.696 4876.385 1160.286 1127.705 Time-to- (1734.172) (1343.523) (603.017) (461.316) Event / Censoring (days)Median 4942 5202 1383.5 1199 Range 10 - 7147 1827 - 7147 10 - 1789 117 - 1823

[0262] Model validation data: Demographic information for the validation dataset is provided for the full follow-up period (19.9 years) and for 5-year (1,825-day) censoring in Tables 9 and 10, respectively.Table 9. Demographic information for the validation dataset for the full follow-up period (up to 19.9 years) for the Prostate Cancer risk test.Malignant Prostate Cancer Diagnosis Co variate Measure TotalNo Yes Sample Size N 1571 1336 235Asturias 107 (6.8%) 91 (6.8%) 16 (6.8%) Bilthoven 136 (8.7%) 121 (9.1%) 15 (6.4%) Cambridge 382 (24.3%) 322 (24.1%) 60 (25.5%) Florence 84 (5.3%) 68 (5.1%) 16 (6.8%) Granada 49 (3.1%) 41 (3.1%) 8 (3.4%) Murcia 96 (6.1%) 85 (6.4%) 11 (4.7%) Subject Site IDNavarra 149 (9.5%) 132 (9.9%) 17 (7.2%) Oxford 121 (7.7%) 96 (7.2%) 25 (10.6%) Ragusa 79 (5%) 70 (5.2%) 9 (3.8%) San 156 (9.9%) 133 (10%) 23 (9.8%) SebastianTurin 153 (9.7%) 129 (9.7%) 24 (10.2%) Varese 59 (3.8%) 48 (3.6%) 11 (4.7%) Unknown 4 (0.3%) 4 (0.3% ) 0 (0.0%) Type 11 Diabetes Status No 1488 (94.7%) 1261 (94.4%) 227 (96.6%) Yes 79 (5%) 71 (5.3%) 8 (3.4%) Current 507 (32.3%) 462 (34.6%) 45 (19.1%) Tobacco Use Status Never 435 (27.7%) 350 (26.2%) 85 (36.2%) Past 629 (40%) 524 (39.2%) 105 (44.7%) Mean (SD) 56.049 (8.865) 55.752 (9.067) 57.736 (7.414) Subject Age (years) Median 56 56 58Range 35 - 75 35 - 75 37 - 75 Mean (SD) 27.297 (3.834) 27.375 (3.895) 26.853 (3.439) Body Mass Index (kg / mA2) Median 26.92 26.995 26.53Range 17.07 - 53.57 17.07 - 53.57 17.68 - 42.21 Mean (SD) 4302.078 4386.058 3824.647 Time-to-Event / Cen soring (1841.98) (1872.781) (1576.522) (days) Median 4790 4954.5 3966Range 16 - 7099 16 - 7099 77 - 6964Table 10. Demographic information for the validation dataset for 5-year (1,825-day ) censoring for the ProstateCancer risk testMalignant Prostate Cancer Diagnosis Covariate Measure TotalNo Yes Censored Sample Size N 1571 1353 30 188Asturias 107 (6.8%) 101 (75%) 1 (3.3%) 5 (2.7%) Bilthoven 136 (8.7%) 118 (8.7%) 2 (6.7%) 16 (8.5%) Cambridge 382 (24.3%) 315 (23.3%) 10 (33.3%) 57 (30.3%) Florence 84 (5.3%) 71 (5.2%) 1 (3.3%) 12 (6.4%)Granada 49 (3.1%) 44 (3.3%) 1 (3.3%) 4 (2.1%) Murcia 96 (6.1%) 86 (6.4%) 1 (3.3%) 9 (4.8%) Subject Site ID Navarra 149 (9.5%) 129 (95%) 2 (6.7%) 18 (9.6%) Oxford 121 (7.7%) 97 (7.2%) 6 (20%) 18 (9.6%) Ragusa 79 (5%) 70 (5.2%) 1 (3.3%) 8 (4.3%) San Sebastian 156 (9.9%) 147 (10.9%) 0 (0.0%) 9 (4.8%) Turin 153 (9.7%) 129 (95%) 4 (13.3%) 20 (10.6%) Varese 59 (3.8%) 46 (3.4%) 1 (3.3%) 12 (6.4%) Unknown 4 (0.3%) 4 (0.3%) 0 (0.0%) 0 (0.0%) Type II Diabetes No 1488 ( 94.7%) 1277 (94.4%) 30 (100%) 181 (96.3%) StatusYes 79 (5%) 72 (5.3%) 0 (0.0%) 7 (3.7%) Current 507 (32.3%) 454 (33.6%) 2 (6.7%,) 51 (27.1%) Tobacco Use Status Never 435 (27.7%) 381 (28.2%.) 9 (30%) 45 (23.9%) Past 629 (40%) 518 (38.3%) 19 (63.3%) 92 (48.9%) Mean (SD) 56.049 (8.865) 55.559 (8.794) 629 (6.656) 58.484 (8.868) Subject Age (years) Median 56 56 62 59Range 35 - 75 35 - 75 45 - 73 39 - 75 Body Mass Index Mean (SD) 27.297 (3.834) 27.363 (3.888) 26662 26926 (3.54) (kg / mA2) (2914)Median 26.92 26.96 26155 26.545 Range 17.07 - 5357 1707 - 53 57 2067 - 31.43 18.34 - 41.56 Mean (Si)) 4302078 4836.81 1121 5 961.255 Time-to- (1841 98) (1353 844) (553.477) (523438) Event / Censoring(days) Median 4790 5131 12835 992Range 16 - 7099 1837 - 7099 77 - 1822 16 - 1822

[0263] Data Quality Control and Pre-Analytics Results: The original clinical dataset included 14,787 samples. After excluding females and samples with missing sample weights, 6,593 samples remained prior to data QC.

[0264] Data QC showed that there 'ere 94 (1.42%) outlier samples, defined as >5% of analytes exceeding 6 median absolute deviations from the median, and there were 104 samples with normalization scale factors outside the recommended range. Table 11 details the samples removed at each step of data cleaning.Talrte 11. Number of individuals removed at each step of data cleaning for the EPIC datasetStep N (removed) N (remaining)Baseline 0 14,787(samples with clinical and proteomic data)Female samples 8,188 6,599Missing sample weights 6 6,593Outside range normalization scale factors 104 6,4891Outliers 94 6,3952'Total number of samples in analysis data used for feature / model selection during refinement; data were split at this step, and training, verification, and validation datasets each contained outliers," Total number of samples in final analysis data after removing outliers from training, verification, and validation datasets; after outlier removal, the final model was fit on the training dataset and used to predict the verification samples.[00265| Additionally, 363 analytes were removed before analysis began as they did not pass target confirmation specificity testing (i e., red-listed features). In total, 6,395 samples and 7,233 analytes were included in the final analysis. No other issues were identified during Data QC or Pre- Analytics.

[0266] Refinement Approach and Results: The selected model for the 5-year prostate cancer risk test is an 10-protem AFT survival model using a Wei bull distribution. The model was developed using the training split (60%) of the EPIC dataset, tested using the verification split (15%), and will be validated on a final held-out dataset (25%). The primary model output is absolute risk (i.e., probability of malignant prostate cancer diagnosis) within five years of blood draw.

[0267] Observations over the entire study follow up period were used, with model performance calculated at five years and final model chosen based on 5-year AUC. Analytes were selected for the final model through a senes of feature filtering and feature reduction methods. Initial feature lists were selected from the POC univariate results, using the top ranked proteins across a sequence of cutoffs from the top 100 to the top 500 proteins in increments of 50. Consensus Nested Cross-Validation (CNCV) (Parvandeh S, et al. BioInformatics 2020;36(10):3093-3098) was used to identify candidate feature sets and optimize the regularization parameter V; the elastic net mixing parameter a was fixed during parameter tuning, taking on values between 0.5 and 1. Following identification of consensus features, AFT Weibull models were fit using only the features with non-zero coefficients in the final elastic net regularized Cox PH model from CNCV. Sample weights were used in all models to account for the probability of participant inclusion in the EPIC study. Promising candidate models, based on full training dataset and cross-validated performance, were examined using the model hardening datasets and analyses Soma Model Assessment (SMA).

[0268] To arrive at the selected model, the top 100 proteins, ranked in increasing order by univariate statistic p- value, were used as the initial input feature list for feature selection and model parameter tuning via CNCV. The parameterization of CNCV included 3 outer folds and 3 inner folds. For each inner fold, features were ranked by absolute value of their coefficient in a multivariate Cox PH model with a ridge penalty, and the regularization parameter (lambda) was chosen by optimizing the 3-fold cross-validated C-index. Proteins ranked in the top 60% wereselected from each inner training fold. For each outer fold and corresponding set of consensus features, Cox PH models with a LASSO penally were trained; similarly, lambda was chosen by optimizing the 3-fold cross-validated C-index. Feature and model selection via CNCV were performed on development data that included outliers, however, the final model was fit excluding outliers.

[0269] Performance metrics for the training and verification data assessed at five years are presented in Table 12. With a 5-year AUC of 0.876 and 0.887 in the training and verification data, respectively, the selected model exceeded the first passing criterion of a 5-year AUC greater than or equal to 0.760,Table 12. Model performance in predicting first primary malignant prostate cancer risk within 5 years of blood draw in cancer-free individuals, along with age-only comparator model. The AUC, sensitivity, and specificity were calculated at 5 years (1825 days). CI = confidence interval; AUC = area under the curve; PEC = predictiveerror curve.AUC at 5 Sensitivity at Specificity at C-index2PEC at 5 Model Dataset N years 5 years15 years1(95% CI) years (95%(95% CI) (95% CI) (95% CI) CI) Training 3835 0.876 0863 0.757 0.688 0.019 Proteomic (0.841, (0.790, 0.935) (0740, 0.771) (0.648, (0.015, 0.910) 0.728) 0023) Verification 989 0.887 0929 0.744 0.680 0014 (0.829, (0.700, 1.000) (0719,0.779) (0.634, (0.008, 0.942) 0.730) 0022) Training 3835 0.704 0808 0.505 0.589 0021 Age-only3(0.651, (0.707, 0.884) (0.485,0.519) (0.557, (0.016, 0.759) 0.619) 0.026) Verification 989 0.821 1 000 0.492 0.559 0015 (0.762, (1.000, 1.000) (0463,0.526) (0.491, (0.008,0.877) 0.623) 0.023) 'Sensitivity and specificity calculated using the linear-space cutoff that maximized Youden's J on the training dataset; cutoff = -9.960 (Proteomic) and cutoff = -10 198 (Age-only),2C-index is not time specific’Model includes only participant age at the time of blood draw as a co variate.

[0270] The prostate cancer test was also required to have statistically significantly greater 5-year AUC (by paired one-sided DeLong’s Test) than two AFT Weibull comparator models: 1) only an intercept term (“Intercept-only'’) model, and 2) a model with only an individual’s age (“Age-only”) at the time of blood draw.

[0271] The selected proteomic model had significantly greater 5-year AUC than the Intercept-only and Age-only models on the training and verification datasets (Table 13).Because there were only 14 malignant prostate cancer diagnoses within 5 years of blood draw in the verification dataset, there was not sufficient statistical power to use the standard 0.05 threshold for statistical significance. Instead, a p- value threshold of 0.1 was used which corresponds to a false positive rate of 10%, which is appropriate to prevent a clinically meaningful difference from being rejected due to small sample size m the verification dataset.Tabie 13. Model performance in predicting first primary malignant prostate cancer risk within 5 years of blood draw in cancer-free individuals. The Area Under the receiver operating characteristic Curve (AUC) was calculated a! 5 years ( 1.825 days). P-values were derived from the Paired DeLong’s test statistic, based on the Observed Difference in 5-year AUC between Proteomic and Comparator models. CI ~ Confidence interval: AUC = area under the curve.5-year AUC (95% CI) ObservedDataset Difference P-value1Proteomic Model Compa rator ModelIntercept-only0.500 0.376 2.33e-97 Training 0876 (0.500, 0.500)(0.841, 0.910)Age-only0.704 0172 2.96e-12 (0651, 0759)Intercept-only0.500 0.387 1 03e-40 Verification 0.887 (0.500, 0.500)(0829. 0.942)Age-only 0.066 0082 0.821(0.762, 0.877)’Calculated from a paired DeLong’s test for differences in 5-year AUC between proteomic and comparator models (p-value threshold = 0.1). Null hypothesis: no difference in AUC between proteomic and comparator model. Alternative hypothesis: proteomic model AUC is greater than comparator model AUC.

[0272] Clinical Validation Plan: Validation is assessed on the remaining 25% hold out portion of the male-only EPIC dataset that has not been used up to this point.

[0273] The selected model from refinement is a 10-feature Accelerated Failure Time (AFT) model with a Weibull distribution. Predicted absolute probabilities for the risk of malignant prostate cancer within 5 years of blood draw will be calculated using the final model. The cutoff that maximized Youden’s J statistic on the training dataset (linear cutoff = -9.960, probability cutoff = 0.007) will be used to calculate sensitivity and specificity. These performance metrics will also be calculated for the Intercept-only and Age-only models. The passing criteria is a 5-year AUC greater than or equal to 0.760 on the validation dataset and statistically significantly greater 5-year AUC than the Intercept-only and Age-only models, using a p-value threshold of 0.1 to determine statistical significance.

[0274] Clinical Results on Validation Data: The performance metrics of the prostate cancer risk model on the validation dataset are shown m Fable 14. The model had a 5-year AUC of 0.837, exceeding the fixed performance criteria of a 5-year AUC of at least 0760, and was statistically significantly greater than the Intercept-only and Age-only comparator model 5-year AUCs of 0.500 and 0,746, respectively (Table 15).Table 14. Performance metrics for the selected proteomic prostate cancer risk model and the age-only model on the validation dataset. AUC, sensitivity, and specificity were calculated at 5 years. Sensitivity and specificity were calculated with the decision cutoff that maximized Youden's.1 index for the respective model. AUC ~ area under the curve: CI = confidence interval: PEC = predictive error curve.AUC at 5 Sensitivity at Specificity at C-index PEC at 5 Model N Dataset years 5 years 5 years (95% years (95%(95% CI) (95% CI)1 (95% CI)1 CI)2 CI) Proteomic 0.837 0.767 0.7.37 0484 00201571 Validation (0.764, (0.600, 0.900) (0.717, 0.769) (0.411, (0.013, 0.893) 0.727) 0.027) Age-o nly3 0.746 0.900 0.492 0.569 0.0211571 Validation (0.673, (0.791, 1.000) (0.462, 0.518) (0.378, (0.013, 0.819) 0.740) 0028)’Sensitivity and specificity calculated using the linear-space cutoff that maximized Youden's J on the training dataset; cutoff = -9.960 (Proteomic) and cutoff = -10.198 (Age-only).2Model adjustment with Inverse Probability of Censoring Weights (IPCW) due to right-censoring was used throughout the analysis. The presence of a single individual in the validation dataset whose event time was much later than expected and had no nearby observations had an extreme IPCW. This sample had a large effect on estimates resulting in a substantially decreased C-index in validation.JModel includes only participant age at the time of blood draw as a covariate.Tabie 15. Model performance in predicting first primary malignant prostate cancer risk within 5 years of blood draw in cancer-free individuals The Area Under the receiver operating characteristic Curve (AUC) was calculated at 5 years (1,825 days). P-values were derived from the Paired DeLong's test statistic, based on the Observed Difference in 5-year AUC between Proteomic and Comparator models. AUC = area under curve; CI = Confidence interval.Dataset 5-year AUC (95% CI) Observed P-value1DifferenceProteomic Model Comparator ModelIntercept-only0500 (0500, 0.500) 0.336 742e-24 Validation 0837(0.764, 0.89.3) Age-only0746 (0673,0.819) 0091 0014^p-values calculated from Delong’s test for differences in AUC with a one-sided alternative that die proteomic 5-year AUC is greater than the comparator model 5-year AUC.Null hypothesis: no difference in AUC between proteomic and comparator model.Alternative hypothesis: proteomic model AUC is greater than comparator model AUC.

[0275] The Kaplan-Meier survival (‘‘Event-free”) curves with subjects in the validation dataset, stratified by risk bin. were visualized for quartiles (FIG. 10). In validation, the KM curve for the highest risk bin (Q4) is well-separated from the lower risk bins, similar to training and verification datasets (FIG 8). The shaded region about each survival curve is the 95% confidence interval (CI) of the KM estimate of the event-free probability.

[0276] Impacts of Imputation: Imputation methods were assessed. Acceptable RFU ranges (extreme value bounds) for model aptamers are calculated. Then, the two imputation methods are applied to the validation dataset: winsorization and feature averaging (zero replacement).Model predictions are made on the original validation dataset without imputation and the imputed validation dataset. The concordance (Lin’s CCC) in model predictions between unimputed and imputed validation datasets is calculated. The imputation approach with the highest CCC was zero replacement (Table 16). For this reason, the average, zero, for imputation is used.Table 16. Imputation tabic for out-of-rangc RFU values in the validation dataset.Imputation Method CCCOriginal validation 1Winsorized validation 0.862Feature Average / Zero Replacement 0.999validation[00277| Predictive variation due to assay noise: Ninety-five percent, 99%, and 99 99% lower and upper tolerance bounds for variation in model predictions due to the assay are given in Table 17. The bounds are given m response (i.e., probability ) and linear space, respectively. Table 17. Tolerance bounds in response and linear predictor space for lhe selected 5-year prostate cancer riskmodel.Prediction Space Bound 95% 99% 99.99%lower -0.109 -0.143 -0.216Linearupper 0 109 0 143 0216lower -0.082 -0.107 -0.161 Responseupper 0.082 0.107 0.161

[0278] EDTA-Citrate Plasma Concordance: The EPIC data used for training were collected in Sarstedt 3.2% trisodium citrate tubes. However, future samples may be collected in alternative collection tubes and buffers, such as, but not limited to EDTA plasma tubes. Thus, the model predictions were tested for concordance between Citrate and ED TA plasma. The training data were jittered according to the differences between matched samples from an internal study whose blood samples were collected with both Citrate plasma and EDTA plasma tubes. FIG. 11 shows a high concordance (CCC > 095) between original training (Citrate) and jittered-training (EDTA) predictions indicating that this prostate cancer risk test can be used with both Citrate and EDTA plasma samples without a bridge. Specifically, using the dataset comparison approach, with a jittered-training vs training CCC > 0,95, the 5-year prostate cancer risk test is supported statistically for use in EDTA plasma.

[0279] Validation Conclusions: The 10-analyte malignant prostate cancer risk model predicts the risk of a future malignant prostate cancer diagnosis within 5 years of blood draw in cancer-free individuals. The model output is the probability (absolute risk) of a first primary’ malignant prostate cancer diagnosis, which is a continuous variable within the range from 00000 to 1.0000. Validation exceeds the performance criteria of 5-year AUC greater than or equal to 0.760 which is also statistically significantly greater than the 5-year AUC of models that include 1) only the intercept, and 2) only participant age at blood draw. Hemoglobin (1000 mg / dl) did not pass interference testing. Based on simulations studying the impacts of imputation, feature average (i.e., zero) as a replacement was determined to be the best approach for imputing analytes that are out of bounds for this model. Additionally, the model was assessed for use with EDTA plasma samples and the 5-year prostate cancer risk test is supported statistically for use in both EDTA and Citrate plasma samples without a bridge.Example 3: Analysis of Prostate Cancer Risk Model Biomarker Panels

[0280] Model biomarker panels comprising various combinations of the biomarkers listed in Table 1 were analyzed to determine the Area Under the Curve (AUC) value for the various combinations, Tire model biomarker panels may be based on a panel of N biomarker proteins having an AUC value of at least 0.60, 0.61, 0.62, 0.63, 0.64, at least 0.65. at least 0.66, at least 0.67, at least 0.68, at least 0.69, at least 0.7, at least 0.71, at least 0.72, at least 0.75, at least 0.8, at least 0 85, at least 0.9, or at least 0.95, where N is 1, 2, 3, 4, 5, 6, 7. 8, 9, and / or 10 of the unique biomarker proteins listed in Table 1. In any of the embodiments described herein, 1, 2. 3, or 4 biomarker protein capture reagents may specifically bind to PSA. The Tables below show exemplary model results when various combinations comprising 1 to 10 biomarker proteins listed in Table 1 were measured.Table 18: Single BiomarkersTarget Names PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP | T106B Mn SOD PTN CDON AUG CDON CDON 0.523688 PTN PTN 0.519387 Mn SOD Mn SOD 0.505539 II 06B i T106B 0.53408 PSMP PSMP i 0.488506 IDE IDE 0522549 SLIT2 SLI1'2 0.513551 Tetranectin Tetranectin 0.514428 PSA 4 PSA 4 0703565 DCE1 DCE1 0.535695 PSA 3 PSA 3 0.694242 PSA 2 PSA 2 0.713731PSA 1 PSA 1 0.707514Table 19: Biomarker Panels including T106B and / or IDEAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN < DON 0.53408 T106B0.55833 DCE1 T106B0.8752 PSA 3 T106B0.595709 SLIT2 T106B0.86061 PSA 4 T106B0.620783 T106B PTN 0.541693 IDE T106B0.872017 PSA 1 T106B0.586568 T106B CDON 0.598855 T106B Mn SOD0.54344 Tetranectin T106B0.544668 PSMP T106B0.884042 PSA 2 T106B0.87376 PSA.3 DCEI T106B0.592682 DCE1 SLIT2 T106B0.858925 DCEI PSA 4 T106B0.62378 DCEI T106B PTN 0561575 DCEI IDE T106B0.8704 PSA 1 DCE1 T106B0.613792 DCEI T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.595925 DCE1 T106B Mn SOD0.55666 DCE1 Tetranectin T106B0.560016 DCE1 PSMP T106B0.882061 PSA 2 DCE1 T106B0.865353 PSA 3 SLIT2 T106B0871928 PSA 3 PSA 4 T106B0.874401 PSA 3 T106B PTN 0.875244 PSA 3 IDE T106B0.8S0314 PSA 1 PSA 3 T106B0.876386 PSA 3 T106B CDON 0.873881 PSA 3 T106B Mn SOD0 8743 PSA 3 Tetranectin T106B0.871658 PSA 3 PSMP T106B0.887236 PSA 2 PSA 3 T106B0.857391 PSA 4 SLIT2 T106B0.616668 SLIT2 T106B PTN 0.598522 SLIT2 IDE T106B0866955 PSA 1 SLIT2 T106B0.617096 SLIT2 T106B CDON 0.621295 SLIT2 T106B Mu SOD0.59772 Tetranectin SLIT2 T106B0.59709 SLIT2 PSMP T106B0.881924 PSA 2 SLIT2 T106B0864599 PSA 4 T106B PTN 0.862433 PSA 4 IDE T106B0.871529 PSA 1 PSA 4 T106B0.863808 PSA 4 T106B CDON 0.858954 PSA 4 T106B Mn SOD0.858819 PSA 4 Tetranectin T106B0862852 PSA 4 PSMP T106B0.879899 PSA 2 PSA 4 T106B0.630206 IDE T106B PTN 0.876301 PSA 1 T106B PTN 0.630258 T106B PTN CDON 0.640233 T106B Mn SOD PTN 0619458 Tetranectin T106B PTN 0.62566 PSMP T106B PTN 0.886131 PSA 2 T106B PTN 0.874502 PSA 1 IDE T106B0.573977 IDE T106B CDON 0.572817 IDE T106B Mn SOD0540334 Tetranectin IDE T106B0.542756 IDE PSMP T106BAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.885042 PSA 2 IDE T106B0.874623 PSA 1 T106B CDON 0.869948 PSA 1 T106B Mn SOD0.868774 PSA 1 Tetranectin T106B0.873901 PSA 1 PS MP T106B0885276 PSA 1 PSA 2 T106B0.601772 T106B Mn SOD CDON 0.587218 Tetranectin T106B CDON 0.585171 PSMP T106B CDON 0.884937 PSA 2 T106B CDON 0.59633 Tetranectin T106B Mn SOD0598682 PSMP T106B Mn SOD0.882408 PSA 2 T106B Mn SOD0.543484 Tetranectin PSMP T106B0.881629 PSA 2 Tetranectin T106B0.88436 PSA 2 PSMP T106B0.862088 PSA 3 DCE1 SLIT2 T106B0870704 PSA 3 DCE1 PSA 4 T106B0.871985 PSA 3 DCE1 T106B PTN 0.873996 PSA 3 DCE1 IDE T106B0.879052 PSA 1 PSA.3 DCE1 T106B0.875034 PSA 3 DCE1 T106B CDON 0.872148 PSA 3 DCE1 T106B Mn SOD0872735 PSA 3 DCE1 Tetranectin T106B0.870527 PSA 3 DCE1 PSMP T106B0.885308 PSA 2 PSA 3 DCE1 T106B0.854805 DCE1 PSA 4 SLIT2 T106B0.615845 DCE1 SLIT2 T106B PTN 0.596354 DCE1 SLIT2 IDE T106B0864413 PSA 1 DCE1 SLIT2 T106B0.629843 DCE1 SLIT2 T106B CDON 0.614438 DCE1 SLIT2 T106B Mn SOD0.594297 DCE1 Tetranectin SLIT2 T106B0.59391 DCE1 SLIT2 PSMP T106B0.879173 PSA 2 DCE1 SLIT2 T106B0862134 DCE1 PSA 4 T106B PTN 0.861215 DCE1 PSA 4 IDE T106B0.870287 PSA 1 DCE1 PSA 4 T106B0.862247 DCE1 PSA 4 T106B CDON 0.856778 DCE1 PSA 4 T106B Mn SOD0.856826 DCE1 PSA 4 Tetranectin T106B0861473 DCE1 PSA 4 PSMP T106B0.877945 PSA 2 DCE1 PSA 4 T106BAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.636297 DCE1 IDE T106B PTN 0.874139 PSA 1 DCE1 T106B PTN 0.645731 DCE1 T106B PTN CDON 0.639503 DCE1 T106B Mn SOD PTN 0.621779 DC E1 Tetranectin T106B PTN 0630095 DCE1 PSMP T106B PTN 0.883606 PSA 2 DCE1 T106B PTN 0.873905 PSA 1 DCE1 IDE T106B0.601935 DCE1 IDE T106B CDON 0.580437 DCE1 IDE T106B Mn SOD0.558189 DCE1 Tetranectin IDE T106B0562164 DCE1 IDE PSMP T106B0.883231 PSA 2 DCE1 IDE T106B0.873086 PSA 1 DCE1 T106B CDON 0.868193 PSA 1 DCE1 T106B Mn SOD0.867213 PSA 1 DCE1 Tetranectin T106B0.872525 PSA 1 DCE1 PSMP T106B0882755 PSA 1 PSA 2 DCE1 T106B0.622441 DCE1 T106B Mn SOD CDON 0.61185 DCE1 Tetranectin T106B CDON 0.612749 DCE1 PSMP T106B CDON 0.882936 PSA 2 DCE1 T106B CDON 0.592905 DCE1 Tetranectin T106B Mn SOD0596455 DCE1 PSMP T106B Mn SOD0.880052 PSA 2 DCE1 T106B Mn SOD0.558167 DCE1 Tetranectin PSMP T106B0.879709 PSA 2 DCE1 Tetranectin T106B0.883049 PSA 2 DCE1 PSMP T106B0.872806 PSA 3 PSA 4 SLIT2 T106B0867616 PSA 3 SLIT2 T106B PTN 0.864022 PSA 3 SLIT2 IDE T106B0.879806 PSA 1 PSA 3 SLIT2 T106B0.865809 PSA 3 SLIT2 T106B CDON 0.863425 PSA 3 SLIT2 T106B Mn SOD0.864861 PSA 3 Tetranectin SLIT2 T106B0.86326 PSA 3 SLIT2 PSMP T106B0.886881 PSA 2 PSA 3 SLIT2 T106B0.87935 PSA 3 PSA 4 T106B PTN 0.873263 PSA 3 PSA 4 IDE T106B0.876563 PSA 1 PSA 3 PSA 4 T106B0.873268 PSA 3 PSA 4 T106B CDON 0.870714 PSA 3 PSA 4 T106B Mn SOD0.870097 PSA 3 PSA 4 Tetranectin T106BAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.871908 PSA 3 PSA 4 PSMP T106B0.882977 PSA 2 PSA.3 PSA 4 T106B0.872307 PSA 3 IDE T106B PTN 0.887987 PSA 1 PSA 3 T106B PTN 0.875131 PSA 3 T106B PTN CDON 0.872904 PSA 3 T106B Mn SOD PTN 0.873167 PSA 3 Tetranectin T106B PTN 0.871291 PSA 3 PSMP T106B PTN 0.891952 PSA 2 PSA 3 T106B PTN 0.881872 PSA 1 PSA 3 IDE T106B0.875732 PSA 3 IDE T106B CDON 0.87432 PSA 3 IDE T106B Mn SOD0.874405 PSA 3 Tetranectin IDE T106B0.869851 PSA 3 IDE PSMP T106B0.888515 PSA 2 PSA 3 IDE T106B0.882065 PSA 1 PSA 3 T106B CDON 0.878917 PSA 1 PSA 3 T106B Mn SOD0.877741 PSA 1 PSA 3 Tetranectin T106B0.880738 PSA 1 PSA 3 PSMP T106B0.88818 PSA 1 PSA 2 PSA 3 T106B0.875409 PSA 3 T106B Mn SOD CDON 0.875313 PSA 3 Tetranectin T106B CDON 0.871727 PSA 3 PSMP T106B CDON 0.887652 PSA 2 PSA 3 T106B CDON 0.872997 PSA 3 Tetranectin T106B Mn SOD0.869702 PSA 3 PSMP T106B Mn SOD0.88618 PSA 2 PSA 3 T106B Mn SOD0.871226 PSA 3 Tetranectin PSMP T106B0.884986 PSA 2 PSA 3 Tetranectin T106B0.886643 PSA 2 PSA 3 PSMP T106B0.859194 PSA 4 SLIT2 T106B PTN 0.857201 PSA 4 SLIT2 IDE T106B0.873699 PSA 1 PSA 4 SLIT2 T106B0.858903 PSA 4 SLIT2 T106B CDON 0.856189 PSA 4 SLIT2 T106B Mn SOD0.856055 PSA 4 Tetranectin SLIT2 T106B0.859549 PSA 4 SLIT2 PSMP T106B0.880786 PSA 2 PSA 4 SLIT2 T106B0.6248 SLIT2 IDE T106B PTN 0.869758 PSA 1 SLIT2 T106B PTN 0.62815 SLIT2 T106B PTN CDON 0.637253 SLIT2 T106B Mn SOD PTN0.617322 Tetranectin SLIT2 T106B PTNAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.620516 SLIT2 PSMP T106B PTN 0.883033 PSA 2 SLIT2 T106B PTN 0.867515 PSA 1 SLIT2 IDE T106B0.624974 SLIT2 IDE T106B CDON 0.62094 SLIT2 IDE T106B Mn SOD0.599716 Tetranectin SLIT2 IDE T106B0.598444 SLIT2 IDE PSMP T106B0.882138 PSA 2 SLIT2 IDE T106B0.868072 PSA 1 SLIT2 T106B CDON 0.865119 PSA 1 SLIT2 T106B Mn SOD0.864692 PSA 1 Tetranectin SLIT2 T106B0.868697 PSA 1 SLIT2 PSMP T106B0.88484 PSA 1 PSA 2 SLIT2 T106B0.628066 SLIT2 T106B Mn SOD CDON 0.617164 Tetranectin SLIT2 T106B CDON 0.613149 SLIT2 PSMP T106B CDON 0.882618 PSA 2 SLIT2 T106B CDON 0.622182 Tetranectin SLIT2 T106B Mn SOD0.621196 SLIT2 PSMP T106B Mn SOD0.880468 PSA 2 SLIT2 T106B Mn SOD0.598268 Tetranectin SLIT2 PSMP T106B0.880359 PSA 2 Tetranectin SLIT2 T106B0.882368 PSA 2 SLIT2 PSMP T106B0.864054 PSA 4 IDE T106B PTN 0.881307 PSA 1 PSA 4 T106B PTN 0.866664 PSA 4 T106B PTN CDON 0.862832 PSA 4 T106B Mn SOD PTN 0.862312 PSA 4 Tetranectin T106B PTN 0.866249 PSA 4 PSMP T106B PTN 0.885413 PSA 2 PSA 4 T106B PTN 0.874123 PSA 1 PSA 4 IDE T106B0.8643 PSA 4 IDE T106B CDON 0.860537 PSA 4 IDE T106B Mn SOD0.860481 PSA 4 Tetranectin IDE T106B0.863349 PSA 4 IDE PSMP T106B0.881585 PSA 2 PSA 4 IDE T106B0.873743 PSA 1 PSA 4 T106B CDON 0.870395 PSA 1 PSA 4 T106B Mn SOD0.869288 PSA 1 PSA 4 Tetranectin T106B0.873687 PSA 1 PSA 4 PSMP T106B0.881694 PSA 1 PSA 2 PSA 4 T106B0.862231 PSA 4 T106B Mn SOD CDON0.860916 PSA 4 Tetranectin T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.863853 PSA 4 PSMP T106B CDON 0.880964 PSA 2 PSA 4 T106B CDON 0.856527 PSA 4 Tetranectin T106B Mn SOD0.860013 PSA 4 PSMP T106B Mn SOD0.878858 PSA 2 PSA 4 T106B Mn SOD0.861674 PSA 4 Tetranectin PSMP T106B0.877826 PSA 2 PSA 4 Tetranectin T106B0.880718 PSA 2 PSA 4 PSMP T106B0.876466 PSA 1 IDE T106B PTN 0.634368 IDE T106B PTN CDON 0.645917 IDE T106B Mn SOD PTN 0.628116 Tetranectin IDE T106B PTN 0.629106 IDE PSMP T106B PTN 0.885966 PSA 2 IDE T106B PTN 0.877959 PSA 1 T106B PTN CDON 0.8748 PSA 1 T106B Mn SOD PTN 0.872588 PSA 1 Tetranectin T106B PTN 0877797 PSA 1 PSMP T106B PTN 0.890193 PSA 1 PSA 2 T106B PTN 0.642628 T106B Mn SOD PTN CDON 0.626069 Tetranectin T106B PTN CDON 0.626035 PSMP T106B PTN CDON 0.886522 PSA 2 T106B PTN CDON 0.638442 Tetranectin T106B Mn SOD PTN 0.641762 PSMP T106B Mn SOD PTN 0.884586 PSA 2 T106B Mn SOD PTN 0.624038 Tetranectin PSMP T106B PTN 0.883735 PSA 2 Tetranectin T106B PTN 0.886176 PSA 2 PSMP T106B PTN 0.875776 PSA 1 IDE T106B CDON 0.87192 PSA 1 IDE T106B Mn SOD0.870448 PSA 1 Tetranectin IDE T106B0.874946 PSA 1 IDE PSMP T106B0.88643 PSA 1 PSA 2 IDE T106B0.588178 IDE T106B Mn SOD CDON 0575169 Tetranectin IDE T106B CDON 0.57429 IDE PSMP T106B CDON 0.885236 PSA 2 IDE T106B CDON 0.569046 Tetranectin IDE T106B Mn SOD0.571849 IDE PSMP T106B Mn SOD0.883525 PSA 2 IDE T106B Mn SOD0.541513 Tetranectin IDE PSMP T106B0.882454 PSA 2 Tetranectin IDE T106BAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN C / DON 0.883646 PSA 2 IDE PSMP T106B0.873013 PSA 1 T106B Mn SOD CDON 0.869907 PSA 1 Tetranectin T106B CDON 0.875252 PSA 1 PSMP T106B CDON 0.885748 PSA 1 PSA 2 T106B CDON 0866251 PSA 1 Tetranectin T106B Mn SOD0.871376 PSA 1 PSMP T106B Mn SOD0.884118 PSA 1 PSA 2 T106B Mn SOD0.871239 PSA 1 Tetranectin PSMP T106B0.882569 PSA 1 PSA 2 Tetranectin T106B0.886341 PSA 1 PSA 2 PSMP T106B0.59751 Tetranectin T106B Mn SOD CDON 0.598048 PSMP T106B Mn SOD CDON 0.883332 PSA 2 T106B Mn SOD CDON 0.584314 Tetranectin PSMP T106B CDON 0.882319 PSA 2 Tetranectin T106B CDON 0.884574 PSA 2 PSMP T106B CDON 0.596362 Tetranectin PSMP T106B Mn SOD0.880085 PSA 2 Tetranectin T106B Mn SOD0.882178 PSA 2 PSMP T106B Mn SOD0.883231 PSA 2 Tetranectin PSMP T106B0.870952 PSA 3 DCE1 PSA 4 SLIT2 T106B0.864615 PSA 3 DCE1 SLIT2 T106B PTN 0.86183 PSA 3 DC E1 SLIT2 IDE T106B0.877648 PSA 1 PSA 3 DCE1 SLIT2 T106B0.863582 PSA 3 DCE1 SLIT2 T106B CDON 0.860126 PSA 3 DCE1 SLIT2 T106B Mn SOD0.861767 PSA 3 DCE1 Tetranectin SLIT2 T106B0.860632 PSA 3 DCE1 SLIT2 PSMP T106B0.884268 PSA 2 PSA 3 DC E1 SLIT2 T106B0.878003 PSA 3 DCE1 PSA 4 T106B PTN 0.872513 PSA 3 DCE1 PSA 4 IDE T106B0.875115 PSA 1 PSA 3 DCE1 PSA 4 T106B0.872324 PSA 3 DCE1 PSA 4 T106B CDON 0.869173 PSA 3 DCE1 PSA 4 T106B Mn SOD0.868725 PSA 3 DCE1 PSA 4 Tetranectin T106B0.87117 PSA 3 DCE1 PSA 4 PSMP T106B0.880984 PSA 2 PSA 3 DCE1 PSA 4 T106B0.870573 PSA 3 DCE1 IDE T106B PTN 0.886127 PSA 1 PSA 3 DCE1 T106B PTN 0.87263 PSA 3 DCE1 T106B PTN CDON 0870416 PSA 3 DCE1 T106B Mn SOD PTN0.870875 PSA 3 DC E1 Tetranectin T106B PTNAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.869274 PSA 3 DCE1 PSMP T106B PTN 0.889685 PSA 2 PSA.3 DCE1 T106B PTN 0.880928 PSA 1 PSA 3 DCE1 IDE T106B0.874373 PSA 3 DCE1 IDE T106B CDON 0.872816 PSA 3 DCE1 IDE T106B Mn SOD0873017 PSA 3 DCE1 Tetranectin IDE T106B0.868875 PSA 3 DCE1 IDE PSMP T106B0.886841 PSA 2 PSA 3 DCE1 IDE T106B0.880536 PSA 1 PSA 3 DCE1 T106B CDON 0.877096 PSA 1 PSA 3 DCE1 T106B Mn SOD0.875934 PSA 1 PSA 3 DCE1 Tetranectin T106B0879722 PSA 1 PSA 3 DCE1 PSMP T106B0.885796 PSA 1 PSA 2 PSA 3 DCE1 T106B0.873873 PSA 3 DCE1 T106B Mn SOD CDON 0.873768 PSA.3 DCE1 Tetranectin T106B CDON 0.870617 PSA 3 DCE1 PSMP T106B CDON 0.885946 PSA 2 PSA 3 DCE1 T106B CDON 0.871259 PSA 3 DCE1 Tetranectin T106B Mn SOD0.868177 PSA 3 DCE1 PSMP T106B Mn SOD0.884328 PSA 2 PSA 3 DCE1 T106B Mn SOD0.869972 PSA 3 DCE1 Tetranectin PSMP T106B0.883138 PSA 2 PSA 3 DCE1 Tetranectin T106B0.885377 PSA 2 PSA 3 DCE1 PSMP T106B0.856648 DC E1 PSA 4 SLIT2 T106B PTN 0.854819 DCE1 PSA 4 SLIT2 IDE T106B0.871844 PSA 1 DCE1 PSA 4 SLIT2 T106B0.856614 DCE1 PSA 4 SLIT2 T106B CDON 0.852954 DCE1 PSA 4 SLIT2 T106B Mn SOD0.853264 DCE1 PSA 4 Tetranectin SLIT2 T106B0.857072 DC E1 PSA 4 SLIT2 PSMP T106B0.87835 PSA 2 DCE1 PSA 4 SLIT2 T106B0.624332 DCE1 SLIT2 IDE T106B PTN 0.867519 PSA 1 DCE1 SLIT2 T106B PTN 0.641101 DCE1 SLIT2 T106B PTN CDON 0.633021 DCE1 SLIT2 T106B Mn SOD PTN 0.615829 DCE1 Tetranectin SLIT2 T106B PTN 0.620613 DCE1 SLIT2 PSMP T106B PTN 0.880807 PSA 2 DCE1 SLIT2 T106B PTN 0.866418 PSA 1 DCE1 SLIT2 IDE T106B0.635659 DCE1 SLIT2 IDE T106B CDON 0.612197 DCE1 SLIT2 IDE T106B Mn SOD0.597129 DCE1 Tetranectin SLIT2 IDE T106B0.59628 DC E1 SLIT2 IDE PSMP T106BAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.880121 PSA 2 DCE1 SLIT2 IDE T106B0.866253 PSA 1 DCE1 SLIT2 T106B CDON 0.862235 PSA 1 DCE1 SLIT2 T106B Mn SOD0.862518 PSA 1 DCE1 Tetranectin SLIT2 T106B0.866616 PSA 1 DC E1 SLIT2 PSMP T106B0.881714 PSA 1 PSA 2 DCE1 SLIT2 T106B0.637333 DCE1 SLIT2 T106B Mn SOD CDON 0.630561 DC E1 Tetranectin SLIT2 T106B CDON 0.628604 DCE1 SLIT2 PSMP T106B CDON 0.880153 PSA 2 DCE1 SLIT2 T106B CDON 0.614982 DCE1 Tetranectin SLIT2 T106B Mn SOD0614478 DCE1 SLIT2 PSMP T106B Mn SOD0.877576 PSA 2 DCE1 SLIT2 T106B Mn SOD0.594773 DCE1 Tetranectin SLIT2 PSMP T106B0.877491 PSA 2 DCE1 Tetranectin SLIT2 T106B0.880472 PSA 2 DCE1 SLIT2 PSMP T106B0.862046 DCE1 PSA 4 IDE T106B PTN 0.879407 PSA 1 DCE1 PSA 4 T106B PTN 0.864542 DCE1 PSA 4 T106B PTN CDON 0.860327 DCE1 PSA 4 T106B Mn SOD PTN 0.860081 DCE1 PSA 4 Tetranectin T106B PTN 0.864551 DCE1 PSA 4 PSMP T106B PTN 0.883404 PSA 2 DCE1 PSA 4 T106B PTN 0.873316 PSA 1 DC E1 PSA 4 IDE T106B0.862951 DCE1 PSA 4 IDE T106B CDON 0.858928 DCE1 PSA 4 IDE T106B Mn SOD0.859121 DC E1 PSA 4 Tetranectin IDE T106B0.862501 DCE1 PSA 4 IDE PSMP T106B0.88004 PSA 2 DCE1 PSA 4 IDE T106B0.87259 PSA 1 DC E1 PSA 4 T106B CDON 0.868673 PSA 1 DCE1 PSA 4 T106B Mn SOD0.868068 PSA 1 DCE1 PSA 4 Tetranectin T106B0.872872 PSA 1 DCE1 PSA 4 PSMP T106B0.879665 PSA 1 PSA 2 DCE1 PSA 4 T106B0.860513 DCE1 PSA 4 T106B Mn SOD CDON 0859811 DCE1 PSA 4 Tetranectin T106B CDON 0.862989 DCE1 PSA 4 PSMP T106B CDON 0.879149 PSA 2 DCE1 PSA 4 T106B CDON 0.854515 DCE1 PSA 4 Tetranectin T106B Mn SOD0.858496 DCE1 PSA 4 PSMP T106B Mn SOD0.876579 PSA 2 DCE1 PSA 4 T106B Mn SOD0.860569 DCE1 PSA 4 Tetranectin PSMP T106B0.876035 PSA 2 DCE1 PSA 4 Tetranectin T106BAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.879746 PSA 2 DCE1 PSA 4 PSMP T106B0.87528 PSA 1 DCE1 IDE T106B PTN 0.650959 DCE1 IDE T106B PTN CDON 0.646381 DCE1 IDE T106B Mn SOD PTN 0.633203 DC E1 Tetranectin IDE T106B PTN 0636968 DCE1 IDE PSMP T106B PTN 0.883719 PSA 2 DCE1 IDE T106B PTN 0.875821 PSA 1 DC E1 T106B PTN CDON 0.872017 PSA 1 DCE1 T106B Mn SOD PTN 0.870452 PSA 1 DCE1 Tetranectin T106B PTN 0.87574 PSA 1 DCE1 PSMP T106B PTN 0887793 PSA 1 PSA 2 DCE1 T106B PTN 0.65517 DCE1 T106B Mn SOD PTN CDON 0.643384 DCE1 Tetranectin T106B PTN CDON 0.643828 DCE1 PSMP T106B PTN CDON 0.88428 PSA 2 DCE1 T106B PTN CDON 0.636698 DCE1 Tetranectin T106B Mn SOD PTN 0641831 DCE1 PSMP T106B Mn SOD PTN 0.88171 PSA 2 DCE1 T106B Mn SOD PTN 0.62816 DCE1 Tetranectin PSMP T106B PTN 0.881291 PSA 2 DCE1 Tetranectin T106B PTN 0.884376 PSA 2 DCE1 PSMP T106B PTN 0.875192 PSA 1 DCE1 IDE T106B CDON 0.871291 PSA 1 DC E1 IDE T106B Mn SOD0.869851 PSA 1 DCE1 Tetranectin IDE T106B0.874772 PSA 1 DCE1 IDE PSMP T106B0.884631 PSA 1 PSA 2 DCE1 IDE T106B0.610521 DCE1 IDE T106B Mn SOD CDON 0.59777 DCE1 Tetranectin IDE T106B CDON 0.602893 DC E1 IDE PSMP T106B CDON 0.883364 PSA 2 DCE1 IDE T106B CDON 0.575262 DCE1 Tetranectin IDE T106B Mn SOD0.580147 DCE1 IDE PSMP T106B Mn SOD0.881391 PSA 2 DCE1 IDE T106B Mn SOD0.558697 DCE1 Tetranectin IDE PSMP T106B0880629 PSA 2 DCE1 Tetranectin IDE T106B0.882771 PSA 2 DCE1 IDE PSMP T106B0.871049 PSA 1 DCE1 T106B Mn SOD CDON 0.869294 PSA 1 DCE1 Tetranectin T106B CDON 0.874092 PSA 1 DCE1 PSMP T106B CDON 0.883299 PSA 1 PSA 2 DCE1 T106B CDON 0864619 PSA 1 DCE1 Tetranectin T106B Mn SOD0.869952 PSA 1 DC E1 PSMP T106B Mn SODAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.881343 PSA 1 PSA 2 DCE1 T106B Mn SOD0.869992 PSA 1 DCE1 Tetranectin PSMP T106B0.880363 PSA 1 PSA 2 DCE1 Tetranectin T106B0.884623 PSA 1 PSA 2 DCE1 PSMP T106B0.617979 DCE1 Tetranectin T106B Mn SOD CDON 0619686 DCE1 PSMP T106B Mn SOD CDON 0.880827 PSA 2 DCE1 T106B Mn SOD CDON 0.610585 DCE1 Tetranectin PSMP T106B CDON 0.880355 PSA 2 DCE1 Tetranectin T106B CDON 0.883235 PSA 2 DCE1 PSMP T106B CDON 0.593014 DCE1 Tetranectin PSMP T106B Mn SOD0877862 PSA 2 DCE1 Tetranectin T106B Mn SOD0.880492 PSA 2 DCE1 PSMP T106B Mn SOD0.881952 PSA 2 DCE1 Tetranectin PSMP T106B0.874651 PSA 3 PSA 4 SLIT2 T106B PTN 0.872521 PSA 3 PSA 4 SLIT2 IDE T106B0.87904 PSA 1 PSA 3 PSA 4 SLIT2 T106B0.873231 PSA 3 PSA 4 SLIT2 T106B CDON 0.871864 PSA 3 PSA 4 SLIT2 T106B Mn SOD0.871505 PSA 3 PSA 4 Tetranectin SLIT2 T106B0.872711 PSA 3 PSA 4 SLIT2 PSMP T106B0.884195 PSA 2 PSA 3 PSA 4 SLIT2 T106B0.865749 PSA 3 SLIT2 IDE T106B PTN 0.882251 PSA 1 PSA 3 SLIT2 T106B PTN 0.867995 PSA 3 SLIT2 T106B PTN CDON 0.865946 PSA 3 SLIT2 T106B Mn SOD PTN 0.867302 PSA 3 Tetranectin SLIT2 T106B PTN 0.865829 PSA 3 SLIT2 PSMP T106B PTN 0.887765 PSA 2 PSA 3 SLIT2 T106B PTN 0.879467 PSA 1 PSA 3 SLIT2 IDE T106B0.864345 PSA 3 SLIT2 IDE T106B CDON 0.862949 PSA 3 SLIT2 IDE T106B Mn SOD0.863461 PSA 3 Tetranectin SLIT2 IDE T106B0.860807 PSA 3 SLIT2 IDE PSMP T106B0.886894 PSA 2 PSA 3 SLIT2 IDE T106B0.880714 PSA 1 PSA 3 SLIT2 T106B CDON 0.878322 PSA 1 PSA 3 SLIT2 T106B Mn SOD0.877926 PSA 1 PSA 3 Tetranectin SLIT2 T106B0.880214 PSA 1 PSA 3 SLIT2 PSMP T106B0.888217 PSA 1 PSA 2 PSA 3 SLIT2 T106B0.864716 PSA 3 SLIT2 T106B Mn SOD CDON 0864785 PSA 3 Tetranectin SLIT2 T106B CDON0.862251 PSA 3 SLIT2 PSMP T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.887023 PSA 2 PSA 3 SLIT2 T106B CDON 0.862893 PSA.3 Tetranectin SLIT2 T106B Mn SOD0.860602 PSA 3 SLIT2 PSMP T106B Mn SOD0.885687 PSA 2 PSA 3 SLIT2 T106B Mn SOD0.863018 PSA 3 Tetranectin SLIT2 PSMP T106B0884933 PSA 2 PSA 3 Tetranectin SLIT2 T106B0.886414 PSA 2 PSA 3 SLIT2 PSMP T106B0.879427 PSA 3 PSA 4 IDE T106B PTN 0.886466 PSA 1 PSA 3 PSA 4 T106B PTN 0.879895 PSA 3 PSA 4 T106B PTN CDON 0.878443 PSA 3 PSA 4 T106B Mn SOD PTN 0876749 PSA 3 PSA 4 Tetranectin T106B PTN 0.878616 PSA 3 PSA 4 PSMP T106B PTN 0.88916 PSA 2 PSA 3 PSA 4 T106B PTN 0.878616 PSA 1 PSA.3 PSA 4 IDE T106B0.873981 PSA 3 PSA 4 IDE T106B CDON 0.872227 PSA 3 PSA 4 IDE T106B Mn SOD0.871416 PSA 3 PSA 4 Tetranectin IDE T106B0.872174 PSA 3 PSA 4 IDE PSMP T106B0.884635 PSA 2 PSA 3 PSA 4 IDE T106B0.878318 PSA 1 PSA.3 PSA 4 T106B CDON 0.875159 PSA 1 PSA 3 PSA 4 T106B Mn SOD0.874102 PSA 1 PSA 3 PSA 4 Tetranectin T106B0.877749 PSA 1 PSA 3 PSA 4 PSMP T106B0.883433 PSA 1 PSA 2 PSA 3 PSA 4 T106B0.872328 PSA 3 PSA 4 T106B Mn SOD CDON 0.871525 PSA 3 PSA 4 Tetranectin T106B CDON 0.872533 PSA 3 PSA 4 PSMP T106B CDON 0.883699 PSA 2 PSA 3 PSA 4 T106B CDON 0.868693 PSA 3 PSA 4 Tetranectin T106B Mn SOD0.870186 PSA 3 PSA 4 PSMP T106B Mn SOD0.881918 PSA 2 PSA 3 PSA 4 T106B Mn SOD0.871061 PSA 3 PSA 4 Tetranectin PSMP T106B0.880589 PSA 2 PSA 3 PSA 4 Tetranectin T106B0.883283 PSA 2 PSA 3 PSA 4 PSMP T106B0.887827 PSA 1 PSA 3 IDE T106B PTN 0.872727 PSA.3 IDE T106B PTN CDON 0.871454 PSA 3 IDE T106B Mn SOD PTN 0.871275 PSA 3 Tetranectin IDE T106B PTN 0.867757 PSA 3 IDE PSMP T106B PTN 0.892053 PSA 2 PSA 3 IDE T106B PTN 0.8886 PSA 1 PSA 3 T106B PTN CDON0.88676 PSA 1 PSA 3 T106B Mn SOD PTNAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.884268 PSA 1 PSA 3 Tetranectin T106B PTN 0.887724 PSA 1 PSA.3 PSMP T106B PTN 0.894029 PSA 1 PSA 2 PSA 3 T106B PPM 0.874026 PSA 3 T106B Mn SOD PTN CDON 0.873627 PSA 3 Tetranectin T106B PTN CDON 0870591 PSA 3 PSMP T106B PTN CDON 0.89219 PSA 2 PSA 3 T106B PTN CDON 0.871803 PSA 3 Tetranectin T106B Mn SOD PTN 0.86924 PSA 3 PSMP T106B Mn SOD PTN 0.891191 PSA 2 PSA 3 T106B Mn SOD PTN 0.870621 PSA 3 Tetranectin PSMP T106B PTN 0889152 PSA 2 PSA 3 Tetranectin T106B PTN 0.890746 PSA 2 PSA 3 PSMP T106B PTN 0.882319 PSA 1 PSA 3 IDE T106B CDON 0.880512 PSA 1 PSA.3 IDE T106B Mn SOD0.878673 PSA 1 PSA 3 Tetranectin UDE T106B0.881109 PSA 1 PSA 3 IDE PSMP T106B0 88906 PSA 1 PSA 2 PSA 3 IDE T106B0.874913 PSA 3 IDE T106B Mn SOD CDON 0.874336 PSA 3 Tetranectin IDE T106B CDON 0.869472 PSA.3 IDE PSMP T106B CDON 0.888386 PSA 2 PSA 3 IDE T106B CDON 0.873276 PSA 3 Tetranectin IDE T106B Mn SOD0 86833 PSA 3 IDE PSMP T106B Mn SOD0.887591 PSA 2 PSA 3 IDE T106B Mn SOD0.869306 PSA 3 Tetranectin IDE PSMP T106B0.885704 PSA 2 PSA 3 Tetranectin IDE T106B0.886756 PSA 2 PSA 3 IDE PSMP T106B0.880492 PSA 1 PSA 3 T106B Mn SOD CDON 0879032 PSA 1 PSA 3 Tetranectin T106B CDON 0.881924 PSA 1 PSA 3 PSMP T106B CDON 0.888592 PSA 1 PSA 2 PSA 3 T106B CDON 0.875623 PSA 1 PSA 3 Tetranectin T106B Mn SOD0.878961 PSA 1 PSA 3 PSMP T106B Mn SOD0.886865 PSA 1 PSA 2 PSA 3 T106B Mn SOD0879189 PSA 1 PSA 3 Tetranectin PSMP T106B0.885187 PSA 1 PSA 2 PSA.3 Tetranectin T106B0.888438 PSA 1 PSA 2 PSA 3 PSMP T106B0.874433 PSA 3 Tetranectin T106B Mn SOD CDON 0.869758 PSA 3 PSMP T106B Mn SOD CDON 0.886486 PSA 2 PSA 3 T106B Mn SOD CDON 0870863 PSA 3 Tetranectin PSMP T106B CDON0.885627 PSA 2 PSA 3 Tetranectin T106B CDONAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLU 2 IDE PSMP T106B Mn SOD PTN CDON 0.886873 PSA 2 PSA 3 PSMP T106B CDON 0.869347 PSA.3 Tetranectin PSMP T106B Mn SOD0.883792 PSA 2 PSA 3 Tetranectin T106B Mn SOD0.885191 PSA 2 PSA 3 PSMP T106B Mn SOD0.885623 PSA 2 PSA 3 Tetranectin PSMP T106B0858663 PSA 4 SLIT2 IDE T106B PTN 0.876281 PSA 1 PSA 4 SLIT2 T106B PTN 0.860708 PSA 4 SLIT2 T106B PTN CDON 0.857459 PSA 4 SLIT2 T106B Mn SOD PTN 0.857766 PSA 4 Tetranectin SLIT2 T106B PTN 0.86086 PSA 4 SLIT2 PSMP T106B PTN 0881533 PSA 2 PSA 4 SLIT2 T106B PTN 0.873961 PSA 1 PSA 4 SLIT2 IDE T106B0.858413 PSA 4 SLIT2 IDE T106B CDON 0.855398 PSA 4 SLIT2 IDE T106B Mn SOD0.85562 PSA 4 Tetranectin SLIT2 UDE T106B0.858193 PSA 4 SLIT2 IDE PSMP T106B0880871 PSA 2 PSA 4 SLIT2 IDE T106B0.874308 PSA 1 PSA 4 SLIT2 T106B CDON 0.872449 PSA 1 PSA 4 SLIT2 T106B Mn SOD0.872005 PSA 1 PSA 4 Tetranectin SLIT2 T106B0.875643 PSA 1 PSA 4 SLIT2 PSMP T106B0.882888 PSA 1 PSA 2 PSA 4 SLIT2 T106B0 85754 PSA 4 SLIT2 T106B Mn SOD CDON 0.856374 PSA 4 Tetranectin SLIT2 T106B CDON 0.858936 PSA 4 SLIT2 PSMP T106B CDON 0.881041 PSA 2 PSA 4 SLIT2 T106B CDON 0.854369 PSA 4 Tetranectin SLIT2 T106B Mn SOD0.857253 PSA 4 SLIT2 PSMP T106B Mn SOD0879758 PSA 2 PSA 4 SLIT2 T106B Mn SOD0.858762 PSA 4 Tetranectin SLIT2 PSMP T106B0.878874 PSA 2 PSA 4 Tetranectin SLIT2 T106B0.881617 PSA 2 PSA 4 SLIT2 PSMP T106B0.870184 PSA 1 SLIT2 IDE T106B PTN 0.637696 SLIT2 IDE T106B PTN CDON 0641198 SLIT2 IDE T106B Mn SOD PTN 0.624708 Tetranectin SLIT2 IDE T106B PTN 0.624322 SLIT2 IDE PSMP T106B PTN 0.883267 PSA 2 SLIT2 IDE T106B PTN 0.870444 PSA 1 SLIT2 T106B PTN CDON 0.868092 PSA 1 SLIT2 T106B Mn SOD PTN 0867051 PSA 1 Tetranectin SLIT2 T106B PTN0.870988 PSA 1 SLIT2 PSMP T106B PTNAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.885917 PSA 1 PSA 2 SLIT2 T106B PTN 0.638273 SLIT2 T106B Mn SOD PTN CDON 0.626906 Tetranectin SLIT2 T106B PTN CDON 0.623852 SLIT2 PSMP T106B PTN CDON 0.88382 PSA 2 SLIT2 T106B PTN CDON 0637196 Tetranectin SLIT2 T106B Mn SOD PTN 0.638894 SLIT2 PSMP T106B Mn SOD PTN 0.881646 PSA 2 SLIT2 T106B Mn SOD PTN 0.62051 Tetranectin SLIT2 PSMP T106B PTN 0.881379 PSA 2 Tetranectin SLIT2 T106B PTN 0.88332 PSA 2 SLIT2 PSMP T106B PTN 0868409 PSA 1 SLIT2 IDE T106B CDON 0.865359 PSA 1 SLIT2 IDE T106B Mn SOD0.865006 PSA 1 Tetranectin SLIT2 IDE T106B0.868052 PSA 1 SLIT2 IDE PSMP T106B0.884982 PSA 1 PSA 2 SLIT2 IDE T106B0.635353 SLIT2 IDE T106B Mn SOD CDON 0622671 Tetranectin SLIT2 IDE T106B CDON 0.61875 SLIT2 IDE PSMP T106B CDON 0.882352 PSA 2 SLIT2 IDE T106B CDON 0.621559 Tetranectin SLIT2 IDE T106B Mn SOD0.619823 SLIT2 IDE PSMP T106B Mn SOD0.880637 PSA 2 SLIT2 IDE T106B Mn SOD0599585 Tetranectin SLIT2 IDE PSMP T106B0.880484 PSA 2 Tetranectin SLIT2 IDE T106B0.881266 PSA 2 SLIT2 IDE PSMP T106B0.867233 PSA 1 SLIT2 T106B Mn SOD CDON 0.864849 PSA 1 Tetranectin SLIT2 T106B CDON 0.868826 PSA 1 SLIT2 PSMP T106B CDON 0884982 PSA 1 PSA 2 SLIT2 T106B CDON 0.862425 PSA 1 Tetranectin SLIT2 T106B Mn SOD0.866519 PSA 1 SLIT2 PSMP T106B Mn SOD0.883521 PSA 1 PSA 2 SLIT2 T106B Mn SOD0.867402 PSA 1 Tetranectin SLIT2 PSMP T106B0.882464 PSA 1 PSA 2 Tetranectin SLIT2 T106B0885825 PSA 1 PSA 2 SLIT2 PSMP T106B0.625982 Tetranectin SLIT2 T106B Mn SOD CDON 0.623336 SLIT2 PSMP T106B Mn SOD CDON 0.881351 PSA 2 SLIT2 T106B Mn SOD CDON 0.613677 Tetranectin SLIT2 PSMP T106B CDON 0.880605 PSA 2 Tetranectin SLIT2 T106B CDON 0 88217 PSA 2 SLIT2 PSMP T106B CDON0.621836 Tetranectin SLIT2 PSMP T106B Mn SODAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.878669 PSA 2 Tetranectin SLIT2 T106B Mn SOD0.880367 PSA 2 SLIT2 PSMP T106B Mn SOD0.881809 PSA 2 Tetranectin SLIT2 PSMP T106B0.881831 PSA 1 PSA 4 IDE T106B PTN 0.865333 PSA 4 IDE T106B PTN CDON 0862447 PSA 4 IDE T106B Mn SOD PTN 0.862138 PSA 4 Tetranectin IDE T106B PTN 0.864974 PSA 4 IDE PSMP T106B PTN 0.885405 PSA 2 PSA 4 IDE T106B PTN 0.882485 PSA 1 PSA 4 T106B PTN CDON 0.87973 PSA 1 PSA 4 T106B Mn SOD PTN 0878003 PSA 1 PSA 4 Tetranectin T106B PTN 0.882537 PSA 1 PSA 4 PSMP T106B PTN 0.888338 PSA 1 PSA 2 PSA 4 T106B PTN 0.865369 PSA 4 T106B Mn SOD PTN CDON 0.863203 PSA. 4 Tetranectin T106B PTN CDON 0.866567 PSA 4 PSMP T106B PTN CDON 0885772 PSA 2 PSA 4 T106B PTN CDON 0.860287 PSA 4 Tetranectin T106B Mn SOD PTN 0.86357 PSA 4 PSMP T106B Mn SOD PTN 0.884026 PSA 2 PSA 4 T106B Mn SOD PTN 0.865087 PSA 4 Tetranectin PSMP T106B PTN 0.882549 PSA 2 PSA 4 Tetranectin T106B PTN 0885845 PSA 2 PSA 4 PSMP T106B PTN 0.875087 PSA 1 PSA 4 IDE T106B CDON 0.872808 PSA 1 PSA 4 IDE T106B Mn SOD0.871468 PSA 1 PSA 4 Tetranectin IDE T106B0.875091 PSA 1 PSA 4 IDE PSMP T106B0.883852 PSA 1 PSA 2 PSA 4 IDE T106B0 86253 PSA 4 IDE T106B Mn SOD CDON 0.861392 PSA 4 Tetranectin IDE T106B CDON 0.863744 PSA 4 IDE PSMP T106B CDON 0.882174 PSA 2 PSA 4 IDE T106B CDON 0.858044 PSA 4 Tetranectin IDE T106B Mn SOD0 86044 PSA 4 IDE PSMP T106B Mn SOD0880524 PSA 2 PSA 4 IDE T106B Mn SOD0.86228 PSA 4 Tetranectin IDE PSMP T106B0.879407 PSA 2 PSA 4 Tetranectin IDE T106B0.88119 PSA 2 PSA 4 IDE PSMP T106B0.872949 PSA 1 PSA 4 T106B Mn SOD CDON 0.871497 PSA 1 PSA 4 Tetranectin T106B CDON 0875236 PSA 1 PSA 4 PSMP T106B CDON0.882622 PSA 1 PSA 2 PSA 4 T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.867693 PSA 1 PSA 4 Tetranectin T106B Ma SOD0.871977 PSA 1 PSA 4 PSMP T106B Mn SOD0.880706 PSA 1 PSA 2 PSA 4 T106B Mn SOD0.872586 PSA 1 PSA 4 Tetranectin PSMP T106B0.879173 PSA 1 PSA 2 PSA 4 Tetranectin T106B0883203 PSA 1 PSA 2 PSA 4 PSMP T106B0.859464 PSA 4 Tetranectin T106B Mn SOD CDON 0.861622 PSA 4 PSMP T106B Mn SOD CDON 0.880016 PSA 2 PSA 4 T106B Mn SOD CDON 0.862033 PSA 4 Tetranectin PSMP T106B CDON 0.878568 PSA 2 PSA 4 Tetranectin T106B CDON 0881218 PSA 2 PSA 4 PSMP T106B CDON 0.858734 PSA 4 Tetranectin PSMP T106B Mn SOD0.876462 PSA 2 PSA 4 Tetranectin T106B Mn SOD0.87935 PSA 2 PSA 4 PSMP T106B Mn SOD0.879552 PSA 2 PSA 4 Tetranectin PSMP T106B0.877596 PSA 1 IDE T106B PTN CDON 0874324 PSA 1 IDE T106B Mn SOD PTN 0.872336 PSA 1 Tetranectin IDE T106B PTN 0.876888 PSA 1 IDE PSMP T106B PTN 0.889975 PSA 1 PSA 2 IDE T106B PTN 0.645838 IDE T106B Mn SOD PTN CDON 0.626591 Tetranectin IDE T106B PTN CDON 062739 IDE PSMP T106B PTN CDON 0.88597 PSA 2 IDE T106B PTN CDON 0.643438 Tetranectin IDE T106B Mn SOD PTN 0.642656 IDE PSMP T106B Mn SOD PTN 0.884534 PSA 2 IDE T106B Mn SOD PTN 0.627588 Tetranectin IDE PSMP T106B PTN 0883223 PSA 2 Tetranectin IDE T106B PTN 0.884538 PSA 2 IDE PSMP T106B PTN 0.876753 PSA 1 T106B Mn SOD PTN CDON 0.872763 PSA 1 Tetranectin T106B PTN CDON 0.878407 PSA 1 PSMP T106B PTN CDON 0.890399 PSA 1 PSA 2 T106B PTN CDON 0870383 PSA 1 Tetranectin T106B Mn SOD PTN 0.875805 PSA 1 PSMP T106B Mn SOD PTN 0.889189 PSA 1 PSA 2 T106B Mn SOD PTN 0.874353 PSA 1 Tetranectin PSMP T106B PTN 0.886853 PSA 1 PSA 2 Tetranectin T106B PTN 0.890835 PSA 1 PSA 2 PSMP T106B PTN 0637527 Tetranectin T106B Mn SOD PTN CDON0.637184 PSMP T106B Mn SOD PTN CDONAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLTE2 IDE PSMP T106B Mn SOD PTN CDON 0.884852 PSA 2 T106B Mn SOD PTN CDON 0.623574 Tetranectin PSMP T106B PTN CDON 0.883529 PSA 2 Tetranectin T106B PTN CDON 0.886022 PSA 2 PSMP T106B PTN CDON 0.640381 Tetranectin PSMP T106B Mn SOD PTN 0882247 PSA 2 Tetranectin T106B Mn SOD PTN 0.884054 PSA 2 PSMP T106B Mn SOD PTN 0.88474 PSA 2 Tetranectin PSMP T106B PTN 0.873784 PSA 1 IDE T106B Mn SOD CDON 0.870843 PSA 1 Tetranectin IDE T106B CDON 0.875426 PSA 1 IDE PSMP T106B CDON 0 88647 PSA 1 PSA 2 IDE T106B CDON 0.868032 PSA 1 Tetranectin IDE T106B Mn SOD0.872102 PSA 1 IDE PSMP T106B Mn SOD0.885211 PSA 1 PSA 2 IDE T106B Mn SOD0.872057 PSA 1 Tetranectin IDE PSMP T106B0.883239 PSA 1 PSA 2 Tetranectin IDE T106B0886087 PSA 1 PSA 2 IDE PSMP T106B0.585955 Tetranectin IDE T106B Mn SOD CDON 0.58409 IDE PSMP T106B Mn SOD CDON 0.88.3634 PSA 2 IDE T106B Mn SOD CDON 0.572781 Tetranectin IDE PSMP T106B CDON 0.882226 PSA 2 Tetranectin IDE T106B CDON 0883626 PSA 2 IDE PSMP T106B CDON 0.569062 Tetranectin IDE PSMP T106B Mn SOD0.881107 PSA 2 Tetranectin IDE T106B Mn SOD0.881589 PSA 2 IDE PSMP T106B Mn SOD0.88242 PSA 2 Tetranectin IDE PSMP T106B0.868689 PSA 1 Tetranectin T106B Mn SOD CDON 0873538 PSA 1 PSMP T106B Mn SOD CDON 0.884695 PSA 1 PSA 2 T106B Mn SOD CDON 0.872251 PSA 1 Tetranectin PSMP T106B CDON 0.883352 PSA 1 PSA 2 Tetranectin T106B CDON 0.886466 PSA 1 PSA 2 PSMP T106B CDON 0.868695 PSA 1 Tetranectin PSMP T106B Mn SOD0880956 PSA 1 PSA 2 Tetranectin T106B Mn SOD0.884917 PSA 1 PSA 2 PSMP T106B Mn SOD0.885191 PSA 1 PSA 2 Tetranectin PSMP T106B0.593337 Tetranectin PSMP T106B Mn SOD CDON 0.881081 PSA 2 Tetranectin T106B Mn SOD CDON 0.882364 PSA 2 PSMP T106B Mn SOD CDON 0882936 PSA 2 Tetranectin PSMP T106B CDON0.881049 PSA 2 Tetranectin PSMP T106B Mn SODAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.873106 PSA 3 DCE1 PSA 4 SLIT2 T106B PTN 0.870767 PSA 3 DCE1 PSA 4 SLIT2 IDE T106B0.877229 PSA 1 PSA 3 DCE1 PSA 4 SLIT2 T106B0.871622 PSA 3 DCE1 PSA 4 SLIT2 T106B CDON 0.869593 PSA 3 DCE1 PSA 4 SLIT2 T106B Mn SOD0869581 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 T106B0.871404 PSA 3 DCE1 PSA 4 SLIT2 PSMP T106B0.881634 PSA 2 PSA 3 DCE1 PSA 4 SLIT2 T106B0.863478 PSA 3 DCE1 SLIT2 IDE T106B PTN 0.880306 PSA 1 PSA 3 DCE1 SLIT2 T106B PTN 0.865587 PSA 3 DCE1 SLIT2 T106B PTN CDON 0862509 PSA 3 DCE1 SLIT2 T106B Mn SOD PTN 0.864155 PSA 3 DCE1 Tetranectin SLIT2 T106B PTN 0.862925 PSA 3 DCE1 SLIT2 PSMP T106B PTN 0.88595 PSA 2 PSA 3 DCE1 SLIT2 T106B PTN 0.87816 PSA 1 PSA 3 DCE1 SLIT2 IDE T106B0.862413 PSA 3 DCE1 SLIT2 IDE T106B CDON 0 86019 PSA 3 DCE1 SLIT2 IDE T106B Mn SOD0.861182 PSA 3 DCE1 Tetranectin SLIT2 IDE T106B0.859036 PSA 3 DCE1 SLIT2 IDE PSMP T106B0.884852 PSA 2 PSA 3 DCE1 SLIT2 IDE T106B0.878411 PSA 1 PSA 3 DCE1 SLIT2 T106B CDON 0.875764 PSA 1 PSA 3 DCE1 SLIT2 T106B Mn SOD0 87551 PSA 1 PSA 3 DCE1 Tetranectin SLIT2 T106B0.878423 PSA 1 PSA 3 DCE1 SLIT2 PSMP T106B0.885373 PSA 1 PSA 2 PSA 3 DCE1 SLIT2 T106B0.862122 PSA 3 DCE1 SLIT2 T106B Mn SOD CDON 0.862465 PSA 3 DCE1 Tetranectin SLIT2 T106B CDON 0.860646 PSA 3 DCE1 SLIT2 PSMP T106B CDON 0884707 PSA 2 PSA 3 DCE1 SLIT2 T106B CDON 0.859488 PSA 3 DCE1 Tetranectin SLIT2 T106B Mn SOD0.857798 PSA 3 DCE1 SLIT2 PSMP T106B Mn SOD0.883251 PSA 2 PSA 3 DCE1 SLIT2 T106B Mn SOD0.860468 PSA 3 DCE1 Tetranectin SLIT2 PSMP T106B0 88246 PSA 2 PSA 3 DCE1 Tetranectin SLIT2 T106B0884465 PSA 2 PSA 3 DCE1 SLIT2 PSMP T106B0.878056 PSA.3 DCE1 PSA 4 IDE T106B PTN 0.88438 PSA 1 PSA 3 DCE1 PSA 4 T106B PTN 0.878786 PSA 3 DCE1 PSA 4 T106B PTN CDON 0.876741 PSA 3 DCE1 PSA 4 T106B Mn SOD PTN 0.875466 PSA 3 DCE1 PSA 4 Tetranectin T106B PTN 0877656 PSA 3 DCE1 PSA 4 PSMP T106B PTN0.887176 PSA 2 PSA 3 DCE1 PSA 4 T106B PTNAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.877628 PSA 1 PSA 3 DCE1 PSA 4 IDE T106B0.873058 PSA.3 DCE1 PSA 4 IDE T106B CDON 0.871251 PSA 3 DCE1 PSA 4 IDE T106B Mn SOD0.870561 PSA 3 DCE1 PSA 4 Tetranectin IDE T106B0.871735 PSA 3 DCE1 PSA 4 IDE PS MP T106B0883076 PSA 2 PSA 3 DCE1 PSA 4 IDE T106B0.877108 PSA 1 PSA 3 DCE1 PSA 4 T106B CDON 0.873473 PSA 1 PSA 3 DCE1 PSA 4 T106B Mn SOD0.872687 PSA 1 PSA 3 DCE1 PSA 4 Tetranectin T106B0.876983 PSA 1 PSA 3 DCE1 PSA 4 PSMP T106B0.881484 PSA 1 PSA 2 PSA 3 DCE1 PSA 4 T106B0870984 PSA 3 DCE1 PSA 4 T106B Mn SOD CDON 0.870557 PSA 3 DCE1 PSA 4 Tetranectin T106B CDON 0.872019 PSA 3 DCE1 PSA 4 PSMP T106B CDON 0.881855 PSA 2 PSA.3 DCE1 PSA 4 T106B CDON 0.867152 PSA 3 DCE1 PSA 4 Tetranectin T106B Mn SOD0.869117 PSA 3 DCE1 PSA 4 PSMP T106B Mn SOD0879887 PSA 2 PSA 3 DCE1 PSA 4 T106B Mn SOD0.870105 PSA 3 DCE1 PSA 4 Tetranectin PSMP T106B0.87912 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin T106B0.881867 PSA 2 PSA.3 DCE1 PSA 4 PSMP T106B0.886196 PSA 1 PSA 3 DCE1 IDE T106B PTN 0.870754 PSA 3 DCE1 IDE T106B PTN CDON 0869105 PSA 3 DCE1 IDE T106B Mn SOD PTN 0.869161 PSA 3 DCE1 Tetranectin IDE T106B PTN 0.86628! PSA 3 DCE1 IDE PSMP T106B PTN 0.889991 PSA 2 PSA 3 DCE1 IDE T106B PTN 0.886482 PSA 1 PSA 3 DCE1 T106B PTN CDON 0.884435 PSA 1 PSA 3 DCE1 T106B Mn SOD PTN 0882142 PSA 1 PSA 3 DCE1 Tetranectin T106B PTN 0.886268 PSA 1 PSA 3 DCE1 PSMP T106B PTN 0.89152 PSA 1 PSA 2 PSA 3 DCE1 T106B PTN 0.871472 PSA 3 DCE1 T106B Mn SOD PTN CDON 0.871307 PSA 3 DCE1 Tetranectin T106B PTN CDON 0.869177 PSA 3 DCE1 PSMP T106B PTN CDON 0889862 PSA 2 PSA 3 DCE1 T106B PTN CDON 0.868786 PSA.3 DCE1 Tetranectin T106B Mn SOD PTN 0.866826 PSA 3 DCE1 PSMP T106B Mn SOD PTN 0.888584 PSA 2 PSA 3 DCE1 T106B Mn SOD PTN 0.868492 PSA 3 DCE1 Tetranectin PSMP T106B PTN 0.887023 PSA 2 PSA 3 DCE1 Tetranectin T106B PTN 0889148 PSA 2 PSA 3 DCE1 PSMP T106B PTN0.881371 PSA 1 PSA 3 DCE1 IDE T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.879447 PSA 1 PSA 3 DCE1 IDE T106B Mn SOD0.877854 PSA 1 PSA.3 DCE1 Tetranectin IDE T106B0.880649 PSA 1 PSA 3 DCE1 IDE PSMP T106B0.887156 PSA 1 PSA 2 PSA 3 DCE1 IDE T106B0.873231 PSA 3 DCE1 IDE T106B Mn SOD CDON 0873138 PSA 3 DCE1 Tetranectin IDE T106B CDON 0.869161 PSA 3 DCE1 IDE PSMP T106B CDON 0.886825 PSA 2 PSA 3 DCE1 IDE T106B CDON 0.871727 PSA 3 DCE1 Tetranectin IDE T106B Mn SOD0.866822 PSA 3 DCE1 IDE PSMP T106B Mn SOD0.885885 PSA 2 PSA 3 DCE1 IDE T106B Mn SOD0868471 PSA 3 DCE1 Tetranectin IDE PSMP T106B0.88428 PSA 2 PSA 3 DCE1 Tetranectin IDE T106B0.885603 PSA 2 PSA 3 DCE1 IDE PSMP T106B0.878681 PSA 1 PSA.3 DCE1 T106B Mn SOD CDON 0.877812 PSA 1 PSA 3 DCE1 Tetranectin T106B CDON 0.880863 PSA 1 PSA 3 DCE1 PSMP T106B CDON 0886414 PSA 1 PSA 2 PSA 3 DCE1 T106B CDON 0.873582 PSA 1 PSA 3 DCE1 Tetranectin T106B Mn SOD0.877576 PSA 1 PSA 3 DCE1 PSMP T106B Mn SOD0.884502 PSA 1 PSA 2 PSA.3 DCE1 T106B Mn SOD0.877922 PSA 1 PSA 3 DCE1 Tetranectin PSMP T106B0.883098 PSA 1 PSA 2 PSA 3 DCE1 Tetranectin T106B0886664 PSA 1 PSA 2 PSA 3 DCE1 PSMP T106B0.872541 PSA 3 DCE1 Tetranectin T106B Mn SOD CDON 0.868609 PSA 3 DCE1 PSMP T106B Mn SOD CDON 0.884691 PSA 2 PSA 3 DCE1 T106B Mn SOD CDON 0.869746 PSA 3 DCE1 Tetranectin PSMP T106B CDON 0.883723 PSA 2 PSA 3 DCE1 Tetranectin T106B CDON 0885764 PSA 2 PSA 3 DCE1 PSMP T106B CDON 0.867616 PSA 3 DCE1 Tetranectin PSMP T106B Mn SOD0.881508 PSA 2 PSA 3 DCE1 Tetranectin T106B Mn SOD0.883941 PSA 2 PSA 3 DCE1 PSMP T106B Mn SOD0.884405 PSA 2 PSA 3 DCE1 Tetranectin PSMP T106B0.856487 DCE1 PSA 4 SLIT2 IDE T106B PTN 0874453 PSA 1 DCE1 PSA 4 SLIT2 T106B PTN 0.858734 DCE1 PSA 4 SLIT2 T106B PTN CDON 0.854809 DCE1 PSA 4 SLIT2 T106B Mn SOD PTN 0.855309 DCE1 PSA 4 Tetranectin SLIT2 T106B PTN 0.858956 DCE1 PSA 4 SLIT2 PSMP T106B PTN 0.879726 PSA 2 DCE1 PSA 4 SLIT2 T106B PTN 0872384 PSA 1 DCE1 PSA 4 SLIT2 IDE T106B0.856342 DCE1 PSA 4 SLIT2 IDE T106B CDONAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.852833 DCE1 PSA 4 SLIT2 IDE T106B Mn SOD0.853442 DCE1 PSA 4 Tetranectin SL.1T2 IDE T106B0.856723 DCE1 PSA 4 SLIT2 IDE PSMP T106B0.879044 PSA 2 DCE1 PSA 4 SLIT2 IDE T106B0.872433 PSA 1 DCE1 PSA 4 SLIT2 T106B CDON 0870119 PSA 1 DCE1 PSA 4 SLIT2 T106B Mn SOD0.870194 PSA 1 DCE1 PSA 4 Tetranectin SLIT2 T106B0.87401 PSA 1 DCE1 PSA 4 SLIT2 PSMP T106B0.880609 PSA 1 PSA 2 DCE1 PSA 4 SLIT2 T106B0.855426 DCE1 PSA 4 SLIT2 T106B Mn SOD CDON 0.854579 DCE1 PSA 4 Tetranectin SLIT2 T106B CDON 0857362 DCE1 PSA 4 SLIT2 PSMP T106B CDON 0.87885 PSA 2 DCE1 PSA 4 SLIT2 T106B CDON 0.851522 DCE1 PSA 4 Tetranectin SLIT2 T106B Mn SOD0.854987 DCE1 PSA 4 SL.1T2 PSMP T106B Mn SOD0.87712 PSA 2 DCE1 PSA 4 SLIT2 T106B Mn SOD0.856733 DCE1 PSA 4 Tetranectin SLIT2 PSMP T106B0876793 PSA 2 DCE1 PSA 4 Tetranectin ST.1T2 T106B0.880056 PSA 2 DCE1 PSA 4 SLIT2 PSMP T106B0.868681 PSA 1 DCE1 SLIT2 IDE T106B PTN 0.649275 DCE1 SL.1T2 IDE T106B PTN CDON 0.63653 DCE1 SLIT2 IDE T106B Mn SOD PTN 0.623703 DCE1 Tetranectin SLIT2 IDE T106B PTN 0625228 DCE1 SLIT2 IDE PSMP T106B PTN 0.880976 PSA 2 DCE1 SLIT2 IDE T106B PTN 0.868984 PSA 1 DCE1 SLIT2 T106B PTN CDON 0.865498 PSA 1 DCE1 SLIT2 T106B Mn SOD PTN 0.864696 PSA 1 DCE1 Tetranectin SLIT2 T106B PTN 0.868929 PSA 1 DCE1 SLIT2 PSMP T106B PTN 0883953 PSA 1 PSA 2 DCE1 SLIT2 T106B PTN 0.647896 DCE1 SLIT2 T106B Mn SOD PTN CDON 0.640153 DCE1 Tetranectin SLIT2 T106B PTN CDON 0.638985 DCE1 SLIT2 PSMP T106B PTN CDON 0.881597 PSA 2 DCE1 SLIT2 T106B PTN CDON 0.632569 DCE1 Tetranectin SLIT2 T106B Mn SOD PTN 0635213 DCE1 SLIT2 PSMP T106B Mn SOD PTN 0.878749 PSA 2 DCE1 SL.1T2 T106B Mn SOD PTN 0.619944 DCE1 Tetranectin SLIT2 PSMP T106B PTN 0.879028 PSA 2 DCE1 Tetranectin SLIT2 T106B PTN 0.881662 PSA 2 DCE1 SLIT2 PSMP T106B PTN 0.867455 PSA 1 DCE1 SLIT2 IDE T106B CDON 0864075 PSA 1 DCE1 SLIT2 IDE T106B Mn SOD0.864171 PSA 1 DCE1 Tetranectin SLIT2 IDE T106BAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.867374 PSA 1 DCE1 SLIT2 IDE PSMP T106B0.88265 PSA 1 PSA 2 DCE1 SLIT2 IDE T106B0.641621 DCE1 SLIT2 IDE T106B Mn SOD CDON 0.634957 DCE1 Tetranectin SLIT2 IDE T106B CDON 0.634175 DCE1 SLIT2 IDE PSMP T106B CDON 0880072 PSA 2 DCE1 SLIT2 IDE T106B CDON 0.612199 DCE1 Tetranectin SLIT2 IDE T106B Mn SOD0.612417 DCE1 SLIT2 IDE PSMP T106B Mn SOD0.878233 PSA 2 DCE1 SLIT2 IDE T106B Mn SOD0.597242 DCE1 Tetranectin SLIT2 IDE PSMP T106B0.878205 PSA 2 DCE1 Tetranectin SLIT2 IDE T106B0879929 PSA 2 DCE1 SLIT2 IDE PSMP T106B0.865035 PSA 1 DCE1 SLIT2 T106B Mn SOD CDON 0.863058 PSA 1 DCE1 Tetranectin SLIT2 T106B CDON 0.867378 PSA 1 DCE1 SLIT2 PSMP T106B CDON 0.882053 PSA 1 PSA 2 DCE1 SLIT2 T106B CDON 0.859662 PSA 1 DCE1 Tetranectin SLIT2 T106B Mn SOD0864163 PSA 1 DCE1 SLIT2 PSMP T106B Mn SOD0.88044 PSA 1 PSA 2 DCE1 SLIT2 T106B Mn SOD0.864948 PSA 1 DCE1 Tetranectin SLIT2 PSMP T106B0.87973 PSA 1 PSA 2 DCE1 Tetranectin SLIT2 T106B0.883832 PSA 1 PSA 2 DCE1 SLIT2 PSMP T106B0.635109 DCE1 Tetranectin SLIT2 T106B Mn SOD CDON 0635026 DCE1 SLIT2 PSMP T106B Mn SOD CDON 0.878346 PSA 2 DCE1 SLIT2 T106B Mn SOD CDON 0.629798 DCE1 Tetranectin SLIT2 PSMP T106B CDON 0.878229 PSA 2 DCE1 Tetranectin SLIT2 T106B CDON 0.880468 PSA 2 DCE1 SLIT2 PSMP T106B CDON 0.614486 DCE1 Tetranectin SLIT2 PSMP T106B Mn SOD0875797 PSA 2 DCE1 Tetranectin SLIT2 T106B Mn SOD0.878209 PSA 2 DCE1 SLIT2 PSMP T106B Mn SOD0.87954 PSA 2 DCE1 Tetranectin SLIT2 PSMP T106B0.880076 PSA 1 DCE1 PSA 4 IDE T106B PTN 0.863381 DCE1 PSA 4 IDE T106B PTN CDON 0.860226 DCE1 PSA 4 IDE T106B Mn SOD PTN 0859904 DCE1 PSA 4 Tetranectin IDE T106B PTN 0.86332 DCE1 PSA 4 IDE PSMP T106B PTN 0.883497 PSA 2 DCE1 PSA 4 IDE T106B PTN 0.880593 PSA 1 DCE1 PSA 4 T106B PTN CDON 0.877612 PSA 1 DCE1 PSA 4 T106B Mn SOD PTN 0.876369 PSA 1 DCE1 PSA 4 Tetranectin T106B PTN 0880928 PSA 1 DCE1 PSA 4 PSMP T106B PTN0.886418 PSA 1 PSA 2 DCE1 PSA 4 T106B PTNAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.863227 DCE1 PSA 4 T106B Mn SOD PTN CDON 0.861715 DCE1 PSA 4 Tetranectin T106B PTN CDON 0.865051 DCE1 PSA 4 PSMP T106B PTN CDON 0.883864 PSA 2 DCE1 PSA 4 T106B PTN CDON 0.858036 DCE1 PSA 4 Tetranectin T106B Mn SOD PTN 0861668 DCE1 PSA 4 PSMP T106B Mn SOD PTN 0.882065 PSA 2 DCE1 PSA 4 T106B Mn SOD PTN 0.863353 DCE1 PSA 4 Tetranectin PSMP T106B PTN 0.880811 PSA 2 DCE1 PSA 4 Tetranectin T106B PTN 0.884598 PSA 2 DCE1 PSA 4 PSMP T106B PTN 0.874437 PSA 1 DCE1 PSA 4 IDE T106B CDON 0871358 PSA 1 DCE1 PSA 4 IDE T106B Mn SOD0.871001 PSA 1 DCE1 PSA 4 Tetranectin IDE T106B0.874451 PSA 1 DCE1 PSA 4 IDE PSMP T106B0.882315 PSA 1 PSA 2 DCE1 PSA 4 IDE T106B0.861025 DCE1 PSA 4 IDE T106B Mn SOD CDON 0.860739 DCE1 PSA 4 Tetranectin IDE T106B CDON 0863078 DCE1 PSA 4 IDE PSMP T106B CDON 0.880552 PSA 2 DCE1 PSA 4 IDE T106B CDON 0.856297 DCE1 PSA 4 Tetranectin IDE T106B Mn SOD0.859444 DCE1 PSA 4 IDE PSMP T106B Mn SOD0.878838 PSA 2 DCE1 PSA 4 IDE T106B Mn SOD0.861513 DCE1 PSA 4 Tetranectin IDE PSMP T106B0877995 PSA 2 DCE1 PSA 4 Tetranectin IDE T106B0.880415 PSA 2 DCE1 PSA 4 IDE PSMP T106B0.871146 PSA 1 DCE1 PSA 4 T106B Mn SOD CDON 0.870609 PSA 1 DCE1 PSA 4 Tetranectin T106B CDON 0.874175 PSA 1 DCE1 PSA 4 PSMP T106B CDON 0.880653 PSA 1 PSA 2 DCE1 PSA 4 T106B CDON 0866261 PSA 1 DCE1 PSA 4 Tetranectin T106B Mn SOD0.871025 PSA 1 DCE1 PSA 4 PSMP T106B Mn SOD0.87837 PSA 1 PSA 2 DCE1 PSA 4 T106B Mn SOD0.871751 PSA 1 DCE1 PSA 4 Tetranectin PSMP T106B0.877475 PSA 1 PSA 2 DCE1 PSA 4 Tetranectin T106B0.881807 PSA 1 PSA 2 DCE1 PSA 4 PSMP T106B0858189 DCE1 PSA 4 Tetranectin T106B Mn SOD CDON 0.860602 DCE1 PSA 4 PSMP T106B Mn SOD CDON 0.878043 PSA 2 DCE1 PSA 4 T106B Mn SOD CDON 0.861739 DCE1 PSA 4 Tetranectin PSMP T106B CDON 0.877168 PSA 2 DCE1 PSA 4 Tetranectin T106B CDON 0.880137 PSA 2 DCE1 PSA 4 PSMP T106B CDON 0857167 DCE1 PSA 4 Tetranectin PSMP T106B Mn SOD0.874387 PSA 2 DCE1 PSA 4 Tetranectin T106B Mn SODAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.87791 PSA 2 DCE1 PSA 4 PSMP T106B Mn SOD0.878604 PSA 2 DCE1 PSA 4 Tetranectin PSMP T106B0.876563 PSA 1 DCE1 IDE T106B PTN CDON 0.872824 PSA 1 DCE1 IDE T106B Mn SOD PTN 0.87166 PSA 1 DCE1 Tetranectin IDE T106B PTN 0876027 PSA 1 DCE1 IDE PSMP T106B PTN 0.887729 PSA 1 PSA 2 DCE1 IDE T106B PTN 0.659265 DCE1 IDE T106B Mn SOD PTN CDON 0.644501 DCE1 Tetranectin IDE T106B PTN CDON 0.646913 DCE1 IDE PSMP T106B PTN CDON 0.883933 PSA 2 DCE1 IDE T106B PTN CDON 0642726 DCE1 Tetranectin IDE T106B Mn SOD PTN 0.645066 DCE1 IDE PSMP T106B Mn SOD PTN 0.881884 PSA 2 DCE1 IDE T106B Mn SOD PTN 0.63432 DCE1 Tetranectin IDE PSMP T106B PTN 0.881109 PSA 2 DCE1 Tetranectin IDE T106B PTN 0.883275 PSA 2 DCE1 IDE PSMP T106B PTN 0874058 PSA 1 DCE1 T106B Mn SOD PTN CDON 0.871226 PSA 1 DCE1 Tetranectin T106B PTN CDON 0.876567 PSA 1 DCE1 PSMP T106B PTN CDON 0.888007 PSA 1 PSA 2 DCE1 T106B PTN CDON 0.868189 PSA 1 DCE1 Tetranectin T106B Mn SOD PTN 0.873489 PSA 1 DCE1 PSMP T106B Mn SOD PTN 0.886309 PSA 1 PSA 2 DCE1 T106B Mn SOD PTN 0.872767 PSA 1 DCE1 Tetranectin PSMP T106B PTN 0.88476 PSA 1 PSA 2 DCE1 Tetranectin T106B PTN 0.88889 PSA 1 PSA 2 DCE1 PSMP T106B PTN 0.651135 DCE1 Tetranectin T106B Mn SOD PTN CDON 0.651992 DCE1 PSMP T106B Mn SOD PTN CDON 0.882301 PSA 2 DCE1 T106B Mn SOD PTN CDON 0.642747 DCE1 Tetranectin PSMP T106B PTN CDON 0.881468 PSA 2 DCE1 Tetranectin T106B PTN CDON 0.88456 PSA 2 DCE1 PSMP T106B PTN CDON 0.639564 DCE1 Tetranectin PSMP T106B Mn SOD PTN 0 87954 PSA 2 DCE1 Tetranectin T106B Mn SOD PTN 0.881944 PSA 2 DCE1 PSMP T106B Mn SOD PTN 0.883142 PSA 2 DCE1 Tetranectin PSMP T106B PTN 0.873138 PSA 1 DCE1 IDE T106B Mn SOD CDON 0.870815 PSA 1 DCE1 Tetranectin IDE T106B CDON 0.875288 PSA 1 DCE1 IDE PSMP T106B CDON 0.884721 PSA 1 PSA 2 DCE1 IDE T106B CDON 0867189 PSA 1 DCE1 Tetranectin IDE T106B Mn SOD0.871646 PSA 1 DCE1 IDE PSMP T106B Mn SODAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.883174 PSA 1 PSA 2 DCE1 IDE T106B Mn SOD0.871995 PSA 1 DCE1 Tetranectin IDE PSMP T106B0.881529 PSA 1 PSA 2 DCE1 Tetranectin IDE T106B0.884933 PSA 1 PSA 2 DCE1 IDE PSMP T106B0.60543 DCE1 Tetranectin IDE T106B Mn SOD CDON 0609682 DCE1 IDE PSMP T106B Mn SOD CDON 0.881452 PSA 2 DCE1 IDE T106B Mn SOD CDON 0.59683 DCE1 Tetranectin IDE PSMP T106B CDON 0.880702 PSA 2 DCE1 Tetranectin IDE T106B CDON 0.882763 PSA 2 DCE1 IDE PSMP T106B CDON 0.575617 DCE1 Tetranectin IDE PSMP T106B Mn SOD0878943 PSA 2 DCE1 Tetranectin IDE T106B Mn SOD0.880218 PSA 2 DCE1 IDE PSMP T106B Mn SOD0.881266 PSA 2 DCE1 Tetranectin IDE PSMP T106B0.867568 PSA 1 DCE1 Tetranectin T106B Mn SOD CDON 0.872049 PSA 1 DCE1 PSMP T106B Mn SOD CDON 0.882089 PSA 1 PSA 2 DCE1 T106B Mn SOD CDON 0871593 PSA 1 DCE1 Tetranectin PSMP T106B CDON 0.881533 PSA 1 PSA 2 DCE1 Tetranectin T106B CDON 0.884594 PSA 1 PSA 2 DCE1 PSMP T106B CDON 0.867112 PSA 1 DCE1 Tetranectin PSMP T106B Mn SOD0.878459 PSA 1 PSA 2 DCE1 Tetranectin T106B Mn SOD0.882932 PSA 1 PSA 2 DCE1 PSMP T106B Mn SOD0.883211 PSA 1 PSA 2 DCE1 Tetranectin PSMP T106B0.614845 DCE1 Tetranectin PSMP T106B Mn SOD CDON 0.878802 PSA 2 DCE1 Tetranectin T106B Mn SOD CDON 0.88075 PSA 2 DCE1 PSMP T106B Mn SOD CDON 0.881617 PSA 2 DCE1 Tetranectin PSMP T106B CDON 0.879496 PSA 2 DCE1 Tetranectin PSMP T106B Mn SOD0874534 PSA 3 PSA 4 SLIT2 IDE T106B PTN 0.881404 PSA 1 PSA 3 PSA 4 SLIT2 T106B PTN 0.874954 PSA 3 PSA 4 SLIT2 T106B PTN CDON 0.87313 PSA 3 PSA 4 SLIT2 T106B Mn SOD PTN 0.873183 PSA 3 PSA 4 Tetranectin SLIT2 T106B PTN 0.874304 PSA 3 PSA 4 SLIT2 PSMP T106B PTN 0885034 PSA 2 PSA 3 PSA 4 SLIT2 T106B PTN 0.879048 PSA 1 PSA.3 PSA 4 SLIT2 IDE T106B0.872977 PSA 3 PSA 4 SLIT2 IDE T106B CDON 0.871456 PSA 3 PSA 4 SLIT2 IDE T106B Mn SOD0.871113 PSA 3 PSA 4 Tetranectin SLIT2 IDE T106B0.87146 PSA 3 PSA 4 SLIT2 IDE PSMP T106B0884558 PSA 2 PSA 3 PSA 4 SLIT2 IDE T106B0.879641 PSA 1 PSA 3 PSA 4 SLIT2 T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.877745 PSA 1 PSA 3 PSA 4 SLIT2 T106B Mn SOD0.877184 PSA 1 PSA 3 PSA 4 Tetranectin SLIT2 T106B0.880133 PSA 1 PSA 3 PSA 4 SLIT2 PSMP T106B0.885006 PSA 1 PSA 2 PSA 3 PSA 4 SLIT2 T106B0.872388 PSA 3 PSA 4 SLIT2 T106B Mn SOD CDON 0871452 PSA 3 PSA 4 Tetranectin SLIT2 T106B CDON 0.872485 PSA 3 PSA 4 SLIT2 PSMP T106B CDON 0.88428 PSA 2 PSA 3 PSA 4 SLIT2 T106B CDON 0.870216 PSA 3 PSA 4 Tetranectin SLIT2 T106B Mn SOD0.871388 PSA 3 PSA 4 SLIT2 PSMP T106B Mn SOD0.883199 PSA 2 PSA 3 PSA 4 SLIT2 T106B Mn SOD0872404 PSA 3 PSA 4 Tetranectin SLIT2 PSMP T106B0.882323 PSA 2 PSA 3 PSA 4 Tetranectin SLIT2 T106B0.884433 PSA 2 PSA 3 PSA 4 SLIT2 PSMP T106B0.881988 PSA 1 PSA.3 SLIT2 IDE T106B PTN 0.86618 PSA 3 SLIT2 IDE T106B PTN CDON 0.864603 PSA 3 SLIT2 IDE T106B Mn SOD PTN 0865244 PSA 3 Tetranectin SLIT2 IDE T106B PTN 0.862897 PSA 3 SLIT2 IDE PSMP T106B PTN 0.8881 PSA 2 PSA 3 SLIT2 IDE T106B PTN 0.882702 PSA 1 PSA.3 SLIT2 T106B PTN CDON 0.880678 PSA 1 PSA 3 SLIT2 T106B Mn SOD PTN 0.879596 PSA 1 PSA 3 Tetranectin SLIT2 T106B PTN 0882247 PSA 1 PSA 3 SLIT2 PSMP T106B PTN 0.889241 PSA 1 PSA 2 PSA 3 SLIT2 T106B PTN 0.867136 PSA 3 SLIT2 T106B Mn SOD PTN CDON 0.866826 PSA 3 Tetranectin SLIT2 T106B PTN CDON 0.864809 PSA 3 SLIT2 PSMP T106B PTN CDON 0.888088 PSA 2 PSA 3 SLIT2 T106B PTN CDON 0865438 PSA 3 Tetranectin SLIT2 T106B Mn SOD PTN 0.86355 PSA 3 SLIT2 PSMP T106B Mn SOD PTN 0.88667 PSA 2 PSA 3 SLIT2 T106B Mn SOD PTN 0.86562 PSA 3 Tetranectin SLIT2 PSMP T106B PTN 0.885583 PSA 2 PSA 3 Tetranectin SLIT2 T106B PTN 0.886966 PSA 2 PSA 3 SLIT2 PSMP T106B PTN 0879901 PSA 1 PSA 3 SLIT2 IDE T106B CDON 0.878181 PSA 1 PSA.3 SLIT2 IDE T106B Mn SOD0.877301 PSA 1 PSA 3 Tetranectin SLIT2 IDE T106B0.878862 PSA 1 PSA 3 SLIT2 IDE PSMP T106B0.888092 PSA 1 PSA 2 PSA 3 SLIT2 IDE T106B0.863248 PSA 3 SLIT2 IDE T106B Mn SOD CDON 0863167 PSA 3 Tetranectin SLIT2 IDE T106B CDON0.860341 PSA 3 SLIT2 IDE PSMP T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.886914 PSA 2 PSA 3 SLIT2 IDE T106B CDON 0.861989 PSA.3 Tetranectin SL.1T2 IDE T106B Mn SOD0.858782 PSA 3 SLIT2 IDE PSMP T106B Mn SOD0.885861 PSA 2 PSA 3 SLIT2 IDE T106B Mn SOD0.860432 PSA 3 Tetranectin SLIT2 IDE PSMP T106B0884522 PSA 2 PSA 3 Tetranectin SLIT2 IDE T106B0.885381 PSA 2 PSA 3 SLIT2 IDE PSMP T106B0.879221 PSA 1 PSA 3 SLIT2 T106B Mn SOD CDON 0.878181 PSA 1 PSA 3 Tetranectin SLIT2 T106B CDON 0.880637 PSA 1 PSA 3 SLIT2 PSMP T106B CDON 0.888366 PSA 1 PSA 2 PSA 3 SLIT2 T106B CDON 0875817 PSA 1 PSA 3 Tetranectin SLIT2 T106B Mn SOD0.87839 PSA 1 PSA 3 SLIT2 PSMP T106B Mn SOD0.886926 PSA 1 PSA 2 PSA 3 SLIT2 T106B Mn SOD0.879322 PSA 1 PSA.3 Tetranectin SL.1T2 PSMP T106B0.885655 PSA 1 PSA 2 PSA 3 Tetranectin SLIT2 T106B0.888507 PSA 1 PSA 2 PSA 3 SLIT2 PSMP T106B0863724 PSA 3 Tetranectin ST.1T2 T106B Mn SOD CDON 0.860844 PSA 3 SLIT2 PSMP T106B Mn SOD CDON 0.886163 PSA 2 PSA 3 SLIT2 T106B Mn SOD CDON 0.861626 PSA.3 Tetranectin SL.1T2 PSMP T106B CDON 0.884937 PSA 2 PSA 3 Tetranectin SLIT2 T106B CDON 0.886321 PSA 2 PSA 3 SLIT2 PSMP T106B CDON 0860424 PSA 3 Tetranectin SLIT2 PSMP T106B Mn SOD0.883784 PSA 2 PSA 3 Tetranectin SLIT2 T106B Mn SOD0.884858 PSA 2 PSA 3 SLIT2 PSMP T106B Mn SOD0.88557 PSA 2 PSA 3 Tetranectin SLIT2 PSMP T106B0.886676 PSA 1 PSA 3 PSA 4 IDE T106B PTN 0.879754 PSA 3 PSA 4 IDE T106B PTN CDON 0 87814 PSA 3 PSA 4 IDE T106B Mn SOD PTN 0.876866 PSA 3 PSA 4 Tetranectin IDE T106B PTN 0.87787 PSA 3 PSA 4 IDE PSMP T106B PTN 0.889576 PSA 2 PSA 3 PSA 4 IDE T106B PTN 0.887063 PSA 1 PSA 3 PSA 4 T106B PTN CDON 0.885111 PSA 1 PSA 3 PSA 4 T106B Mn SOD PTN 0883041 PSA 1 PSA 3 PSA 4 Tetranectin T106B PTN 0.886869 PSA 1 PSA.3 PSA 4 PSMP T106B PTN 0.890822 PSA 1 PSA 2 PSA 3 PSA 4 T106B PTN 0.879254 PSA 3 PSA 4 T106B Mn SOD PTN CDON 0.877487 PSA 3 PSA 4 Tetranectin T106B PTN CDON 0.878822 PSA 3 PSA 4 PSMP T106B PTN CDON 0889334 PSA 2 PSA 3 PSA 4 T106B PTN CDON0.875688 PSA 3 PSA 4 Tetranectin T106B Mn SOD PTNAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.877144 PSA 3 PSA 4 PSMP T106B Mn SOD PTN 0.888326 PSA 2 PSA.3 PSA 4 T106B Mn SOD PTN 0.877051 PSA 3 PSA 4 Tetranectin PSMP T106B PTN 0.886305 PSA 2 PSA 3 PSA 4 Tetranectin T106B PTN 0.888664 PSA 2 PSA 3 PSA 4 PSMP T106B PTN 0 87931 PSA 1 PSA 3 PSA 4 IDE T106B CDON 0.877398 PSA 1 PSA 3 PSA 4 IDE T106B Mn SOD0.875994 PSA 1 PSA 3 PSA 4 Tetranectin IDE T106B0.8786 PSA 1 PSA 3 PSA 4 IDE PSMP T106B0.885542 PSA 1 PSA 2 PSA 3 PSA 4 IDE T106B0.872868 PSA 3 PSA 4 IDE T106B Mn SOD CDON 0871944 PSA 3 PSA 4 Tetranectin IDE T106B CDON 0.872209 PSA 3 PSA 4 IDE PSMP T106B CDON 0.88484 PSA 2 PSA 3 PSA 4 IDE T106B CDON 0.870141 PSA.3 PSA 4 Tetranectin IDE T106B Mn SOD0.870484 PSA 3 PSA 4 IDE PSMP T106B Mn SOD0.883606 PSA 2 PSA 3 PSA 4 IDE T106B Mn SOD0871142 PSA 3 PSA 4 Tetranectin IDE PSMP T106B0.882267 PSA 2 PSA 3 PSA 4 Tetranectin IDE T106B0.883566 PSA 2 PSA 3 PSA 4 IDE PSMP T106B0.876728 PSA 1 PSA.3 PSA 4 T106B Mn SOD CDON 0.875631 PSA 1 PSA 3 PSA 4 Tetranectin T106B CDON 0.878782 PSA 1 PSA 3 PSA 4 PSMP T106B CDON 0884308 PSA 1 PSA 2 PSA 3 PSA 4 T106B CDON 0.872493 PSA 1 PSA 3 PSA 4 Tetranectin T106B Mn SOD0.875998 PSA 1 PSA 3 PSA 4 PSMP T106B Mn SOD0.882477 PSA 1 PSA 2 PSA 3 PSA 4 T106B Mn SOD0.876232 PSA 1 PSA 3 PSA 4 Tetranectin PSMP T106B0.881293 PSA 1 PSA 2 PSA 3 PSA 4 Tetranectin T106B0884336 PSA 1 PSA 2 PSA 3 PSA 4 PSMP T106B0.870303 PSA 3 PSA 4 Tetranectin T106B Mn SOD CDON 0.871162 PSA 3 PSA 4 PSMP T106B Mn SOD CDON 0.882876 PSA 2 PSA 3 PSA 4 T106B Mn SOD CDON 0.871549 PSA 3 PSA 4 Tetranectin PSMP T106B CDON 0.881323 PSA 2 PSA 3 PSA 4 Tetranectin T106B CDON 0883517 PSA 2 PSA 3 PSA 4 PSMP T106B CDON 0.869222 PSA.3 PSA 4 Tetranectin PSMP T106B Mn SOD0.879358 PSA 2 PSA 3 PSA 4 Tetranectin T106B Mn SOD0.8819 PSA 2 PSA 3 PSA 4 PSMP T106B Mn SOD0.882186 PSA 2 PSA 3 PSA 4 Tetranectin PSMP T106B0.887866 PSA 1 PSA 3 IDE T106B PTN CDON 0886615 PSA 1 PSA 3 IDE T106B Mn SOD PTN0.883679 PSA 1 PSA 3 Tetranectin IDE T106B PTNAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.886748 PSA 1 PSA 3 IDE PSMP T106B PTN 0.893707 PSA 1 PSA 2 PSA 3 IDE T106B PTN 0.871985 PSA 3 IDE T106B Mn SOD PTN CDON 0.871295 PSA 3 Tetranectin IDE T106B PTN CDON 0.867378 PSA 3 IDE PSMP T106B PTN CDON 0892041 PSA 2 PSA 3 IDE T106B PTN CDON 0.870371 PSA 3 Tetranectin IDE T106B Mn SOD PTN 0.866291 PSA 3 IDE PSMP T106B Mn SOD PTN 0.891266 PSA 2 PSA 3 IDE T106B Mn SOD PTN 0.867039 PSA 3 Tetranectin IDE PSMP T106B PTN 0.888527 PSA 2 PSA 3 Tetranectin IDE T106B PTN 0889764 PSA 2 PSA 3 IDE PSMP T106B PTN 0.88745 PSA 1 PSA 3 T106B Mn SOD PTN CDON 0.884808 PSA 1 PSA 3 Tetranectin T106B PTN CDON 0.887922 PSA 1 PSA.3 PSMP T106B PTN CDON 0.894144 PSA 1 PSA 2 PSA 3 T106B PTN CDON 0.882872 PSA 1 PSA 3 Tetranectin T106B Mn SOD PTN 0 88621 PSA 1 PSA 3 PSMP T106B Mn SOD PTN 0.892936 PSA 1 PSA 2 PSA 3 T106B Mn SOD PTN 0.885062 PSA 1 PSA 3 Tetranectin PSMP T106B PTN 0.890294 PSA 1 PSA 2 PSA.3 Tetranectin T106B PTN 0.89359 PSA 1 PSA 2 PSA 3 PSMP T106B PTN 0.87242 PSA 3 Tetranectin T106B Mn SOD PTN CDON 0869004 PSA 3 PSMP T106B Mn SOD PTN CDON 0.89123 PSA 2 PSA 3 T106B Mn SOD PTN CDON 0.869665 PSA 3 Tetranectin PSMP T106B PTN CDON 0.889326 PSA 2 PSA 3 Tetranectin T106B PTN CDON 0.890822 PSA 2 PSA 3 PSMP T106B PTN CDON 0.868564 PSA 3 Tetranectin PSMP T106B Mn SOD PTN 0888148 PSA 2 PSA 3 Tetranectin T106B Mn SOD PTN 0.88937 PSA 2 PSA 3 PSMP T106B Mn SOD PTN 0.889148 PSA 2 PSA 3 Tetranectin PSMP T106B PTN 0.880899 PSA 1 PSA 3 IDE T106B Mn SOD CDON 0.879201 PSA 1 PSA 3 Tetranectin IDE T106B CDON 0.881331 PSA 1 PSA 3 IDE PSMP T106B CDON 0889035 PSA 1 PSA 2 PSA 3 IDE T106B CDON 0.877059 PSA 1 PSA.3 Tetranectin IDE T106B Mn SOD0.879338 PSA 1 PSA 3 IDE PSMP T106B Mn SOD0.88793 PSA 1 PSA 2 PSA 3 IDE T106B Mn SOD0.878991 PSA 1 PSA 3 Tetranectin IDE PSMP T106B0.885756 PSA 1 PSA 2 PSA 3 Tetranectin IDE T106B0888249 PSA 1 PSA 2 PSA 3 IDE PSMP T106B0.873687 PSA 3 Tetranectin IDE T106B Mn SOD CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.868245 PSA 3 IDE PSMP T106B Mn SOD CDON 0.887515 PSA 2 PSA.3 IDE T106B Mn SOD CDON 0.868588 PSA 3 Tetranectin IDE PSMP T106B CDON 0.885919 PSA 2 PSA 3 Tetranectin IDE T106B CDON 0.886752 PSA 2 PSA 3 IDE PSMP T106B CDON 0867685 PSA 3 Tetranectin IDE PSMP T106B Mn SOD0.884477 PSA 2 PSA 3 Tetranectin IDE T106B Mn SOD0.885409 PSA 2 PSA 3 IDE PSMP T106B Mn SOD0.884998 PSA 2 PSA 3 Tetranectin IDE PSMP T106B0.877451 PSA 1 PSA 3 Tetranectin T106B Mn SOD CDON 0.880089 PSA 1 PSA 3 PSMP T106B Mn SOD CDON 0887478 PSA 1 PSA 2 PSA 3 T106B Mn SOD CDON 0.879859 PSA 1 PSA 3 Tetranectin PSMP T106B CDON 0.8857 PSA 1 PSA 2 PSA 3 Tetranectin T106B CDON 0.888563 PSA 1 PSA 2 PSA.3 PSMP T106B CDON 0.877007 PSA 1 PSA 3 Tetranectin PSMP T106B Mn SOD0.88359 PSA 1 PSA 2 PSA 3 Tetranectin T106B Mn SOD0886817 PSA 1 PSA 2 PSA 3 PSMP T106B Mn SOD0.886833 PSA 1 PSA 2 PSA 3 Tetranectin PSMP T106B0.869488 PSA 3 Tetranectin PSMP T106B Mn SOD CDON 0.884425 PSA 2 PSA.3 Tetranectin T106B Mn SOD CDON 0.885361 PSA 2 PSA 3 PSMP T106B Mn SOD CDON 0.885698 PSA 2 PSA 3 Tetranectin PSMP T106B CDON 0884017 PSA 2 PSA 3 Tetranectin PSMP T106B Mn SOD0.876789 PSA 1 PSA 4 SLIT2 IDE T106B PTN 0.859855 PSA 4 SLIT2 IDE T106B PTN CDON 0.856951 PSA 4 SLIT2 IDE T106B Mn SOD PTN 0.857375 PSA 4 Tetranectin SLIT2 IDE T106B PTN 0.85967 PSA 4 SLIT2 IDE PSMP T106B PTN 0881928 PSA 2 PSA 4 SLIT2 IDE T106B PTN 0.876918 PSA 1 PSA 4 SLIT2 T106B PTN CDON 0.874687 PSA 1 PSA 4 SLIT2 T106B Mn SOD PTN 0.87399 PSA 1 PSA 4 Tetranectin SLIT2 T106B PTN 0.877507 PSA 1 PSA 4 SLIT2 PSMP T106B PTN 0.884296 PSA 1 PSA 2 PSA 4 SLIT2 T106B PTN 0.859198 PSA 4 SLIT2 T106B Mn SOD PTN CDON 0.857199 PSA 4 Tetranectin SL.1T2 T106B PTN CDON 0.860408 PSA 4 SLIT2 PSMP T106B PTN CDON 0.881831 PSA 2 PSA 4 SLIT2 T106B PTN CDON 0.855785 PSA 4 Tetranectin SLIT2 T106B Mn SOD PTN 0.85854 PSA 4 SLIT2 PSMP T106B Mn SOD PTN 0880262 PSA 2 PSA 4 SLIT2 T106B Mn SOD PTN0.860138 PSA 4 Tetranectin SLIT2 PSMP T106B PTNAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.879964 PSA 2 PSA 4 Tetranectin SLIT2 T106B PTN 0.882291 PSA 2 PSA 4 SLIT2 PSMP T106B PTN 0.874143 PSA 1 PSA 4 SLIT2 IDE T106B CDON 0.87257 PSA 1 PSA 4 SLIT2 IDE T106B Mn SOD0.871775 PSA 1 PSA 4 Tetranectin SLIT2 IDE T106B0.8748 PSA 1 PSA 4 SLIT2 IDE PSMP T106B0.883747 PSA 1 PSA 2 PSA 4 SLIT2 IDE T106B0.856947 PSA 4 SLIT2 IDE T106B Mn SOD CDON 0.855608 PSA 4 Tetranectin SLIT2 IDE T106B CDON 0.857463 PSA 4 SLIT2 IDE PSMP T106B CDON 0.881371 PSA 2 PSA 4 SLIT2 IDE T106B CDON 0.85374 PSA 4 Tetranectin SLIT2 IDE T106B Mn SOD0.855547 PSA 4 SLIT2 IDE PSMP T106B Mn SOD0.880081 PSA 2 PSA 4 SLIT2 IDE T106B Mn SOD0.85733 PSA 4 Tetranectin SLIT2 IDE PSMP T106B0.879229 PSA 2 PSA 4 Tetranectin SLIT2 IDE T106B0.880657 PSA 2 PSA 4 SLIT2 IDE PSMP T106B0.873505 PSA 1 PSA 4 SLIT2 T106B Mn SOD CDON 0.872078 PSA 1 PSA 4 Tetranectin SLIT2 T106B CDON 0.875567 PSA 1 PSA 4 SLIT2 PSMP T106B CDON 0.883178 PSA 1 PSA 2 PSA 4 SLIT2 T106B CDON 0.87021 PSA 1 PSA 4 Tetranectin SLIT2 T106B Mn SOD0.873998 PSA 1 PSA 4 SLIT2 PSMP T106B Mn SOD0.881956 PSA 1 PSA 2 PSA 4 SLIT2 T106B Mn SOD0.87474 PSA 1 PSA 4 Tetranectin SLIT2 PSMP T106B0.880803 PSA 1 PSA 2 PSA 4 Tetranectin SLIT2 T106B0.884393 PSA 1 PSA 2 PSA 4 SLIT2 PSMP T106B0.855293 PSA 4 Tetranectin SLIT2 T106B Mn SOD CDON 0.856981 PSA 4 SLIT2 PSMP T106B Mn SOD CDON 0880129 PSA 2 PSA 4 SLIT2 T106B Mn SOD CDON 0.857342 PSA 4 Tetranectin SLIT2 PSMP T106B CDON 0.878699 PSA 2 PSA 4 Tetranectin SLIT2 T106B CDON 0.881347 PSA 2 PSA 4 SLIT2 PSMP T106B CDON 0.856386 PSA 4 Tetranectin SLIT2 PSMP T106B Mn SOD0.877658 PSA 2 PSA 4 Tetranectin SLIT2 T106B Mn SOD0880133 PSA 2 PSA 4 SLIT2 PSMP T106B Mn SOD0.880843 PSA 2 PSA 4 Tetranectin SLIT2 PSMP T106B0.870942 PSA 1 SLIT2 IDE T106B PTN CDON 0.86802 PSA 1 SLIT2 IDE T106B Mn SOD PTN 0.867604 PSA 1 Tetranectin SLIT2 IDE T106B PTN 0.870617 PSA 1 SLIT2 IDE PSMP T106B PTN 0885881 PSA 1 PSA 2 SLIT2 IDE T106B PTN0.646764 SLIT2 IDE T106B Mn SOD PTN CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.633608 Tetranectin SLIT2 IDE T106B PTN CDON 0.630468 SLIT2 IDE PSMP T106B PTN CDON 0.883053 PSA 2 SLIT2 IDE T106B PTN CDON 0.640718 Tetranectin SLIT2 IDE T106B Mn SOD PTN 0.639175 SLIT2 IDE PSMP T106B Mn SOD PTN 0881617 PSA 2 SLIT2 IDE T106B Mn SOD PTN 0.624316 Tetranectin SLIT2 IDE PSMP T106B PTN 0.881266 PSA 2 Tetranectin SLIT2 IDE T106B PTN 0.882041 PSA 2 SLIT2 IDE PSMP T106B PTN 0.869048 PSA 1 SLIT2 T106B Mn SOD PTN CDON 0.865839 PSA 1 Tetranectin SLIT2 T106B PTN CDON 0.870763 PSA 1 SLIT2 PSMP T106B PTN CDON 0.886341 PSA 1 PSA 2 SLIT2 T106B PTN CDON 0.865033 PSA 1 Tetranectin SLIT2 IT06B Mn SOD PTN 0.869193 PSA 1 SLIT2 PSMP T106B Mn SOD PTN 0.884566 PSA 1 PSA 2 SLIT2 T106B Mn SOD PTN 0.868875 PSA 1 Tetranectin SLIT2 PSMP T106B PTN 0883687 PSA 1 PSA 2 Tetranectin SLIT2 T106B PTN 0.886684 PSA 1 PSA 2 SLIT2 PSMP T106B PTN 0.636561 Tetranectin SLIT2 T106B Mn SOD PTN CDON 0.633283 SLIT2 PSMP T106B Mn SOD PTN CDON 0.882275 PSA 2 SLIT2 T106B Mn SOD PTN CDON 0.623574 Tetranectin SLIT2 PSMP T106B PTN CDON 0881202 PSA 2 Tetranectin SLIT2 T106B PTN CDON 0.883045 PSA 2 SLIT2 PSMP T106B PTN CDON 0.63859 Tetranectin SLIT2 PSMP T106B Mn SOD PTN 0.879621 PSA 2 Tetranectin SLIT2 T106B Mn SOD PTN 0.881331 PSA 2 SLIT2 PSMP T106B Mn SOD PTN 0.882444 PSA 2 Tetranectin SLIT2 PSMP T106B PTN 0866644 PSA 1 SLIT2 IDE T106B Mn SOD CDON 0.864712 PSA 1 Tetranectin SLIT2 IDE T106B CDON 0.868068 PSA 1 SLIT2 IDE PSMP T106B CDON 0.884804 PSA 1 PSA 2 SLIT2 IDE T106B CDON 0.862425 PSA 1 Tetranectin SLIT2 IDE T106B Mn SOD0 86572 PSA 1 SLIT2 IDE PSMP T106B Mn SOD0 88363 PSA 1 PSA 2 SLIT2 IDE T106B Mn SOD0.866571 PSA 1 Tetranectin SLIT2 IDE PSMP T106B0.882126 PSA 1 PSA 2 Tetranectin SLIT2 IDE T106B0.884735 PSA 1 PSA 2 SLIT2 IDE PSMP T106B0.631178 Tetranectin SLIT2 IDE T106B Mn SOD CDON 0.627894 SLIT2 IDE PSMP T106B Mn SOD CDON 0881097 PSA 2 SLIT2 IDE T106B Mn SOD CDON0.61691 Tetranectin SLIT2 IDE PSMP T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.880343 PSA 2 Tetranectin SLIT2 IDE T106B CDON 0.880694 PSA 2 SLIT2 IDE PSMP T106B CDON 0.621059 Tetranectin SLIT2 IDE PSMP T106B Mn SOD0.878858 PSA 2 Tetranectin SLIT2 IDE T106B Mn SOD0.879294 PSA 2 SLIT2 IDE PSMP T106B Mn SOD0880589 PSA 2 Tetranectin SLIT2 IDE PSMP T106B0.863369 PSA 1 Tetranectin SLIT2 T106B Mn SOD CDON 0.867584 PSA 1 SLIT2 PSMP T106B Mn SOD CDON 0.883868 PSA 1 PSA 2 SLIT2 T106B Mn SOD CDON 0.866914 PSA 1 Tetranectin SLIT2 PSMP T106B CDON 0.882727 PSA 1 PSA 2 Tetranectin SLIT2 T106B CDON 0 88555 PSA 1 PSA 2 SLIT2 PSMP T106B CDON 0.864704 PSA 1 Tetranectin SLIT2 PSMP T106B Mn SOD0.880883 PSA 1 PSA 2 Tetranectin SLIT2 T106B Mn SOD0.884356 PSA 1 PSA 2 SLIT2 PSMP T106B Mn SOD0.885113 PSA 1 PSA 2 Tetranectin SLIT2 PSMP T106B0.621977 Tetranectin SLIT2 PSMP T106B Mn SOD CDON 0879455 PSA 2 Tetranectin SLIT2 T106B Mn SOD CDON 0.880565 PSA 2 SLIT2 PSMP T106B Mn SOD CDON 0.881129 PSA 2 Tetranectin SLIT2 PSMP T106B CDON 0.879643 PSA 2 Tetranectin SLIT2 PSMP T106B Mn SOD0.882487 PSA 1 PSA 4 IDE T106B PTN CDON 0.880351 PSA 1 PSA 4 IDE T106B Mn SOD PTN 0878197 PSA 1 PSA 4 Tetranectin IDE T106B PTN 0.882206 PSA 1 PSA 4 IDE PSMP T106B PTN 0.888459 PSA 1 PSA 2 PSA 4 IDE T106B PTN 0.86403 PSA 4 IDE T106B Mn SOD PTN CDON 0.862542 PSA 4 Tetranectin IDE T106B PTN CDON 0.864672 PSA 4 IDE PSMP T106B PTN CDON 0885449 PSA 2 PSA 4 IDE T106B PTN CDON 0.859767 PSA 4 Tetranectin IDE T106B Mn SOD PTN 0.862304 PSA 4 IDE PSMP T106B Mn SOD PTN 0.884332 PSA 2 PSA 4 IDE T106B Mn SOD PTN 0.86372 PSA 4 Tetranectin IDE PSMP T106B PTN 0.882646 PSA 2 PSA 4 Tetranectin IDE T106B PTN 0884679 PSA 2 PSA 4 IDE PSMP T106B PTN 0.881101 PSA 1 PSA 4 T106B Mn SOD PTN CDON 0.878782 PSA 1 PSA 4 Tetranectin T106B PTN CDON 0.883029 PSA 1 PSA 4 PSMP T106B PTN CDON 0.88835 PSA 1 PSA 2 PSA 4 T106B PTN CDON 0.876535 PSA 1 PSA 4 Tetranectin T106B Mn SOD FIN 0880532 PSA 1 PSA 4 PSMP T106B Mn SOD PTN0.886837 PSA 1 PSA 2 PSA 4 T106B Mn SOD PTNAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0 88027 PSA 1 PSA 4 Tetranectin PSMP T106B PTN 0.885107 PSA 1 PSA 2 PSA 4 Tetranectin T106B PTN 0.889084 PSA 1 PSA 2 PSA 4 PSMP T106B PTN 0.862005 PSA 4 Tetranectin T106B Mn SOD PTN CDON 0.864724 PSA 4 PSMP T106B Mn SOD PTN CDON 0884711 PSA 2 PSA 4 T106B Mn SOD PTN CDON 0.864224 PSA 4 Tetranectin PSMP T106B PTN CDON 0.882561 PSA 2 PSA 4 Tetranectin T106B PTN CDON 0.885631 PSA 2 PSA 4 PSMP T106B PTN CDON 0.862183 PSA 4 Tetranectin PSMP T106B Mn SOD PTN 0.88121 PSA 2 PSA 4 Tetranectin T106B Mn SOD PTN 0883929 PSA 2 PSA 4 PSMP T106B Mn SOD PTN 0.883997 PSA 2 PSA 4 Tetranectin PSMP T106B PTN 0.873977 PSA 1 PSA 4 IDE T106B Mn SOD CDON 0.872792 PSA 1 PSA 4 Tetranectin IDE T106B CDON 0.875426 PSA 1 PSA 4 IDE PSMP T106B CDON 0.884143 PSA 1 PSA 2 PSA 4 IDE T106B CDON 0869766 PSA 1 PSA 4 Tetranectin IDE T106B Mn SOD0.873348 PSA 1 PSA 4 IDE PSMP T106B Mn SOD0.882468 PSA 1 PSA 2 PSA 4 IDE T106B Mn SOD0.87355 PSA 1 PSA 4 Tetranect n IDE PSMP T106B0.880803 PSA 1 PSA 2 PSA 4 Tetranect n IDE T106B0.883997 PSA 1 PSA 2 PSA 4 IDE PSMP T106B0860033 PSA 4 Tetranectin IDE T106B Mn SOD CDON 0.861182 PSA 4 IDE PSMP T106B Mn SOD CDON 0.881045 PSA 2 PSA 4 IDE T106B Mn SOD CDON 0.861638 PSA 4 Tetranectin IDE PSMP T106B CDON 0.879548 PSA 2 PSA 4 Tetranectin IDE T106B CDON 0.881291 PSA 2 PSA 4 IDE PSMP T106B CDON 0858932 PSA 4 Tetranectin IDE PSMP T106B Mn SOD0.878378 PSA 2 PSA 4 Tetranectin IDE T106B Mn SOD0.87977 PSA 2 PSA 4 IDE PSMP T106B Mn SOD0.880105 PSA 2 PSA 4 Tetranectin IDE PSMP T106B0.870218 PSA 1 PSA 4 Tetranectin T106B Mn SOD CDON 0.873687 PSA 1 PSA 4 PSMP T106B Mn SOD CDON 0881605 PSA 1 PSA 2 PSA 4 T106B Mn SOD CDON 0.873828 PSA 1 PSA 4 Tetranectin PSMP T106B CDON 0.87998 PSA 1 PSA 2 PSA 4 Tetranectin T106B CDON 0.883386 PSA 1 PSA 2 PSA 4 PSMP T106B CDON 0.870553 PSA 1 PSA 4 Tetranectin PSMP T106B Mn SOD0.877693 PSA 1 PSA 2 PSA 4 Tetranectin T106B Mn SOD0881791 PSA 1 PSA 2 PSA 4 PSMP T106B Mn SOD0.881884 PSA 1 PSA 2 PSA 4 Tetranectin PSMP T106BAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0 85996 PSA 4 Tetranectin PSMP T106B Mn SOD CDON 0.878116 PSA 2 PSA 4 Tetranectin T106B Mn SOD CDON 0.879867 PSA 2 PSA 4 PSMP T106B Mn SOD CDON 0.879776 PSA 2 PSA 4 Tetranectin PSMP T106B CDON 0.878068 PSA 2 PSA 4 Tetranectin PSMP T106B Mn SOD0875781 PSA 1 IDE T106B Mn SOD PTN CDON 0.872356 PSA 1 Tetranectin IDE T106B PTN CDON 0.877221 PSA 1 IDE PSMP T106B PTN CDON 0.889903 PSA 1 PSA 2 IDE T106B PTN CDON 0.870057 PSA 1 Tetranectin IDE T106B Mn SOD PTN 0.874381 PSA 1 IDE PSMP T106B Mn SOD PTN 0888676 PSA 1 PSA 2 IDE T106B Mn SOD PTN 0.873877 PSA 1 Tetranectin IDE PSMP T106B PTN 0.886123 PSA 1 PSA 2 Tetranectin IDE T106B PTN 0.889407 PSA 1 PSA 2 IDE PSMP T106B PTN 0.63847! Tetranectin IDE T106B Mn SOD PTN CDON 0.637644 IDE PSMP T106B Mn SOD PTN CDON 0884614 PSA 2 IDE T106B Mn SOD PTN CDON 0.62143 Tetranectin IDE PSMP T106B PTN CDON 0.882832 PSA 2 Tetranectin IDE T106B PTN CDON 0.88428 PSA 2 IDE PSMP T106B PTN CDON 0.640929 Tetranectin IDE PSMP T106B Mn SOD PTN 0.881928 PSA 2 Tetranectin IDE T106B Mn SOD PTN 0882581 PSA 2 IDE PSMP T106B Mn SOD PTN 0.883148 PSA 2 Tetranectin IDE PSMP T106B PTN 0.871255 PSA 1 Tetranectin T106B Mn SOD PTN CDON 0.876936 PSA 1 PSMP T106B Mn SOD PTN CDON 0.88934 PSA 1 PSA 2 T106B Mn SOD PTN CDON 0.874349 PSA 1 Tetranectin PSMP T106B PTN CDON 0887039 PSA 1 PSA 2 Tetranectin T106B PTN CDON 0.890685 PSA 1 PSA 2 PSMP T106B PTN CDON 0.872316 PSA 1 Tetranectin PSMP T106B Mn SOD PTN 0.885361 PSA 1 PSA 2 Tetranectin T106B Mn SOD PTN 0.889479 PSA 1 PSA 2 PSMP T106B Mn SOD PTN 0 88885 PSA 1 PSA 2 Tetranectin PSMP T106B PTN 063336 Tetranectin PSMP T106B Mn SOD PTN CDON 0.882388 PSA 2 Tetranectin T106B Mn SOD PTN CDON 0.883937 PSA 2 PSMP T106B Mn SOD PTN CDON 0.883989 PSA 2 Tetranectin PSMP T106B PTN CDON 0.882856 PSA 2 Tetranectin PSMP T106B Mn SOD PTN 0.869452 PSA 1 Tetranectin IDE T106B Mn SOD CDON 0873025 PSA 1 IDE PSMP T106B Mn SOD CDON0.885256 PSA 1 PSA 2 IDE T106B Mn SO!) CDONAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLII 2 IDE PSMP T106B Mn SOD PTN CDON 0.871811 PSA 1 Tetranectin IDE PSMP T106B CDON 0.8834 PSA 1 PSA 2 Tetranectin IDE T106B CDON 0.886059 PSA 1 PSA 2 IDE PSMP T106B CDON 0.869524 PSA 1 Tetranectin IDE PSMP T106B Mn SOD0.881726 PSA 1 PSA 2 Tetranectin IDE T106B Mn SOD0884473 PSA 1 PSA 2 IDE PSMP T106B Mn SOD0.884308 PSA 1 PSA 2 Tetranectin IDE PSMP T106B0.580982 Tetranectin IDE PSMP T106B Mn SOD CDON 0.881194 PSA 2 Tetranectin IDE T106B Mn SOD CDON 0.881694 PSA 2 IDE PSMP T106B Mn SOD CDON 0.881698 PSA 2 Tetranectin IDE PSMP T106B CDON 0880552 PSA 2 Tetranectin IDE PSMP T106B Mn SOD0.870385 PSA 1 Tetranectin PSMP T106B Mn SOD CDON 0.881892 PSA 1 PSA 2 Tetranectin T106B Mn SOD CDON 0.885103 PSA 1 PSA 2 PSMP T106B Mn SOD CDON 0.88509 PSA 1 PSA 2 Tetranectin PSMP T106B CDON 0.883243 PSA 1 PSA 2 Tetranectin PSMP T106B Mn SOD0 88121 PSA 2 Tetranectin PSMP T106B Mn SOD CDON 0.873126 PSA 3 DCE1 PSA 4 SLIT2 IDE T106B PTN 0.879504 PSA 1 PSA 3 DCE1 PSA 4 SLIT2 T106B PTN 0.873328 PSA.3 DCE1 PSA 4 SLIT2 T106B PTN CDON 0.871481 PSA 3 DCE1 PSA 4 SLIT2 T106B Mn SOD PTN 0.871537 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 T106B PTN 0 87313 PSA 3 DCE1 PSA 4 SLIT2 PSMP T106B PTN 0.883429 PSA 2 PSA 3 DCE1 PSA 4 SLIT2 T106B PTN 0.877434 PSA 1 PSA 3 DCE1 PSA 4 SLIT2 IDE T106B0.871166 PSA 3 DCE1 PSA 4 SLIT2 IDE T106B CDON 0.869197 PSA 3 DCE1 PSA 4 SLIT2 IDE T106B Mn SOD0.869609 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE T106B0870133 PSA 3 DCE1 PSA 4 SLIT2 IDE PSMP T106B0.882444 PSA 2 PSA 3 DCE1 PSA 4 SLIT2 IDE T106B0.877789 PSA 1 PSA 3 DCE1 PSA 4 SLIT2 T106B CDON 0.875478 PSA 1 PSA 3 DCE1 PSA 4 SLIT2 T106B Mn SOD0.875276 PSA 1 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 T106B0.878685 PSA 1 PSA 3 DCE1 PSA 4 SLIT2 PSMP T106B0882545 PSA 1 PSA 2 PSA 3 DCE1 PSA 4 SLIT2 T106B0.8705 PSA.3 DCE1 PSA 4 SLIT2 T106B Mn SOD CDON 0.869835 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 T106B CDON 0.871255 PSA 3 DCE1 PSA 4 SLIT2 PSMP T106B CDON 0.882105 PSA 2 PSA 3 DCE1 PSA 4 SLIT2 T106B CDON 0.867891 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 T106B Mn SOD0 86946 PSA 3 DCE1 PSA 4 SLIT2 PSMP T106B Mn SOD0.880641 PSA 2 PSA 3 DCE1 PSA 4 SLIT2 T106B Mn SODAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.870831 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 PSMP T106B0.880294 PSA 2 PSA.3 DCE1 PSA 4 Tetranectin SLIT2 T106B0.882456 PSA 2 PSA 3 DCE1 PSA 4 SLIT2 PSMP T106B0.881287 PSA 1 PSA 3 DCE1 SLIT2 IDE T106B PTN 0.864643 PSA 3 DCE1 SLIT2 IDE T106B PTN CDON 0 86188 PSA 3 DCE1 SLIT2 IDE T106B Mn SOD PTN 0.862808 PSA 3 DCE1 Tetranectin SLIT2 IDE T106B PTN 0.861428 PSA 3 DCE1 SLIT2 IDE PSMP T106B PTN 0.886393 PSA 2 PSA 3 DCE1 SLIT2 IDE T106B PTN 0.881119 PSA 1 PSA 3 DCE1 SLIT2 T106B PTN CDON 0.878846 PSA 1 PSA 3 DCE1 SLIT2 T106B Mn SOD PTN 0878035 PSA 1 PSA 3 DCE1 Tetranectin SLIT2 T106B PTN 0.880649 PSA 1 PSA 3 DCE1 SLIT2 PSMP T106B PTN 0.887035 PSA 1 PSA 2 PSA 3 DCE1 SLIT2 T106B PTN 0.864188 PSA.3 DCE1 SLIT2 T106B Mn SOD PTN CDON 0.864639 PSA 3 DCE1 Tetranectin SLIT2 T106B PTN CDON 0.863199 PSA 3 DCE1 SLIT2 PSMP T106B PTN CDON 0886381 PSA 2 PSA 3 DCE1 SLIT2 T106B PTN CDON 0.861945 PSA 3 DCE1 Tetranectin SLIT2 T106B Mn SOD PTN 0.860351 PSA 3 DCE1 SLIT2 PSMP T106B Mn SOD PTN 0.88457 PSA 2 PSA.3 DCE1 SLIT2 T106B Mn SOD PTN 0.862659 PSA 3 DCE1 Tetranectin SLIT2 PSMP T106B PTN 0.883872 PSA 2 PSA 3 DCE1 Tetranectin SLIT2 T106B PTN 0 88576 PSA 2 PSA 3 DCE1 SLIT2 PSMP T106B PTN 0.878564 PSA 1 PSA 3 DCE1 SLIT2 IDE T106B CDON 0.876474 PSA 1 PSA 3 DCE1 SLIT2 IDE T106B Mn SOD0.875889 PSA 1 PSA 3 DCE1 Tetranectin SLIT2 IDE T106B0.878007 PSA 1 PSA 3 DCE1 SLIT2 IDE PSMP T106B0.885857 PSA 1 PSA 2 PSA 3 DCE1 SLIT2 IDE T106B0861061 PSA 3 DCE1 SLIT2 IDE T106B Mn SOD CDON 0.861618 PSA 3 DCE1 Tetranectin SLIT2 IDE T106B CDON 0.859145 PSA 3 DCE1 SLIT2 IDE PSMP T106B CDON 0.884933 PSA 2 PSA 3 DCE1 SLIT2 IDE T106B CDON 0.859403 PSA 3 DCE1 Tetranectin SLIT2 IDE T106B Mn SOD0.856661 PSA 3 DCE1 SLIT2 IDE PSMP T106B Mn SOD0883812 PSA 2 PSA 3 DCE1 SLIT2 IDE T106B Mn SOD0.858815 PSA.3 DCE1 Tetranectin SLIT2 IDE PSMP T106B0.8829 PSA 2 PSA 3 DCE1 Tetranectin SLIT2 IDE T106B0.883788 PSA 2 PSA 3 DCE1 SLIT2 IDE PSMP T106B0.876579 PSA 1 PSA 3 DCE1 SLIT2 T106B Mn SOD CDON 0.876273 PSA 1 PSA 3 DCE1 Tetranectin SLIT2 T106B CDON 0878725 PSA 1 PSA 3 DCE1 SLIT2 PSMP T106B CDON0.885716 PSA 1 PSA 2 PSA 3 DCE1 SLIT2 T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0 87313 PSA 1 PSA 3 DCE1 Tetranectin SLIT2 T106B Mn SOD0.876252 PSA 1 PSA.3 DCE1 SL.1T2 PSMP T106B Mn SOD0.883892 PSA 1 PSA 2 PSA 3 DCE1 SLIT2 T106B Mn SOD0.877414 PSA 1 PSA 3 DCE1 Tetranectin SLIT2 PSMP T106B0.883158 PSA 1 PSA 2 PSA 3 DCE1 Tetranectin SLIT2 T106B0886333 PSA 1 PSA 2 PSA 3 DCE1 SLIT2 PSMP T106B0.861158 PSA 3 DCE1 Tetranectin SLIT2 T106B Mn SOD CDON 0.858629 PSA 3 DCE1 SLIT2 PSMP T106B Mn SOD CDON 0.883775 PSA 2 PSA 3 DCE1 SLIT2 T106B Mn SOD CDON 0.860025 PSA 3 DCE1 Tetranectin SLIT2 PSMP T106B CDON 0.882658 PSA 2 PSA 3 DCE1 Tetranectin SLIT2 T106B CDON 0884445 PSA 2 PSA 3 DCE1 SLIT2 PSMP T106B CDON 0.857633 PSA 3 DCE1 Tetranectin SLIT2 PSMP T106B Mn SOD0.880843 PSA 2 PSA 3 DCE1 Tetranectin SLIT2 T106B Mn SOD0.883021 PSA 2 PSA.3 DCE1 SL.1T2 PSMP T106B Mn SOD0.883852 PSA 2 PSA 3 DCE1 Tetranectin SLIT2 PSMP T106B0.884933 PSA 1 PSA 3 DCE1 PSA 4 IDE T106B PTN 0878314 PSA 3 DCE1 PSA 4 IDE T106B PTN CDON 0.876692 PSA 3 DCE1 PSA 4 IDE T106B Mn SOD PTN 0.875385 PSA 3 DCE1 PSA 4 Tetranectin IDE T106B PTN 0.876837 PSA.3 DCE1 PSA 4 IDE PSMP T106B PTN 0.887353 PSA 2 PSA 3 DCE1 PSA 4 IDE T106B PTN 0.885365 PSA 1 PSA 3 DCE1 PSA 4 T106B PTN CDON 0883332 PSA 1 PSA 3 DCE1 PSA 4 T106B Mn SOD PTN 0.881561 PSA 1 PSA 3 DCE1 PSA 4 Tetranectin T106B PTN 0.885244 PSA 1 PSA 3 DCE1 PSA 4 PSMP T106B PTN 0.888701 PSA 1 PSA 2 PSA 3 DCE1 PSA 4 T106B PTN 0.877471 PSA 3 DCE1 PSA 4 T106B Mn SOD PTN CDON 0.876131 PSA 3 DCE1 PSA 4 Tetranectin T106B PTN CDON 0878108 PSA 3 DCE1 PSA 4 PSMP T106B PTN CDON 0.887583 PSA 2 PSA 3 DCE1 PSA 4 T106B PTN CDON 0.873994 PSA 3 DCE1 PSA 4 Tetranectin T106B Mn SOD PTN 0.875853 PSA 3 DCE1 PSA 4 PSMP T106B Mn SOD PTN 0.886381 PSA 2 PSA 3 DCE1 PSA 4 T106B Mn SOD PTN 0.875986 PSA 3 DCE1 PSA 4 Tetranectin PSMP T106B PTN 0884489 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin T106B PTN 0.887341 PSA 2 PSA.3 DCE1 PSA 4 PSMP T106B PTN 0.878201 PSA 1 PSA 3 DCE1 PSA 4 IDE T106B CDON 0.876107 PSA 1 PSA 3 DCE1 PSA 4 IDE T106B Mn SOD0.875087 PSA 1 PSA 3 DCE1 PSA 4 Tetranectin IDE T106B0.87812 PSA 1 PSA 3 DCE1 PSA 4 IDE PSMP T106B0883957 PSA 1 PSA 2 PSA 3 DCE1 PSA 4 IDE T106B0.871682 PSA 3 DCE1 PSA 4 IDE T106B Mn SOD CDONAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.871372 PSA 3 DCE1 PSA 4 Tetranectin IDE T106B CDON 0.871932 PSA.3 DCE1 PSA 4 IDE PSMP T106B CDON 0.883275 PSA 2 PSA 3 DCE1 PSA 4 IDE T106B CDON 0.868681 PSA 3 DCE1 PSA 4 Tetranectin IDE T106B Mn SOD0.869617 PSA 3 DCE1 PSA 4 IDE PSMP T106B Mn SOD0881779 PSA 2 PSA 3 DCE1 PSA 4 IDE T106B Mn SOD0.870839 PSA 3 DCE1 PSA 4 Tetranectin IDE PSMP T106B0.881093 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin IDE T106B0.882787 PSA 2 PSA 3 DCE1 PSA 4 IDE PSMP T106B0.875432 PSA 1 PSA 3 DCE1 PSA 4 T106B Mn SOD CDON 0.874716 PSA 1 PSA 3 DCE1 PSA 4 Tetranectin T106B CDON 0 87808 PSA 1 PSA 3 DCE1 PSA 4 PSMP T106B CDON 0.882553 PSA 1 PSA 2 PSA 3 DCE1 PSA 4 T106B CDON 0.870793 PSA 1 PSA 3 DCE1 PSA 4 Tetranectin T106B Mn SOD0.874897 PSA 1 PSA.3 DCE1 PSA 4 PSMP T106B Mn SOD0.88052 PSA 1 PSA 2 PS / X 3 DCE1 PSA 4 T106B Mn SOD0.875559 PSA 1 PSA 3 DCE1 PSA 4 Tetranectin PSMP T106B0879516 PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin T106B0.882981 PSA 1 PSA 2 PSA 3 DCE1 PSA 4 PSMP T106B0.869282 PSA 3 DCE1 PSA 4 Tetranectin T106B Mn SOD CDON 0.870363 PSA.3 DCE1 PSA 4 PSMP T106B Mn SOD CDON 0.880738 PSA 2 PSA 3 DCE1 PSA 4 T106B Mn SOD CDON 0.871109 PSA 3 DCE1 PSA 4 Tetranectin PSMP T106B CDON 0880109 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin T106B CDON 0.882206 PSA 2 PSA 3 DCE1 PSA 4 PSMP T106B CDON 0.868064 PSA 3 DCE1 PSA 4 Tetranectin PSMP T106B Mn SOD0.877366 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin T106B Mn SOD0.880544 PSA 2 PSA 3 DCE1 PSA 4 PSMP T106B Mn SOD0.881113 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin PSMP T106B0886321 PSA 1 PSA 3 DCE1 IDE T106B PTN CDON 0.884828 PSA 1 PSA 3 DCE1 IDE T106B Mn SOD PTN 0.882501 PSA 1 PSA 3 DCE1 Tetranectin IDE T106B PTN 0.885667 PSA 1 PSA 3 DCE1 IDE PSMP T106B PTN 0.89152 PSA 1 PSA 2 PSA 3 DCE1 IDE T106B PTN 0.869411 PSA 3 DCE1 IDE T106B Mn SOD PTN CDON 0869117 PSA 3 DCE1 Tetranectin IDE T106B PTN CDON 0.866176 PSA.3 DCE1 IDE PSMP T106B PTN CDON 0.88954 PSA 2 PSA 3 DCE1 IDE T106B PTN CDON 0.86808 PSA 3 DCE1 Tetranectin IDE T106B Mn SOD PTN 0.864175 PSA 3 DCE1 IDE PSMP T106B Mn SOD PTN 0.888882 PSA 2 PSA 3 DCE1 IDE T106B Mn SOD PTN 0865482 PSA 3 DCE1 Tetranectin IDE PSMP T106B PTN0.88674 PSA 2 PSA 3 DCE1 Tetranectin IDE T106B PTNAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.888338 PSA 2 PSA 3 DCE1 IDE PSMP T106B PTN 0.885014 PSA 1 PSA.3 DCE1 T106B Mn SOD PTN CDON 0.882678 PSA 1 PSA 3 DCE1 Tetranectin T106B PTN CDON 0.886345 PSA 1 PSA 3 DCE1 PSMP T106B PTN CDON 0.891682 PSA 1 PSA 2 PSA 3 DCE1 T106B PTN CDON 0880504 PSA 1 PSA 3 DCE1 Tetranectin T106B Mn SOD PTN 0.884276 PSA 1 PSA 3 DCE1 PSMP T106B Mn SOD PTN 0.890185 PSA 1 PSA 2 PSA 3 DCE1 T106B Mn SOD PTN 0.883727 PSA 1 PSA 3 DCE1 Tetranectin PSMP T106B PTN 0.887882 PSA 1 PSA 2 PSA 3 DCE1 Tetranectin T106B PTN 0.891722 PSA 1 PSA 2 PSA 3 DCE1 PSMP T106B PTN 0869964 PSA 3 DCE1 Tetranectin T106B Mn SOD PTN CDON 0.86706 PSA 3 DCE1 PSMP T106B Mn SOD PTN CDON 0.888604 PSA 2 PSA 3 DCE1 T106B Mn SOD PTN CDON 0.867971 PSA.3 DCE1 Tetranectin PSMP T106B PTN CDON 0.887107 PSA 2 PSA 3 DCE1 Tetranectin T106B PTN CDON 0.889148 PSA 2 PSA 3 DCE1 PSMP T106B PTN CDON 0866116 PSA 3 DCE1 Tetranectin PSMP T106B Mn SOD PTN 0.885704 PSA 2 PSA 3 DCE1 Tetranectin T106B Mn SOD PTN 0.887571 PSA 2 PSA 3 DCE1 PSMP T106B Mn SOD PTN 0.887642 PSA 2 PSA.3 DCE1 Tetranectin PSMP T106B PTN 0.879711 PSA 1 PSA 3 DCE1 IDE T106B Mn SOD CDON 0.878604 PSA 1 PSA 3 DCE1 Tetranectin IDE T106B CDON 088091 1 PSA 1 PSA 3 DCE1 IDE PSMP T106B CDON 0.887039 PSA 1 PSA 2 PSA 3 DCE1 IDE T106B CDON 0.875974 PSA 1 PSA 3 DCE1 Tetranectin IDE T106B Mn SOD0.878511 PSA 1 PSA 3 DCE1 IDE PSMP T106B Mn SOD0.88601 PSA 1 PSA 2 PSA 3 DCE1 IDE T106B Mn SOD0 87858 PSA 1 PSA 3 DCE1 Tetranectin IDE PSMP T106B0884243 PSA 1 PSA 2 PSA 3 DCE1 Tetranectin IDE T106B0.886768 PSA 1 PSA 2 PSA 3 DCE1 IDE PSMP T106B0.872312 PSA 3 DCE1 Tetranectin IDE T106B Mn SOD CDON 0.867302 PSA 3 DCE1 IDE PSMP T106B Mn SOD CDON 0.885601 PSA 2 PSA 3 DCE1 IDE T106B Mn SOD CDON 0.868032 PSA 3 DCE1 Tetranectin IDE PSMP T106B CDON 0884465 PSA 2 PSA 3 DCE1 Tetranectin IDE T106B CDON 0.885643 PSA 2 PSA.3 DCE1 IDE PSMP T106B CDON 0.866487 PSA 3 DCE1 Tetranectin IDE PSMP T106B Mn SOD0.883001 PSA 2 PSA 3 DCE1 Tetranectin IDE T106B Mn SOD0.884132 PSA 2 PSA 3 DCE1 IDE PSMP T106B Mn SOD0.884259 PSA 2 PSA 3 DCE1 Tetranectin IDE PSMP T106B0876043 PSA 1 PSA 3 DCE1 Tetranectin T106B Mn SOD CDON0.878705 PSA 1 PSA 3 DCE1 PSMP T106B Mn SOD CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.885147 PSA 1 PSA 2 PSA 3 DCE1 T106B Mn SOD CDON 0.879032 PSA 1 PSA.3 DCE1 Tetranectin PSMP T106B CDON 0.883933 PSA 1 PSA 2 PSA 3 DCE1 Tetranectin T106B CDON 0.887059 PSA 1 PSA 2 PSA 3 DCE1 PSMP T106B CDON 0.875417 PSA 1 PSA 3 DCE1 Tetranectin PSMP T106B Mn SOD0881258 PSA 1 PSA 2 PSA 3 DCE1 Tetranectin T106B Mn SOD0.885167 PSA 1 PSA 2 PSA 3 DCE1 PSMP T106B Mn SOD0.885341 PSA 1 PSA 2 PSA 3 DCE1 Tetranectin PSMP T106B0.868177 PSA 3 DCE1 Tetranectin PSMP T106B Mn SOD CDON 0.882553 PSA 2 PSA 3 DCE1 Tetranectin T106B Mn SOD CDON 0.883989 PSA 2 PSA 3 DCE1 PSMP T106B Mn SOD CDON 0884441 PSA 2 PSA 3 DCE1 Tetranectin PSMP T106B CDON 0.882533 PSA 2 PSA 3 DCE1 Tetranectin PSMP T106B Mn SOD0.875599 PSA 1 DCE1 PSA 4 SLIT2 IDE IT06B PTN 0.858528 DCE1 PSA 4 SLIT2 IDE T106B PTN CDON 0.854539 DCE1 PSA 4 SLIT2 IDE T106B Mn SOD PTN 0.855313 DCE1 PSA 4 Tetranectin SLIT2 IDE T106B PTN 0858012 DCE1 PSA 4 SLIT2 IDE PSMP T106B PTN 0.88048 PSA 2 DCE1 PSA 4 SLIT2 IDE T106B PTN 0.875655 PSA 1 DCE1 PSA 4 SLIT2 T106B PTN CDON 0.872929 PSA 1 DCE1 PSA 4 SLIT2 T106B Mn SOD PTN 0.872497 PSA 1 DCE1 PSA 4 Tetranectin SLIT2 T106B PTN 0.876043 PSA 1 DCE1 PSA 4 SLIT2 PSMP T106B PTN 0882319 PSA 1 PSA 2 DCE1 PSA 4 SLIT2 T106B PTN 0.857314 DCE1 PSA 4 SLIT2 T106B Mn SOD PTN CDON 0.855846 DCE1 PSA 4 Tetranectin SLIT2 T106B PTN CDON 0.859145 DCE1 PSA 4 SLIT2 PSMP T106B PTN CDON 0.879992 PSA 2 DCE1 PSA 4 SLIT2 T106B PTN CDON 0.853317 DCE1 PSA 4 Tetranectin SLIT2 T106B Mn SOD PTN 0856148 DCE1 PSA 4 SLIT2 PSMP T106B Mn SOD PTN 0.878439 PSA 2 DCE1 PSA 4 SLIT2 T106B Mn SOD PTN 0.858472 DCE1 PSA 4 Tetranectin SLIT2 PSMP T106B PTN 0.877989 PSA 2 DCE1 PSA 4 Tetranectin SLIT2 T106B PTN 0.880782 PSA 2 DCE1 PSA 4 SLIT2 PSMP T106B PTN 0.872808 PSA 1 DCE1 PSA 4 SLIT2 IDE T106B CDON 0870581 PSA 1 DCE1 PSA 4 SLIT2 IDE T106B Mn SOD0.870835 PSA 1 DCE1 PSA 4 Tetranectin SLIT2 IDE T106B0.873554 PSA 1 DCE1 PSA 4 SLIT2 IDE PSMP T106B0.881791 PSA 1 PSA 2 DCE1 PSA 4 SLIT2 IDE T106B0.854942 DCE1 PSA 4 SLIT2 IDE T106B Mn SOD CDON 0.854127 DCE1 PSA 4 Tetranectin SLIT2 IDE T106B CDON 0856334 DCE1 PSA 4 SLIT2 IDE PSMP T106B CDON0.879524 PSA 2 DCE1 PSA 4 SLIT2 IDE T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.851231 DCE1 PSA 4 Tetranectin SLIT2 IDE T106B Mn SOD0.853688 DCE1 PSA 4 SLIT2 IDE PSMP T106B Mn SOD0.877922 PSA 2 DCE1 PSA 4 SLIT2 IDE T106B Mn SOD0.855842 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B0.877535 PSA 2 DCE1 PSA 4 Tetranectin SLIT2 IDE T106B0.879484 PSA 2 DCE1 PSA 4 SLIT2 IDE PSMP T106B0.871259 PSA 1 DCE1 PSA 4 SLIT2 T106B Mn SOD CDON 0.870605 PSA 1 DCE1 PSA 4 Tetranectin SLIT2 T106B CDON 0.874062 PSA 1 DCE1 PSA 4 SLIT2 PSMP T106B CDON 0.880932 PSA 1 PSA 2 DCE1 PSA 4 SLIT2 T106B CDON 0.868254 PSA 1 DCE1 PSA 4 Tetranectin SLIT2 T106B Mn SOD0.87219 PSA 1 DCE1 PSA 4 SLIT2 PSMP T106B Mn SOD0.879367 PSA 1 PSA 2 DCE1 PSA 4 SLIT2 T106B Mn SOD0.873627 PSA 1 DCE1 PSA 4 Tetranectin SLIT2 PSMP T106B0.878725 PSA 1 PSA 2 DCE1 PSA 4 Tetranectin SLIT2 T106B0.882561 PSA 1 PSA 2 DCE1 PSA 4 SLIT2 PSMP T106B0.853357 DCE1 PSA 4 Tetranectin SLIT2 T106B Mn SOD CDON 0855664 DCE1 PSA 4 SLIT2 PSMP T106B Mn SOD CDON 0.877862 PSA 2 DCE1 PSA 4 SLIT2 T106B Mn SOD CDON 0.85608 DCE1 PSA 4 Tetranectin SLIT2 PSMP T106B CDON 0.876866 PSA 2 DCE1 PSA 4 Tetranectin SLIT2 T106B CDON 0.879822 PSA 2 DCE1 PSA 4 SLIT2 PSMP T106B CDON 0.854156 DCE1 PSA 4 Tetranectin SLIT2 PSMP T106B Mn SOD0.87518 PSA 2 DCE1 PSA 4 Tetranectin SLIT2 T106B Mn SOD0.878314 PSA 2 DCE1 PSA 4 SLIT2 PSMP T106B Mn SOD0.879302 PSA 2 DCE1 PSA 4 Tetranectin SLIT2 PSMP T106B0.87 PSA 1 DCE1 SLIT2 IDE T106B PTN CDON 0.866293 PSA 1 DCE1 SLIT2 IDE T106B Mn SOD PTN 0.866128 PSA 1 DCE1 Tetranectin SLIT2 IDE T106B PTN 0869415 PSA 1 DCE1 SLIT2 IDE PSMP T106B PTN 0.884598 PSA 1 PSA 2 DCE1 SLIT2 IDE T106B PTN 0.655404 DCE1 SLIT2 IDE T106B Mn SOD PTN CDON 0.645957 DCE1 Tetranectin SLIT2 IDE T106B PTN CDON 0.645788 DCE1 SLIT2 IDE PSMP T106B PTN CDON 0.881527 PSA 2 DCE1 SLIT2 IDE T106B PTN CDON 0635115 DCE1 Tetranectin SLIT2 IDE T106B Mn SOD PTN 0.635655 DCE1 SLIT2 IDE PSMP T106B Mn SOD PTN 0.879282 PSA 2 DCE1 SLIT2 IDE T106B Mn SOD PTN 0.624651 DCE1 Tetranectin SLIT2 IDE PSMP T106B PTN 0.879387 PSA 2 DCE1 Tetranectin SLIT2 IDE T106B PTN 0.880686 PSA 2 DCE1 SLIT2 IDE PSMP T106B PTN 0.867277 PSA 1 DCE1 SLIT2 T106B Mn SOD PTN CDON0.863897 PSA 1 DCE1 Tetranectin SLIT2 T106B PTN CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.869524 PSA 1 DCE1 SLIT2 PSMP T106B PTN CDON 0.884578 PSA 1 PSA 2 DCE1 SLIT2 T106B PTN CDON 0.862227 PSA 1 DCE1 Tetranectin SLIT2 T106B Mn SOD PTN 0.866616 PSA 1 DCE1 SLIT2 PSMP T106B Mn SOD PTN 0.882493 PSA 1 PSA 2 DCE1 SLIT2 T106B Mn SOD PTN 0.866614 PSA 1 DCE1 Tetranectin SLIT2 PSMP T106B PTN 0.88144 PSA 1 PSA 2 DCE1 Tetranectin SLIT2 T106B PTN 0.885191 PSA 1 PSA 2 DCE1 SLIT2 PSMP T106B PTN 0.645961 DCE1 Tetranectin SLIT2 T106B Mn SOD PTN CDON 0.645175 DCE1 SLIT2 PSMP T106B Mn SOD PTN CDON 0.879713 PSA 2 DCE1 SLIT2 T106B Mn SOD PTN CDON 0.639447 DCE1 Tetranectin SLIT2 PSMP T106B PTN CDON 0.879254 PSA 2 DCE1 Tetranectin SLIT2 T106B PTN CDON 0.881567 PSA 2 DCE1 SLIT2 PSMP T106B PTN CDON 0.634223 DCE1 Tetranectin SLIT2 PSMP T106B Mn SOD PTN 0.877152 PSA 2 DCE1 Tetranectin SLIT2 T106B Mn SOD PTN 0.87906 PSA 2 DCE1 SLIT2 PSMP T106B Mn SOD PTN 0880928 PSA 2 DCE1 Tetranectin SLIT2 PSMP T106B PTN 0.865968 PSA 1 DCE1 SLIT2 IDE T106B Mn SOD CDON 0.86426 PSA 1 DCE1 Tetranectin SLIT2 IDE T106B CDON 0.867523 PSA 1 DCE1 SLIT2 IDE PSMP T106B CDON 0.882932 PSA 1 PSA 2 DCE1 SLIT2 IDE T106B CDON 0.861059 PSA 1 DCE1 Tetranectin SLIT2 IDE T106B Mn SOD0864728 PSA 1 DCE1 SLIT2 IDE PSMP T106B Mn SOD0.881172 PSA 1 PSA 2 DCE1 SLIT2 IDE T106B Mn SOD0.865857 PSA 1 DCE1 Tetranectin SLIT2 IDE PSMP T106B0.880214 PSA 1 PSA 2 DCE1 Tetranectin SLIT2 IDE T106B0.883219 PSA 1 PSA 2 DCE1 SLIT2 IDE PSMP T106B0.638277 DCE1 Tetranectin SLIT2 IDE T106B Mn SOD CDON 0639056 DCE1 SLIT2 IDE PSMP T106B Mn SOD CDON 0.878495 PSA 2 DCE1 SLIT2 IDE T106B Mn SOD CDON 0.632743 DCE1 Tetranectin SLIT2 IDE PSMP T106B CDON 0.878423 PSA 2 DCE1 Tetranectin SLIT2 IDE T106B CDON 0.879439 PSA 2 DCE1 SLIT2 IDE PSMP T106B CDON 0.612592 DCE1 Tetranectin SLIT2 IDE PSMP T106B Mn SOD0.8767 PSA 2 DCE1 Tetranectin SLIT2 IDE T106B Mn SOD0.877656 PSA 2 DCE1 SLIT2 IDE PSMP T106B Mn SOD0.878979 PSA 2 DCE1 Tetranectin SLIT2 IDE PSMP T106B0.861505 PSA 1 DCE1 Tetranectin SLIT2 T106B Mn SOD CDON 0.865632 PSA 1 DCE1 SLIT2 PSMP T106B Mn SOD CDON 0.881016 PSA 1 PSA 2 DCE1 SLIT2 T106B Mn SOD CDON 0.865527 PSA 1 DCE1 Tetranectin SLIT2 PSMP T106B CDON0.880076 PSA 1 PSA 2 DCE1 Tetranectin SLIT2 T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.883521 PSA 1 PSA 2 DCE1 SLIT2 PSMP T106B CDON 0.862207 PSA 1 DCE1 Tetranectin SLIT2 PSMP T106B Mn SOD0.878096 PSA 1 PSA 2 DCE1 Tetranectin SLIT2 T106B Mn SOD0.881988 PSA 1 PSA 2 DCE1 SLIT2 PSMP T106B Mn SOD0.882731 PSA 1 PSA 2 DCE1 Tetranectin SLIT2 PSMP T106B0.633731 DCE1 Tetranectin SLIT2 PSMP T106B Mn SOD CDON 0.876648 PSA 2 DCE1 Tetranectin SLIT2 T106B Mn SOD CDON 0.878285 PSA 2 DCE1 SLIT2 PSMP T106B Mn SOD CDON 0.879322 PSA 2 DCE1 Tetranectin SLIT2 PSMP T106B CDON 0.877289 PSA 2 DCE1 Tetranectin SLIT2 PSMP T106B Mn SOD0.880847 PSA 1 DCE1 PSA 4 IDE T106B PTN CDON 0878459 PSA 1 DCE1 PSA 4 IDE T106B Mn SOD PTN 0.876926 PSA 1 DCE1 PSA 4 Tetranectin IDE T106B PTN 0.881053 PSA 1 DCE1 PSA 4 IDE PSMP T106B PTN 0.886833 PSA 1 PSA 2 DCE1 PSA 4 IDE T106B PTN 0.862013 DCE1 PSA 4 IDE T106B Mn SOD PTN CDON 0.861146 DCE1 PSA 4 Tetranectin IDE T106B PTN CDON 0.863429 DCE1 PSA 4 IDE PSMP T106B PTN CDON 0.883719 PSA 2 DCE1 PSA 4 IDE T106B PTN CDON 0.857524 DCE1 PSA 4 Tetranectin IDE T106B Mn SOD PTN 0.860718 DCE1 PSA 4 IDE PSMP T106B Mn SOD PTN 0.8824 PSA 2 DCE1 PSA 4 IDE T106B Mn SOD PTN 0.862094 DCE1 PSA 4 Tetranectin IDE PSMP T106B PTN 0881343 PSA 2 DCE1 PSA 4 Tetranectin IDE T106B PTN 0.883461 PSA 2 DCE1 PSA 4 IDE PSMP T106B PTN 0.879137 PSA 1 DCE1 PSA 4 T106B Mn SOD PTN CDON 0.877491 PSA 1 DCE1 PSA 4 Tetranectin T106B PTN CDON 0.88142 PSA 1 DCE1 PSA 4 PSMP T106B PTN CDON 0.886615 PSA 1 PSA 2 DCE1 PSA 4 T106B PTN CDON 0.874607 PSA 1 DCE1 PSA 4 Tetranectin T106B Mn SOD PTN 0.879084 PSA 1 DCE1 PSA 4 PSMP T106B Mn SOD PTN 0.884735 PSA 1 PSA 2 DCE1 PSA 4 T106B Mn SOD PTN 0.878995 PSA 1 DCE1 PSA 4 Tetranectin PSMP T106B PTN 0.883279 PSA 1 PSA 2 DCE1 PSA 4 Tetranectin T106B PTN 0.887684 PSA 1 PSA 2 DCE1 PSA 4 PSMP T106B PTN 0860347 DCE1 PSA 4 Tetranectin T106B Mn SOD PTN CDON 0.863207 DCE1 PSA 4 PSMP T106B Mn SOD PTN CDON 0.882626 PSA 2 DCE1 PSA 4 T106B Mn SOD PTN CDON 0.863377 DCE1 PSA 4 Tetranectin PSMP T106B PTN CDON 0.880694 PSA 2 DCE1 PSA 4 Tetranectin T106B PTN CDON 0.884393 PSA 2 DCE1 PSA 4 PSMP T106B PTN CDON 0.860265 DCE1 PSA 4 Tetranectin PSMP T106B Mn SOD PTN0.879108 PSA 2 DCE1 PSA 4 Tetranectin T106B Mn SOD PTNAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.882561 PSA 2 DCE1 PSA 4 PSMP T106B Mn SOD PTN 0.882864 PSA 2 DCE1 PSA 4 Tetranectin PSMP T106B PTN 0.872739 PSA 1 DCE1 PSA 4 IDE T106B Mn SOD CDON 0.872662 PSA 1 DCE1 PSA 4 Tetranectin IDE T106B CDON 0.875236 PSA 1 DCE1 PSA 4 IDE PSMP T106B CDON 0.88259 PSA 1 PSA 2 DCE1 PSA 4 IDE T106B CDON 0.868512 PSA 1 DCE1 PSA 4 Tetranectin IDE T106B Mn SOD0.872412 PSA 1 DCE1 PSA 4 IDE PSMP T106B Mn SOD0.880928 PSA 1 PSA 2 DCE1 PSA 4 IDE T106B Mn SOD0.873296 PSA 1 DCE1 PSA 4 Tetranectin IDE PSMP T106B0.879564 PSA 1 PSA 2 DCE1 PSA 4 Tetranectin IDE T106B0.883094 PSA 1 PSA 2 DCE1 PSA 4 IDE PSMP T106B0.858968 DCE1 PSA 4 Tetranectin IDE T106B Mn SOD CDON 0.860335 DCE1 PSA 4 IDE PSMP T106B Mn SOD CDON 0.87911 PSA 2 DCE1 PSA 4 IDE T106B Mn SOD CDON 0.861796 DCE1 PSA 4 Tetranectin IDE PSMP T106B CDON 0.878592 PSA 2 DCE1 PSA 4 Tetranectin IDE T106B CDON 0.880548 PSA 2 DCE1 PSA 4 IDE PSMP T106B CDON 0.857996 DCE1 PSA 4 Tetranectin IDE PSMP T106B Mn SOD0.876591 PSA 2 DCE1 PSA 4 Tetranectin IDE T106B Mn SOD0.878745 PSA 2 DCE1 PSA 4 IDE PSMP T106B Mn SOD0.879516 PSA 2 DCE1 PSA 4 Tetranectin IDE PSMP T106B0.868976 PSA 1 DCE1 PSA 4 Tetranectin T106B Mn SOD CDON 0872554 PSA 1 DCE1 PSA 4 PSMP T106B Mn SOD CDON 0.879564 PSA 1 PSA 2 DCE1 PSA 4 T106B Mn SOD CDON 0.873505 PSA 1 DCE1 PSA 4 Tetranectin PSMP T106B CDON 0.8786 PSA 1 PSA 2 DCE1 PSA 4 Tetranectin T106B CDON 0.882295 PSA 1 PSA 2 DCE1 PSA 4 PSMP T106B CDON 0.869593 PSA 1 DCE1 PSA 4 Tetranectin PSMP T106B Mn SOD0875684 PSA 1 PSA 2 DCE1 PSA 4 Tetranectin T106B Mn SOD0.88027 PSA 1 PSA 2 DCE1 PSA 4 PSMP T106B Mn SOD0.880734 PSA 1 PSA 2 DCE1 PSA 4 Tetranectin PSMP T106B0.859428 DCE1 PSA 4 Tetranectin PSMP T106B Mn SOD CDON 0.876208 PSA 2 DCE1 PSA 4 Tetranectin T106B Mn SOD CDON 0.8786 PSA 2 DCE1 PSA 4 PSMP T106B Mn SOD CDON 0.878987 PSA 2 DCE1 PSA 4 Tetranectin PSMP T106B CDON 0.876866 PSA 2 DCE1 PSA 4 Tetranectin PSMP T106B Mn SOD0.874655 PSA 1 DCE1 IDE T106B Mn SOD PTN CDON 0.87171 PSA 1 DCE1 Tetranectin IDE T106B PTN CDON 0.876704 PSA 1 DCE1 IDE PSMP T106B PTN CDON 0.887656 PSA 1 PSA 2 DCE1 IDE T106B PTN CDON 0.868516 PSA 1 DCE1 Tetranectin IDE T106B Mn SOD PTN0.873292 PSA 1 DCE1 IDE PSMP T106B Mn SOD PTNAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.88645 PSA 1 PSA 2 DCE1 IDE T106B Mn SOD PTN 0.873042 PSA 1 DCE1 Tetranectin IDE PSMP T106B PTN 0.884683 PSA 1 PSA 2 DCE1 Tetranectin IDE T106B PTN 0.887753 PSA 1 PSA 2 DCE1 IDE PSMP T106B PTN 0.652613 DCE1 Tetranectin IDE T106B Mn SOD PTN CDON 0.654047 DCE1 IDE PSMP T106B Mn SOD PTN CDON 0.881928 PSA 2 DCE1 IDE T106B Mn SOD PTN CDON 0.641528 DCE1 Tetranectin IDE PSMP T106B PTN CDON 0.880867 PSA 2 DCE1 Tetranectin IDE T106B PTN CDON 0.883308 PSA 2 DCE1 IDE PSMP T106B PTN CDON 0.642264 DCE1 Tetranectin IDE PSMP T106B Mn SOD PTN 0879496 PSA 2 DCE1 Tetranectin IDE T106B Mn SOD PTN 0.880682 PSA 2 DCE1 IDE PSMP T106B Mn SOD PTN 0.88169 PSA 2 DCE1 Tetranectin IDE PSMP T106B PTN 0.869468 PSA 1 DCE1 Tetranectin T106B Mn SOD PTN CDON 0.874633 PSA 1 DCE1 PSMP T106B Mn SOD PTN CDON 0.88668 PSA 1 PSA 2 DCE1 T106B Mn SOD PTN CDON 0.87307 PSA 1 DCE1 Tetranectin PSMP T106B PTN CDON 0.88474 PSA 1 PSA 2 DCE1 Tetranectin T106B PTN CDON 0.888925 PSA 1 PSA 2 DCE1 PSMP T106B PTN CDON 0.870174 PSA 1 DCE1 Tetranectin PSMP T106B Mn SOD PTN 0.88311 PSA 1 PSA 2 DCE1 Tetranectin T106B Mn SOD PTN 0.887075 PSA 1 PSA 2 DCE1 PSMP T106B Mn SOD PTN 0886974 PSA 1 PSA 2 DCE1 Tetranectin PSMP T106B PTN 0.649289 DCE1 Tetranectin PSMP T106B Mn SOD PTN CDON 0.880032 PSA 2 DCE1 Tetranectin T106B Mn SOD PTN CDON 0.882085 PSA 2 DCE1 PSMP T106B Mn SOD PTN CDON 0.882751 PSA 2 DCE1 Tetranectin PSMP T106B PTN CDON 0.880966 PSA 2 DCE1 Tetranectin PSMP T106B Mn SOD PTN 0868935 PSA 1 DCE1 Tetranectin IDE T106B Mn SOD CDON 0.873038 PSA 1 DCE1 IDE PSMP T106B Mn SOD CDON 0.883166 PSA 1 PSA 2 DCE1 IDE T106B Mn SOD CDON 0.872203 PSA 1 DCE1 Tetranectin IDE PSMP T106B CDON 0.881863 PSA 1 PSA 2 DCE1 Tetranectin IDE T106B CDON 0.884977 PSA 1 PSA 2 DCE1 IDE PSMP T106B CDON 0.869028 PSA 1 DCE1 Tetranectin IDE PSMP T106B Mn SOD0.879923 PSA 1 PSA 2 DCE1 Tetranectin IDE T106B Mn SOD0.883158 PSA 1 PSA 2 DCE1 IDE PSMP T106B Mn SOD0.88338 PSA 1 PSA 2 DCE1 Tetranectin IDE PSMP T106B0.602768 DCE1 Tetranectin IDE PSMP T106B Mn SOD CDON 0.879165 PSA 2 DCE1 Tetranectin IDE T106B Mn SOD CDON 0.880141 PSA 2 DCE1 IDE PSMP T106B Mn SOD CDON0.880794 PSA 2 DCE1 Tetranectin IDE PSMP T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.879068 PSA 2 DCE1 Tetranectin IDE PSMP T106B Mn SOD0.869617 PSA 1 DCE1 Tetranectin PSMP T106B Mn SOD CDON 0.879647 PSA 1 PSA 2 DCE1 Tetranectin T106B Mn SOD CDON 0.88313 PSA 1 PSA 2 DCE1 PSMP T106B Mn SOD CDON 0.883933 PSA 1 PSA 2 DCE1 Tetranectin PSMP T106B CDON 0.881305 PSA 1 PSA 2 DCE1 Tetranectin PSMP T106B Mn SOD0.879701 PSA 2 DCE1 Tetranectin PSMP T106B Mn SOD CDON 0.881476 PSA 1 PSA 3 PSA 4 SLIT2 IDE T106B PTN 0.874708 PSA 3 PSA 4 SLIT2 IDE T106B PTN CDON 0.873114 PSA 3 PSA 4 SLIT2 IDE T106B Mn SOD PTN 0.872836 PSA 3 PSA 4 Tetranectin SLIT2 IDE T106B PTN 0873473 PSA 3 PSA 4 SLIT2 IDE PSMP T106B PTN 0.885175 PSA 2 PSA 3 PSA 4 SLIT2 IDE T106B PTN 0.881605 PSA 1 PSA 3 PSA 4 SLIT2 T106B PTN CDON 0.879843 PSA 1 PSA.3 PSA 4 SLIT2 T106B Mn SOD PTN 0.878975 PSA 1 PSA 3 PSA 4 Tetranectin SLIT2 T106B PTN 0.881759 PSA 1 PSA 3 PSA 4 SLIT2 PSMP T106B PTN 0.886615 PSA 1 PSA 2 PSA 3 PSA 4 SLIT2 T106B PTN 0.873864 PSA 3 PSA 4 SLIT2 T106B Mn SOD PTN CDON 0.872529 PSA 3 PSA 4 Tetranectin SLIT2 T106B PTN CDON 0.87378 PSA.3 PSA 4 SLIT2 PSMP T106B PTN CDON 0.885215 PSA 2 PSA 3 PSA 4 SLIT2 T106B PTN CDON 0.871747 PSA 3 PSA 4 Tetranectin SLIT2 T106B Mn SOD PTN 0872469 PSA 3 PSA 4 SLIT2 PSMP T106B Mn SOD PTN 0.883973 PSA 2 PSA 3 PSA 4 SLIT2 T106B Mn SOD PTN 0.873505 PSA 3 PSA 4 Tetranectin SLIT2 PSMP T106B PTN 0.883029 PSA 2 PSA 3 PSA 4 Tetranectin SLIT2 T106B PTN 0.884941 PSA 2 PSA 3 PSA 4 SLIT2 PSMP T106B PTN 0.879237 PSA 1 PSA 3 PSA 4 SLIT2 IDE T106B CDON 0.877761 PSA 1 PSA 3 PSA 4 SLIT2 IDE T106B Mn SOD0.877013 PSA 1 PSA 3 PSA 4 Tetranectin SLIT2 IDE T106B0.879016 PSA 1 PSA 3 PSA 4 SLIT2 IDE PSMP T106B0.885558 PSA 1 PSA 2 PSA 3 PSA 4 SLIT2 IDE T106B0.871852 PSA 3 PSA 4 SLIT2 IDE T106B Mn SOD CDON 0.870803 PSA 3 PSA 4 Tetranectin SLIT2 IDE T106B CDON 0.87113 PSA 3 PSA 4 SLIT2 IDE PSMP T106B CDON 0.884534 PSA 2 PSA.3 PSA 4 SLIT2 IDE T106B CDON 0.869786 PSA 3 PSA 4 Tetranectin SLIT2 IDE T106B Mn SOD0.869988 PSA 3 PSA 4 SLIT2 IDE PSMP T106B Mn SOD0.883525 PSA 2 PSA 3 PSA 4 SLIT2 IDE T106B Mn SOD0.871037 PSA 3 PSA 4 Tetranectin SLIT2 IDE PSMP T106B0.882473 PSA 2 PSA 3 PSA 4 Tetranectin SLIT2 IDE T106B0.883495 PSA 2 PSA 3 PSA 4 SLIT2 IDE PSMP T106BAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.877983 PSA 1 PSA 3 PSA 4 SLIT2 T106B Mn SOD CDON 0.876737 PSA 1 PSA.3 PSA 4 Tetranectin SLIT2 T106B CDON 0.879996 PSA 1 PSA 3 PSA 4 SLIT2 PSMP T106B CDON 0.885211 PSA 1 PSA 2 PSA 3 PSA 4 SLIT2 T106B CDON 0.875216 PSA 1 PSA 3 PSA 4 Tetranectin SLIT2 T106B Mn SOD0878237 PSA 1 PSA 3 PSA 4 SLIT2 PSMP T106B Mn SOD0.884159 PSA 1 PSA 2 PSA.3 PSA 4 SLIT2 T106B Mn SOD0.879173 PSA 1 PSA 3 PSA 4 Tetranectin SLIT2 PSMP T106B0.883013 PSA 1 PSA 2 PSA 3 PSA 4 Tetranectin SLIT2 T106B0.885812 PSA 1 PSA 2 PSA 3 PSA 4 SLIT2 PSMP T106B0.870363 PSA 3 PSA 4 Tetranectin SLIT2 T106B Mn SOD CDON 0.87119 PSA 3 PSA 4 SLIT2 PSMP T106B Mn SOD CDON 0.883501 PSA 2 PSA 3 PSA 4 SLIT2 T106B Mn SOD CDON 0.871468 PSA 3 PSA 4 Tetranectin SLIT2 PSMP T106B CDON 0.882009 PSA 2 PSA.3 PSA 4 Tetranectin SLIT2 T106B CDON 0.884098 PSA 2 PSA 3 PSA 4 SLIT2 PSMP T106B CDON 0.870615 PSA 3 PSA 4 Tetranectin SLIT2 PSMP T106B Mn SOD0880932 PSA 2 PSA 3 PSA 4 Tetranectin SLIT2 T106B Mn SOD0.883029 PSA 2 PSA 3 PSA 4 SLIT2 PSMP T106B Mn SOD0.883711 PSA 2 PSA 3 PSA 4 Tetranectin SLIT2 PSMP T106B0.882436 PSA 1 PSA.3 SLIT2 IDE T106B PTN CDON 0.880552 PSA 1 PSA 3 SLIT2 IDE T106B Mn SOD PTN 0.879241 PSA 1 PSA 3 Tetranectin SLIT2 IDE T106B PTN 0.881525 PSA 1 PSA 3 SLIT2 IDE PSMP T106B PTN 0.889326 PSA 1 PSA 2 PSA 3 SLIT2 IDE T106B PTN 0.865357 PSA 3 SLIT2 IDE T106B Mn SOD PTN CDON 0.864877 PSA 3 Tetranectin SLIT2 IDE T106B PTN CDON 0.862501 PSA 3 SLIT2 IDE PSMP T106B PTN CDON 0.888277 PSA 2 PSA 3 SLIT2 IDE T106B PTN CDON 0864006 PSA 3 Tetranectin SLIT2 IDE T106B Mn SOD PTN 0.861178 PSA 3 SLIT2 IDE PSMP T106B Mn SOD PTN 0.887152 PSA 2 PSA 3 SLIT2 IDE T106B Mn SOD PTN 0.862614 PSA 3 Tetranectin SLIT2 IDE PSMP T106B PTN 0.885986 PSA 2 PSA 3 Tetranectin SLIT2 IDE T106B PTN 0.886482 PSA 2 PSA 3 SLIT2 IDE PSMP T106B PTN 0881315 PSA 1 PSA 3 SLIT2 T106B Mn SOD PTN CDON 0.87887 PSA 1 PSA.3 Tetranectin SLIT2 T106B PTN CDON 0.882194 PSA 1 PSA 3 SLIT2 PSMP T106B PTN CDON 0.889737 PSA 1 PSA 2 PSA 3 SLIT2 T106B PTN CDON 0.877531 PSA 1 PSA 3 Tetranectin SLIT2 T106B Mn SOD PTN 0.880379 PSA 1 PSA 3 SLIT2 PSMP T106B Mn SOD PTN 0.88793 PSA 1 PSA 2 PSA 3 SLIT2 T106B Mn SOD PTN0.880121 PSA 1 PSA 3 Tetranectin SLIT2 PSMP T106B PTNAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.886623 PSA 1 PSA 2 PSA 3 Tetranectin SLIT2 T106B PTN 0.8891 PSA 1 PSA 2 PSA.3 SLIT2 PSMP T106B PTN 0.865841 PSA 3 Tetranectin SLIT2 T106B Mn SOD PTN CDON 0.863631 PSA 3 SLIT2 PSMP T106B Mn SOD PTN CDON 0.887297 PSA 2 PSA 3 SLIT2 T106B Mn SOD PTN CDON 0.863816 PSA 3 Tetranectin SLIT2 PSMP T106B PTN CDON 0.885345 PSA 2 PSA 3 Tetranectin SLIT2 T106B PTN CDON 0.886712 PSA 2 PSA 3 SLIT2 PSMP T106B PTN CDON 0.863244 PSA 3 Tetranectin SLIT2 PSMP T106B Mn SOD PTN 0.884548 PSA 2 PSA 3 Tetranectin SLIT2 T106B Mn SOD PTN 0.885534 PSA 2 PSA 3 SLIT2 PSMP T106B Mn SOD PTN 0.885691 PSA 2 PSA 3 Tetranectin SLIT2 PSMP T106B PTN 0.878697 PSA 1 PSA 3 SLIT2 IDE T106B Mn SOD CDON 0.87687 PSA 1 PSA 3 Tetranectin SLIT2 IDE T106B CDON 0.879108 PSA 1 PSA.3 SLIT2 IDE PSMP T106B CDON 0.888063 PSA 1 PSA 2 PSA 3 SLIT2 IDE T106B CDON 0.875474 PSA 1 PSA 3 Tetranectin SLIT2 IDE T106B Mn SOD0877293 PSA 1 PSA 3 SLIT2 IDE PSMP T106B Mn SOD0.886817 PSA 1 PSA 2 PSA 3 SLIT2 IDE T106B Mn SOD0.877664 PSA 1 PSA 3 Tetranectin SLIT2 IDE PSMP T106B0.885276 PSA 1 PSA 2 PSA.3 Tetranectin SLIT2 IDE T106B0.887164 PSA 1 PSA 2 PSA 3 SLIT2 IDE PSMP T106B0.862155 PSA 3 Tetranectin SLIT2 IDE T106B Mn SOD CDON 0858899 PSA 3 SLIT2 IDE PSMP T106B Mn SOD CDON 0.885821 PSA 2 PSA 3 SLIT2 IDE T106B Mn SOD CDON 0.859327 PSA 3 Tetranectin SLIT2 IDE PSMP T106B CDON 0.884558 PSA 2 PSA 3 Tetranectin SLIT2 IDE T106B CDON 0.885349 PSA 2 PSA 3 SLIT2 IDE PSMP T106B CDON 0.858581 PSA 3 Tetranectin SLIT2 IDE PSMP T106B Mn SOD0.883582 PSA 2 PSA 3 Tetranectin SLIT2 IDE T106B Mn SOD0.883929 PSA 2 PSA 3 SLIT2 IDE PSMP T106B Mn SOD0.884066 PSA 2 PSA 3 Tetranectin SLIT2 IDE PSMP T106B0.876482 PSA 1 PSA 3 Tetranectin SLIT2 T106B Mn SOD CDON 0.878905 PSA 1 PSA 3 SLIT2 PSMP T106B Mn SOD CDON 0.887244 PSA 1 PSA 2 PSA 3 SLIT2 T106B Mn SOD CDON 0.879056 PSA 1 PSA 3 Tetranectin SLIT2 PSMP T106B CDON 0.885528 PSA 1 PSA 2 PSA.3 Tetranectin SLIT2 T106B CDON 0.888317 PSA 1 PSA 2 PSA 3 SLIT2 PSMP T106B CDON 0.877116 PSA 1 PSA 3 Tetranectin SLIT2 PSMP T106B Mn SOD0.88405 PSA 1 PSA 2 PSA 3 Tetranectin SLIT2 T106B Mn SOD0.886861 PSA 1 PSA 2 PSA 3 SLIT2 PSMP T106B Mn SOD0.887382 PSA 1 PSA 2 PSA 3 Tetranectin SLIT2 PSMP T106B0.860404 PSA 3 Tetranectin SLIT2 PSMP T106B Mn SOD CDONAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLI '12 IDE PSMP T106B Mn SOD PTN CDON 0.883989 PSA 2 PSA 3 Tetranectin SLIT2 T106B Mn SOD CDON 0.884848 PSA 2 PSA 3 SLIT2 PSMP T106B Mn SOD CDON 0.884986 PSA 2 PSA 3 Tetranectin SLIT2 PSMP T106B CDON 0.883917 PSA 2 PSA 3 Tetranectin SLIT2 PSMP T106B Mn SOD0.886813 PSA 1 PSA 3 PSA 4 IDE T106B PTN CDON 0 88574 PSA 1 PSA 3 PSA 4 IDE T106B Mn SOD PTN 0.88315 PSA 1 PSA 3 PSA 4 Tetranectin IDE T106B PTN 0.886167 PSA 1 PSA 3 PSA 4 IDE PSMP T106B PTN 0.891218 PSA 1 PSA 2 PSA 3 PSA 4 IDE T106B PTN 0.878447 PSA 3 PSA 4 IDE T106B Mn SOD PTN CDON 0.876914 PSA 3 PSA 4 Tetranectin IDE T106B PTN CDON 0877975 PSA 3 PSA 4 IDE PSMP T106B PTN CDON 0.889515 PSA 2 PSA 3 PSA 4 IDE T106B PTN CDON 0.875502 PSA 3 PSA 4 Tetranectin IDE T106B Mn SOD PTN 0.876156 PSA 3 PSA 4 IDE PSMP T106B Mn SOD PTN 0.8884! PSA 2 PSA 3 PSA 4 IDE T106B Mn SOD PTN 0.876176 PSA 3 PSA 4 Tetranectin IDE PSMP T106B PTN 0886208 PSA 2 PSA 3 PSA 4 Tetranectin IDE T106B PTN 0.88816 PSA 2 PSA 3 PSA 4 IDE PSMP T106B PTN 0.885825 PSA 1 PSA 3 PSA 4 T106B Mn SOD PTN CDON 0.883287 PSA 1 PSA 3 PSA 4 Tetranectin T106B PTN CDON 0.886994 PSA 1 PSA 3 PSA 4 PSMP T106B PTN CDON 0.891052 PSA 1 PSA 2 PSA 3 PSA 4 T106B PTN CDON 0.881585 PSA 1 PSA 3 PSA 4 Tetranectin T106B Mn SOD PTN 0.885026 PSA 1 PSA 3 PSA 4 PSMP T106B Mn SOD PTN 0.88981 PSA 1 PSA 2 PSA 3 PSA 4 T106B Mn SOD PTN 0.884312 PSA 1 PSA 3 PSA 4 Tetranectin PSMP T106B PTN 0.887543 PSA 1 PSA 2 PSA 3 PSA 4 Tetranectin T106B PTN 0.890869 PSA 1 PSA 2 PSA 3 PSA 4 PSMP T106B PTN 0.876454 PSA 3 PSA 4 Tetranectin T106B Mn SOD PTN CDON 0.877567 PSA 3 PSA 4 PSMP T106B Mn SOD PTN CDON 0.888434 PSA 2 PSA 3 PSA 4 T106B Mn SOD PTN CDON 0.877027 PSA 3 PSA 4 Tetranectin PSMP T106B PTN CDON 0.886188 PSA 2 PSA 3 PSA 4 Tetranectin T106B PTN CDON 0.888612 PSA 2 PSA 3 PSA 4 PSMP T106B PTN CDON 0.875446 PSA 3 PSA 4 Tetranectin PSMP T106B Mn SOD PTN 0.885179 PSA 2 PSA.3 PSA 4 Tetranectin T106B Mn SOD PTN 0.887285 PSA 2 PSA 3 PSA 4 PSMP T106B Mn SOD PTN 0.886958 PSA 2 PSA 3 PSA 4 Tetranectin PSMP T106B PTN 0.878003 PSA 1 PSA 3 PSA 4 IDE T106B Mn SOD CDON 0.876579 PSA 1 PSA 3 PSA 4 Tetranectin IDE T106B CDON 0878903 PSA 1 PSA 3 PSA 4 IDE PSMP T106B CDON0.885659 PSA 1 PSA 2 PSA 3 PSA 4 IDE T106B CDONAUC PSA 1 PSA 2 PSA 3 DC E1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.874401 PSA 1 PSA 3 PSA 4 Tetranectin IDE T106B Mn SOD0.87691 PSA 1 PSA 3 PSA 4 IDE PSMP T106B Mn SOD0.884223 PSA 1 PSA 2 PSA 3 PSA 4 IDE T106B Mn SOD0.877051 PSA 1 PSA 3 PSA 4 Tetranectin IDE PSMP T106B0.882723 PSA 1 PSA 2 PSA 3 PSA 4 Tetranectin IDE T106B0.885064 PSA 1 PSA 2 PSA 3 PSA 4 IDE PSMP T106B0.871299 PSA 3 PSA 4 Tetranectin IDE T106B Mn SOD CDON 0.870996 PSA 3 PSA 4 IDE PSMP T106B Mn SOD CDON 0.883812 PSA 2 PSA 3 PSA 4 IDE T106B Mn SOD CDON 0.871287 PSA 3 PSA 4 Tetranectin IDE PSMP T106B CDON 0.882247 PSA 2 PSA 3 PSA 4 Tetranectin IDE T106B CDON 0.883582 PSA 2 PSA 3 PSA 4 IDE PSMP T106B CDON 0.86948 PSA 3 PSA 4 Tetranectin IDE PSMP T106B Mn SOD0.881119 PSA 2 PSA 3 PSA 4 Tetranectin IDE T106B Mn SOD0.882231 PSA 2 PSA.3 PSA 4 IDE PSMP T106B Mn SOD0.882462 PSA 2 PSA 3 PSA 4 Tetranectin IDE PSMP T106B0.874304 PSA 1 PSA 3 PSA 4 Tetranectin T106B Mn SOD CDON 0.87695 PSA 1 PSA 3 PSA 4 PSMP T106B Mn SOD CDON 0.883275 PSA 1 PSA 2 PSA 3 PSA 4 T106B Mn SOD CDON 0.876991 PSA 1 PSA 3 PSA 4 Tetranectin PSMP T106B CDON 0.882013 PSA 1 PSA 2 PSA 3 PSA 4 Tetranectin T106B CDON 0.884614 PSA 1 PSA 2 PSA 3 PSA 4 PSMP T106B CDON 0.874502 PSA 1 PSA 3 PSA 4 Tetranectin PSMP T106B Mn SOD0.87979 PSA 1 PSA 2 PSA 3 PSA 4 Tetranectin T106B Mn SOD0.882981 PSA 1 PSA 2 PSA 3 PSA 4 PSMP T106B Mn SOD0.883251 PSA 1 PSA 2 PSA 3 PSA 4 Tetranectin PSMP T106B0.870093 PSA 3 PSA 4 Tetranectin PSMP T106B Mn SOD CDON 0.880536 PSA 2 PSA 3 PSA 4 Tetranectin T106B Mn SOD CDON 0.882303 PSA 2 PSA 3 PSA 4 PSMP T106B Mn SOD CDON 0.882126 PSA 2 PSA 3 PSA 4 Tetranectin PSMP T106B CDON 0.880411 PSA 2 PSA 3 PSA 4 Tetranectin PSMP T106B Mn SOD0.886575 PSA 1 PSA 3 IDE T106B Mn SOD PTN CDON 0.883808 PSA 1 PSA 3 Tetranectin IDE T106B PTN CDON 0.886764 PSA 1 PSA 3 IDE PSMP T106B PTN CDON 0.893477 PSA 1 PSA 2 PSA 3 IDE T106B PTN CDON 0.882634 PSA 1 PSA 3 Tetranectin IDE T106B Mn SOD PTN 0.885155 PSA 1 PSA.3 IDE PSMP T106B Mn SOD PTN 0.892557 PSA 1 PSA 2 PSA 3 IDE T106B Mn SOD PTN 0.883598 PSA 1 PSA 3 Tetranectin IDE PSMP T106B PTN 0.889685 PSA 1 PSA 2 PSA 3 Tetranectin IDE T106B PTN 0.892186 PSA 1 PSA 2 PSA 3 IDE PSMP T106B PTN 0.870371 PSA 3 Tetranectin IDE T106B Mn SOD PTN CDON0.866003 PSA 3 IDE PSMP T106B Mn SOD PTN CDONAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.890947 PSA 2 PSA 3 IDE T106B Mn SOD PTN CDON 0.865849 PSA.3 Tetranectin IDE PSMP T106B PTN CDON 0.888531 PSA 2 PSA 3 Tetranectin IDE T106B PTN CDON 0.889697 PSA 2 PSA 3 IDE PSMP T106B PTN CDON 0.865664 PSA 3 Tetranectin IDE PSMP T106B Mn SOD PTN 0887696 PSA 2 PSA 3 Tetranectin IDE T106B Mn SOD PTN 0.888184 PSA 2 PSA 3 IDE PSMP T106B Mn SOD PTN 0.887398 PSA 2 PSA 3 Tetranectin IDE PSMP T106B PTN 0.883537 PSA 1 PSA 3 Tetranectin T106B Mn SOD PTN CDON 0.886603 PSA 1 PSA 3 PSMP T106B Mn SOD PTN CDON 0.892964 PSA 1 PSA 2 PSA 3 T106B Mn SOD PTN CDON 0885058 PSA 1 PSA 3 Tetranectin PSMP T106B PTN CDON 0.890371 PSA 1 PSA 2 PSA 3 Tetranectin T106B PTN CDON 0.89367 PSA 1 PSA 2 PSA 3 PSMP T106B PTN CDON 0.883469 PSA 1 PSA.3 Tetranectin PSMP T106B Mn SOD PTN 0.888987 PSA 1 PSA 2 PSA 3 Tetranectin T106B Mn SOD PTN 0.892147 PSA 1 PSA 2 PSA 3 PSMP T106B Mn SOD PTN 0891179 PSA 1 PSA 2 PSA 3 Tetranectin PSMP T106B PTN 0.868124 PSA 3 Tetranectin PSMP T106B Mn SOD PTN CDON 0.888543 PSA 2 PSA 3 Tetranectin T106B Mn SOD PTN CDON 0.88939 PSA 2 PSA.3 PSMP T106B Mn SOD PTN CDON 0.888914 PSA 2 PSA 3 Tetranectin PSMP T106B PTN CDON 0.887692 PSA 2 PSA 3 Tetranectin PSMP T106B Mn SOD PTN 0877789 PSA 1 PSA 3 Tetranectin IDE T106B Mn SOD CDON 0.87952 PSA 1 PSA 3 IDE PSMP T106B Mn SOD CDON 0.887837 PSA 1 PSA 2 PSA 3 IDE T106B Mn SOD CDON 0.8791 PSA 1 PSA 3 Tetranectin IDE PSMP T106B CDON 0.886034 PSA 1 PSA 2 PSA 3 Tetranectin IDE T106B CDON 0.888221 PSA 1 PSA 2 PSA 3 IDE PSMP T106B CDON 0 8771 PSA 1 PSA 3 Tetranectin IDE PSMP T106B Mn SOD0.884586 PSA 1 PSA 2 PSA 3 Tetranectin IDE T106B Mn SOD0.886619 PSA 1 PSA 2 PSA 3 IDE PSMP T106B Mn SOD0.88618 PSA 1 PSA 2 PSA 3 Tetranectin IDE PSMP T106B0.86737 PSA 3 Tetranectin IDE PSMP T106B Mn SOD CDON 0.884812 PSA 2 PSA 3 Tetranectin IDE T106B Mn SOD CDON 0885357 PSA 2 PSA 3 IDE PSMP T106B Mn SOD CDON 0.884957 PSA 2 PSA.3 Tetranectin IDE PSMP T106B CDON 0.883558 PSA 2 PSA 3 Tetranectin IDE PSMP T106B Mn SOD0.878128 PSA 1 PSA 3 Tetranectin PSMP T106B Mn SOD CDON 0.884752 PSA 1 PSA 2 PSA 3 Tetranectin T106B Mn SOD CDON 0.887099 PSA 1 PSA 2 PSA 3 PSMP T106B Mn SOD CDON 0886756 PSA 1 PSA 2 PSA 3 Tetranectin PSMP T106B CDON0.885107 PSA 1 PSA 2 PSA 3 Tetranectin PSMP T106B Mn SODAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.884175 PSA 2 PSA 3 Tetranectin PSMP T106B Mn SOD CDON 0.877011 PSA 1 PSA 4 SLIT2 IDE T106B PTN CDON 0.87526 PSA 1 PSA 4 SLIT2 IDE T106B Mn SOD PTN 0.874619 PSA 1 PSA 4 Tetranectin SLIT2 IDE T106B PTN 0.877144 PSA 1 PSA 4 SLIT2 IDE PSMP T106B PTN 0884596 PSA 1 PSA 2 PSA 4 SLIT2 IDE T106B PTN 0.858254 PSA 4 SLIT2 IDE T106B Mn SOD PTN CDON 0.856463 PSA 4 Tetranectin SLIT2 IDE T106B PTN CDON 0.859069 PSA 4 SLIT2 IDE PSMP T106B PTN CDON 0.882033 PSA 2 PSA 4 SLIT2 IDE T106B PTN CDON 0.854809 PSA 4 Tetranectin SLIT2 IDE T106B Mn SOD PTN 0857044 PSA 4 SLIT2 IDE PSMP T106B Mn SOD PTN 0.880714 PSA 2 PSA 4 SLIT2 IDE T106B Mn SOD PTN 0.859174 PSA 4 Tetranectin SLIT2 IDE PSMP T106B PTN 0.880054 PSA 2 PSA 4 Tetranectin SLIT2 IDE T106B PTN 0.881488 PSA 2 PSA 4 SLIT2 IDE PSMP T106B PTN 0.875845 PSA 1 PSA 4 SLIT2 T106B Mn SOD PTN CDON 0873368 PSA 1 PSA 4 Tetranectin SLIT2 T106B PTN CDON 0.877374 PSA 1 PSA 4 SLIT2 PSMP T106B PTN CDON 0.884397 PSA 1 PSA 2 PSA 4 SLIT2 T106B PTN CDON 0.872618 PSA 1 PSA 4 Tetranectin SLIT2 T106B Mn SOD PTN 0.875736 PSA 1 PSA 4 SLIT2 PSMP T106B Mn SOD PTN 0.882723 PSA 1 PSA 2 PSA 4 SLIT2 T106B Mn SOD PTN 0876006 PSA 1 PSA 4 Tetranectin SLIT2 PSMP T106B PTN 0.88217 PSA 1 PSA 2 PSA 4 Tetranectin SLIT2 T106B PTN 0.884905 PSA 1 PSA 2 PSA 4 SLIT2 PSMP T106B PTN 0.85589 PSA 4 Tetranectin SLIT2 T106B Mn SOD PTN CDON 0.858573 PSA 4 SLIT2 PSMP T106B Mn SOD PTN CDON 0.880883 PSA 2 PSA 4 SLIT2 T106B Mn SOD PTN CDON 0857875 PSA 4 Tetranectin SLIT2 PSMP T106B PTN CDON 0.878963 PSA 2 PSA 4 Tetranectin SLIT2 T106B PTN CDON 0.881424 PSA 2 PSA 4 SLIT2 PSMP T106B PTN CDON 0.857391 PSA 4 Tetranectin SLIT2 PSMP T106B Mn SOD PTN 0.878382 PSA 2 PSA 4 Tetranectin SLIT2 T106B Mn SOD PTN 0.880351 PSA 2 PSA 4 SLIT2 PSMP T106B Mn SOD PTN 0881141 PSA 2 PSA 4 Tetranectin SLIT2 PSMP T106B PTN 0.873146 PSA 1 PSA 4 SLIT2 IDE T106B Mn SOD CDON 0.871888 PSA 1 PSA 4 Tetranectin SLIT2 IDE T106B CDON 0.874441 PSA 1 PSA 4 SLIT2 IDE PSMP T106B CDON 0.883755 PSA 1 PSA 2 PSA 4 SLIT2 IDE T106B CDON 0.87027 PSA 1 PSA 4 Tetranectin SLIT2 IDE T106B Mn SOD0873078 PSA 1 PSA 4 SLIT2 IDE PSMP T106B Mn SOD0.882412 PSA 1 PSA 2 PSA 4 SLIT2 IDE T106B Mn SODAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.873844 PSA 1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B0.881026 PSA 1 PSA 2 PSA 4 Tetranectin SL.1T2 IDE T106B0.88384 PSA 1 PSA 2 PSA 4 SLIT2 IDE PSMP T106B0.854531 PSA 4 Tetranectin SLIT2 IDE T106B Mn SOD CDON 0.855537 PSA 4 SLIT2 IDE PSMP T106B Mn SOD CDON 0880452 PSA 2 PSA 4 SLIT2 IDE T106B Mn SOD CDON 0.855801 PSA 4 Tetranectin SLIT2 IDE PSMP T106B CDON 0.87902 PSA 2 PSA 4 Tetranectin SLIT2 IDE T106B CDON 0.880589 PSA 2 PSA 4 SLIT2 IDE PSMP T106B CDON 0.854781 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD0.878189 PSA 2 PSA 4 Tetranectin SLIT2 IDE T106B Mn SOD0879342 PSA 2 PSA 4 SLIT2 IDE PSMP T106B Mn SOD0.879955 PSA 2 PSA 4 Tetranectin SLIT2 IDE PSMP T106B0.870754 PSA 1 PSA 4 Tetranectin SLIT2 T106B Mn SOD CDON 0.874256 PSA 1 PSA 4 SL.1T2 PSMP T106B Mn SOD CDON 0.882267 PSA 1 PSA 2 PSA 4 SLIT2 T106B Mn SOD CDON 0.874264 PSA 1 PSA 4 Tetranectin SLIT2 PSMP T106B CDON 0880625 PSA 1 PSA 2 PSA 4 Tetranectin SLIT2 T106B CDON 0.883977 PSA 1 PSA 2 PSA 4 SLIT2 PSMP T106B CDON 0.873155 PSA 1 PSA 4 Tetranectin SLIT2 PSMP T106B Mn SOD0.879379 PSA 1 PSA 2 PSA 4 Tetranectin SL.1T2 T106B Mn SOD0.882973 PSA 1 PSA 2 PSA 4 SLIT2 PSMP T106B Mn SOD0.883449 PSA 1 PSA 2 PSA 4 Tetranectin SLIT2 PSMP T106B0855757 PSA 4 Tetranectin SLIT2 PSMP T106B Mn SOD CDON 0.878241 PSA 2 PSA 4 Tetranectin SLIT2 T106B Mn SOD CDON 0.88 PSA 2 PSA 4 SLIT2 PSMP T106B Mn SOD CDON 0.879984 PSA 2 PSA 4 Tetranectin SLIT2 PSMP T106B CDON 0.879294 PSA 2 PSA 4 Tetranectin SLIT2 PSMP T106B Mn SOD0.869504 PSA 1 SLIT2 IDE T106B Mn SOD PTN CDON 0866418 PSA 1 Tetranectin SLIT2 IDE T106B PTN CDON 0.870629 PSA 1 SLIT2 IDE PSMP T106B PTN CDON 0.886034 PSA 1 PSA 2 SLIT2 IDE T106B PTN CDON 0.865107 PSA 1 Tetranectin SLIT2 IDE T106B Mn SOD PTN 0.86825 PSA 1 SLIT2 IDE PSMP T106B Mn SOD PTN 0.884897 PSA 1 PSA 2 SLIT2 IDE T106B Mn SOD PTN 0868637 PSA 1 Tetranectin SLIT2 IDE PSMP T106B PTN 0.883376 PSA 1 PSA 2 Tetranectin SL.1T2 IDE T106B PTN 0.885615 PSA 1 PSA 2 SLIT2 IDE PSMP T106B PTN 0.642706 Tetranectin SLIT2 IDE T106B Mn SOD PTN CDON 0.639066 SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0.881904 PSA 2 SLIT2 IDE T106B Mn SOD PTN CDON 0.627686 Tetranectin SLIT2 IDE PSMP T106B PTN CDON0.880782 PSA 2 Tetranectin SLIT2 IDE T106B PTN CDONAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SLIT2 IDE PSMP T106B Mn SOD PTN CDON 0 88165 PSA 2 SLIT2 IDE PSMP T106B PTN CDON 0.638971 Tetranectin SL.1T2 IDE PSMP T106B Mn SOD PTN 0.879637 PSA 2 Tetranectin SLIT2 IDE T106B Mn SOD PTN 0.880153 PSA 2 SLIT2 IDE PSMP T106B Mn SOD PTN 0.881049 PSA 2 Tetranectin SLIT2 IDE PSMP T106B PTN 0 86447 PSA 1 Tetranectin SLIT2 T106B Mn SOD PTN CDON 0.869068 PSA 1 SLIT2 PSMP T106B Mn SOD PTN CDON 0.885195 PSA 1 PSA 2 SLIT2 T106B Mn SOD PTN CDON 0.867051 PSA 1 Tetranectin SLIT2 PSMP T106B PTN CDON 0.882755 PSA 1 PSA 2 Tetranectin SLIT2 T106B PTN CDON 0.886373 PSA 1 PSA 2 SLIT2 PSMP T106B PTN CDON 0866309 PSA 1 Tetranectin SLIT2 PSMP T106B Mn SOD PTN 0.882122 PSA 1 PSA 2 Tetranectin SLIT2 T106B Mn SOD PTN 0.884933 PSA 1 PSA 2 SLIT2 PSMP T106B Mn SOD PTN 0.885119 PSA 1 PSA 2 Tetranectin SL.1T2 PSMP T106B PTN 0.632114 Tetranectin SLIT2 PSMP T106B Mn SOD PTN CDON 0.879887 PSA 2 Tetranectin SLIT2 T106B Mn SOD PTN CDON 0880899 PSA 2 ST.1T2 PSMP T106B Mn SOD PTN CDON 0.881279 PSA 2 Tetranectin SLIT2 PSMP T106B PTN CDON 0.880218 PSA 2 Tetranectin SLIT2 PSMP T106B Mn SOD PTN 0.863474 PSA 1 Tetranectin SL.1T2 IDE T106B Mn SOD CDON 0.866015 PSA 1 SLIT2 IDE PSMP T106B Mn SOD CDON 0.883755 PSA 1 PSA 2 SLIT2 IDE T106B Mn SOD CDON 0865624 PSA 1 Tetranectin SLIT2 IDE PSMP T106B CDON 0.882037 PSA 1 PSA 2 Tetranectin SLIT2 IDE T106B CDON 0.884457 PSA 1 PSA 2 SLIT2 IDE PSMP T106B CDON 0.863849 PSA 1 Tetranectin SLIT2 IDE PSMP T106B Mn SOD0.88073 PSA 1 PSA 2 Tetranectin SLIT2 IDE T106B Mn SOD0.883154 PSA 1 PSA 2 SLIT2 IDE PSMP T106B Mn SOD0 88317 PSA 1 PSA 2 Tetranectin SLIT2 IDE PSMP T106B0.623937 Tetranectin SLIT2 IDE PSMP T106B Mn SOD CDON 0.878979 PSA 2 Tetranectin SLIT2 IDE T106B Mn SOD CDON 0.879193 PSA 2 SLIT2 IDE PSMP T106B Mn SOD CDON 0.879782 PSA 2 Tetranectin SLIT2 IDE PSMP T106B CDON 0.878503 PSA 2 Tetranectin SLIT2 IDE PSMP T106B Mn SOD0865156 PSA 1 Tetranectin SLIT2 PSMP T106B Mn SOD CDON 0.881363 PSA 1 PSA 2 Tetranectin SL.1T2 T106B Mn SOD CDON 0.884199 PSA 1 PSA 2 SLIT2 PSMP T106B Mn SOD CDON 0.88438 PSA 1 PSA 2 Tetranectin SLIT2 PSMP T106B CDON 0.883154 PSA 1 PSA 2 Tetranectin SLIT2 PSMP T106B Mn SOD0.879556 PSA 2 Tetranectin SLIT2 PSMP T106B Mn SOD CDON 0881061 PSA 1 PSA 4 IDE T106B Mn SOD PTN CDON0.878294 PSA 1 PSA 4 Tetranectin IDE T106B PTN CDONAUC PSA 1 PSA 2 PSA 3 DCE1 PSA 4 Tetranectin SI. IT' IDE PSMP T106B Mn SOD PTN CDON 0.882618 PSA 1 PSA 4 IDE PSMP T106B PTN CDON 0.888479 PSA 1 PSA 2 PSA 4 IDE T106B PTN CDON 0.876886 PSA 1 PSA 4 Tetranectin IDE T106B Mn SOD PTN 0.880435 PSA 1 PSA 4 IDE PSMP T106B Mn SOD PTN 0.887305 PSA 1 PSA 2 PSA 4 IDE T106B Mn SOD PTN 0880032 PSA 1 PSA 4 Tetranectin IDE PSMP T106B PTN 0.885397 PSA 1 PSA 2 PSA 4 Tetranectin IDE T106B PTN 0.888253 PSA 1 PSA 2 PSA 4 IDE PSMP T106B PTN 0.861311 PSA 4 Tetranectin IDE T106B Mn SOD PTN CDON 0.862526 PSA 4 IDE PSMP T106B Mn SOD PTN CDON 0.884497 PSA 2 PSA 4 IDE T106B Mn SOD PTN CDON 0862812 PSA 4 Tetranectin IDE PSMP T106B PTN CDON 0.882475...

Claims

1. What is claimed is:

1. A method of predicting prostate cancer risk in a subject, comprising forming a biomarker panel comprising N biomarker proteins, and detecting a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 and wherein at least 1, at least 2, at least 3. at least 4. at least 5, at least 6, at least 7, at least 8. at least 9, or 10 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN.

2. A method of detecting levels of N biomarker proteins in a sample, comprising forming a biomarker panel comprising N biomarker proteins, and detecting the level of each of the N biomarker proteins in the sample from a subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10, and wherein at least 1, at least 2. at least 3, at least 4, at least 5, at least 6. at least 7, at least 8, at least 9, or 10 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN.

3. A method of predicting prostate cancer risk m a subject, comprising(a) detecting a level of IDE and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3. at least 4, at least 5. at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD. Tetranectin, and PTN;(b) detecting a level of T106B and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, PSA, CDON, DCE1. PSMP, SLIT2, Mn SOD, Tetranectin, and PTN:(c) detecting a level of PSA and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN;(d) detecting a level of CDON and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, PSA. DCEI, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN;(e) detecting a level of DCEI and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5. at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6. at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN;(f) detecting a level of PSMP and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9. and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCE1, SLIT2, Mn SOD, Tetranectin, and PTN;(g) detecting a level of SLIT2 and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, al least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9. and wherein at least 1. at least 2, at least 3, at least 4, at least 5. at least 6. at least 7. at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCEI, PSMP, Mn SOD, Tetranectin, and PTN;(h) detecting a level of Mn SOD and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1. at least 2, at least 3, at least 4. at least 5, at least 6, at least 7, at least 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCEI, PSMP, SLIT2, Tetranectin, and PTN;(i) detecting a level of and Tetranectin a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4. at least 5. at least 6, at least 7, at feast 8, or at least 9, and wherein at least 1, at least 2, at least 3, at least 4. at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCEI, PSMP, SLIT2, Mn SOD, and PTN; or(j ) detecting a level of PTN and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7,at least 8, or at least 9, and wherein at least 1, at least 2, at least 3. at least 4, at least 5, at least 6, at least 7, at least 8, or 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, and Tetranectin.

4. The method according to any one of the preceding claims, wherein N is 2 to 10, N is 3 to 10, N is 4 to 10, N is 5 to 10, N is 6 to 10, N is 7 to 10, N is 8 to 10, orN is 9 to 10, preferably wherein N is 2. N is 3. N is 4. N is 5. N is 6. N is 7. N is 8. N is 9. or N is 10.

5. The method according to any one of the preceding claims, wherein at least one of the N biomarker proteins is IDE, or at least one of the N biomarker proteins is T106B, or at least one of the N biomarker proteins is PSA. or at least one of N biomarker proteins is CDON, or at least one of the N biomarker proteins is DCE1, or at least one of the N biomarker proteins is PSMP, or at least one of the N biomarker proteins is SLIT2, or at least one of the N biomarker proteins is Mn SOD, or at least one of the N biomarker proteins is Tetranectin, or at least one of the N biomarker proteins is PTN.

6. The method according to any one of the preceding claims, wherein each of the N biomarker proteins is selected from IDE. T106B, PSA, CDON, DCE1. PSMP. SLIT2, Mn SOD, Tetranectin, and PTN.

7. The method according to any one of the preceding claims, wherein at least 2, at least 3, at least 4. at least 5. at least 6, or at least 7. or at least 8, or at least 9 of the N biomarker proteins are selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN.

8. The method according to any one of claims 1-3, wherein(i) 2 of the N biomarker proteins are IDE and T106B. or 2 of the N biomarker proteins are IDE and PSA, or 2 of the N biomarker proteins are IDE and CDON, or 2 of the N biomarker proteins are IDE and DCE1, or 2 of the N biomarker proteins are IDE and PSMP. or 2 of the N biomarker proteins are IDE and SLIT'2, or 2 of the N biomarker proteins are IDE and Mn SOD, or 2 of the N biomarker proteins are IDE and Tetranectin, or 2 of the N biomarker proteins are IDE and PTN;(ii) 2 of the N biomarker proteins are T106B and CDON, or 2 of the N biomarker proteins are T106B and DCE1, or 2 of the N biomarker proteins are T106B andPSMP, or 2 of the N biomarker proteins are T106B and SLIT2, or 2 of the N biomarker proteins are T106B and Mn SOD. or 2 of the N biomarker proteins are T106B and Tetranectin, or 2 of the N biomarker proteins are T106B and PTN; (iii) 2 of the N biomarker proteins are PSA and CDON. or 2 of the N biomarker proteins are PSA and DCE1, or 2 of the N biomarker proteins are PSA and PSMP, or 2 of the N biomarker proteins are PSA and SLIT2, or 2 of the N biomarker proteins are PSA and Mn SOD. or 2 of the N biomarker proteins are PSA and Tetranectin, or 2 of the N biomarker proteins are PSA and P I N;(iv) 2 of the N biomarker proteins are CDON and DCE1, or 2 of the N biomarker proteins are CDON and PSMP, or 2 of the N biomarker proteins are CDON and SLIT2, or 2 of the N biomarker proteins are CDON and Mn SOD, or 2 of the N bioinarker proteins are CDON and Tetranectin, or 2 of the N biomarker proteins are CDON and PTN;(v) 2 of the N biomarker proteins are DCE1 and PSMP, or 2 of the N biomarker proteins are DCE1 and SLIT2, or 2 of the N biomarker proteins are DCE1 and Mn SOD. or 2 of the N biomarker proteins are DCE1 and Tetranectin, or 2 of the N biomarker proteins are DCE1 and PTN;(vi) 2 of the N biomarker proteins are PSMP and SLIT2, or 2 of the N biomarker proteins are PSMP and Mn SOD. or 2 of the N biomarker proteins are PSMP and Tetranectin, or 2 of the N biomarker proteins are PSMP and PTN;(vii) 2 of the N biomarker proteins are SLIT2 and Mn SOD, or 2 of the N biomarker proteins are SLIT2 and Tetranectin, or 2 of the N biomarker proteins are SLIT2 and PTN;(viii ) 2 of the N biomarker proteins are Mn SOD and Tetranectin, or 2 of the N biomarker proteins are Mn SOD and PTN: or(ix) 2 of the N biomarker proteins are Tetranectin and PTN.

9. The method according to any one of claims 1-3, wherein 3 of the N biomarker proteins are IDE, T106B, and PSA, or 3 of the N biomarker proteins are IDE, T106B, and CDON, or 3 of the N biomarker proteins are IDE, T106B, and DCE1, or 3 of the N biomarker proteins are IDE, T106B, and PSMP. or 3 of the N biomarker proteins are IDE, T106B, and SLIT2. or 3 of the N biomarker proteins are IDE, T106B, and Mn SOD, or 3 of the N biomarker proteins are IDE, T106B, and Tetranectin, or 3 of the N biomarker proteins are IDE, T106B, and PTN.

10. The method according to any one of the preceding claims, wherein the sample is a blood sample, a plasma sample, a serum sample, or a urine sample.

11. The method according to any one of the preceding claims, wherein the risk of the subject prostate cancer within 5 years from the date that the sample was taken from the subject is predicted.

12. The method according to any one of the preceding claims, wherein detecting is performed using mass spectrometry, an aptamer based assay, and / or an antibody based assay,13. The method of any one of claims 1-12, wherein the method comprises contacting biomarker proteins of the sample from the subject with a set of capture reagents, wherein each capture reagent of the set of capture reagents specifically binds to one biomarker protein being detected.

14. The method of claim 13, wherein 2, 3, or 4 of the capture reagents bind to the same biomarker protein being detected.

15. The method of claim 14, wherein 2, 3, or 4 capture reagents specifically bind to PSA.

16. The method of any one of claims 1-15. wherein the method comprises contacting biomarker proteins of the sample from the subject with a set of capture reagents, wherein each capture reagent of the set of capture reagents specifically binds to a different biomarker protein being detected.

17. The method according to any one of claims 13-16, wherein each biomarker capture reagent is an antibody or an aptamer.

18. The method according to claim 35, wherein each biomarker capture reagent is an aptamer, preferably wherein at least one aptamer is a slow off-rate aptamer.

19. The method according to claim 18, wherein at least one slow off-rate aptamer comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 nucleotides with modifications.

20. The method according to claim 18 or 19, wherein each slow off-rate aptamer binds to its target protein with an off rate (t'A) of > 20 minutes, > 30 minutes. > 60 minutes, > 90 minutes, > 120 minutes, > 150 minutes, > 180 minutes, > 210 minutes, or > 240 minutes.

21. The method according to any one of the preceding claims, wherein the level of each biomarker protein measured is determined from a relative florescence unit (RFU) or a protein concentration.

22. The method according to any one of the preceding claims, wherein predicting the risk of prostate cancer in the subject is based on input of the levels of the N biomarker proteins measured in a statistical model.

23. The method according to claim 22, wherein the predicting comprises analyzing the levels of the N biomarker protein using a survival model.

24. The method according to claim 23, wherein the survival model is an Accelerated Failure Time (AFT) model with a Weibull distribution.

25. The method according to any one of claims 22-24, wherein the model has an area under the curve (AUC) selected from at least 0.6, at least 0.61, at least 0.62, at least 0.

63. at least 0.64, at least 0.65, at least 0.66, at least 0.67, at least 0.68, at least 0.69, at least 0.7, at least 0.75, at least 0.8, at least 0.85, at least 0.9, or at least 0.95.

26. The method according to any one of the preceding claims, wherein the method comprises predicting a risk of prostate cancer in a subject for the purpose of determining a medical insurance premium or life insurance premium27. The method according to claim 26, wherein the method further comprises determining coverage for medical insurance or life insurance.

28. The method according to any one of claims 1-26, wherein the method further comprises using information resulting from the method to predict and / or manage the utilization of medical resources.

29. A kit comprising N biomarker protein capture reagents, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7. at least 8, at least 9, or at least 10, and wherein at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 of the N biomarker protein capture reagents specifically binds to a biomarker protein selected from IDE, T106B, PSA, CDON, DCE1, PSMP, SLIT2, Mn SOD, Tetranectin, and PTN.

Images